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Zinc is an important micronutrient for all living organisms. While most of the 
cellular zinc is tightly bound to proteins, the rapid exchange kinetics with extracellular 
ligands indicates the presence of a kinetically labile pool. The biological function and 
regulation of this labile pool is still poorly understood. Zinc selective fluorescence 
sensors are ideally suited to gain information about the role of zinc in living systems and 
are attracting an increasing amount of interest. 
The most promising approach comes in the form of ratiometric sensors which 
undergo a spectral shift upon coordination of the analyte. Unlike sensors based on the 
switch-on mechanism, ratiometric sensors allow for quantitative analyte measurements 
independent of the fluorophore concentration. The major challenge in designing this type 
of sensor lies in the necessity to achieve a spectral-shift upon binding of the metal ion. To 
develop a new class of ratiometric sensors, the utility of excited-state intramolecular 
proton transfer (ESIPT) as potential switching mechanism was explored. 
In the absence of ZnII at neutral pH, 2-(2’-sulfonamidophenyl)benzimidazole 
fluorophores undergoes ESIPT to yield a highly Stokes-shifted emission from the 
proton-transfer tautomer. Coordination of ZnII inhibits the ESIPT process and yields a 
significant hypsochromic shift of the fluorescence emission maximum. By implementing 
structural modifications, we were able to gauge free ZnII concentrations in the millimolar 
to picomolar range. 
To tune the peak excitation towards lower energy, a property that is of particular 
 xix 
importance in the light of biological applications, we modified the parent molecule 
through extension of the conjugated pi-system and through selective introduction of 
substituents. These studies revealed that the annulation position and the nature of the 
substituents strongly influenced the photophysical properties of the fluorophores. Several 
of the target molecules revealed emission ratiometric properties with a large dynamic 
range combined with a peak absorption beyond 350 nm, thus rendering these probes 
promising candidates for biological applications. 
To gain more insights into the origin of the substituent effects, five derivatives were 
studied based on solvatochromic shift analysis and quantum chemical calculations. The 
results showed that the observed negative solvatochromic shift behavior is most 
pronounced in protic solvents presumably due to specific hydrogen-bonding interactions. 
The extrapolated gas-phase emission energies correlated qualitatively well with the trends 
in Stokes shifts, suggesting that solute-solvent interactions do not play a significant role 
in explaining the emission energy shifts. The quantum chemical calculations confirmed 
the moderately polarized nature of the ESIPT tautomers and provided a rationale for the 
observed emission shifts. 
The presented work demonstrates the potential of 2-(2’-arylsulfonamidophenyl)- 
benzimidazoles as ratiometric cation sensors. Notably, the fluorophore platform offers a 
tunable peak absorption and emission, adjustable zinc affinity with a wide dynamic range, 
little solvent polarity dependence, and a strong emission ratiometric response. All these 







1.1. Zinc in Biology 
Zinc is an essential trace element and the second most abundant transition metal 
after iron in the body.1-3 It supports a healthy immune system4-10 and is vital for growth 
and development,11-13 reproduction14,15 and neurological functions. Zinc can be found in 
all tissues and fluids in the form of Zn2+ ions. Interestingly, serum and tissue levels of 
zinc are typically not correlated with each other.16 Normally Zn2+ ions are considered 
nontoxic; however, an overdose of zinc can result in clinical conditions,17 some of which 
are similar to those observed with copper deficiency, for example reduced superoxide 
dismutase (SOD) activity.18,19 In multicellular organisms, zinc predominately located 
inside cells. At the cellular level, zinc plays catalytic, structural as well as regulatory 
roles. 
Given its Lewis acidic properties, zinc is utilized by more than 300 enzymes for 
their catalytic functions and is responsible for stimulating the activity of more than 100 
enzymes. Those enzymes include DNA and RNA polymerases,20 alkaline phosphatases 
(AP),21 peptidases, 22 carbonic anhydrases,23 Alcohol dehydrogenases (ADH),24 where 
Zn2+ ion may be directly involved into the bond-making or breaking step, or affects the 
catalytical reaction by stabilizing the active site conformation. The structure of the 
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catalytical and co-catalytic zinc motifs has been investigated and proven to be different.25 
About one thousand transcription factors and other proteins contain zinc finger domains, 
where the Zn2+ is crucial to fold and stabilize the proteins in the correct tertiary 
structure.26 Given this abundance of zinc finger domains in transcription factors, zinc 
may play also a critical role in regulating gene expression. Similarly, alcohol 
dehydrogenases contain two zinc sites, but only one of them is responsible for their 
catalytic function, whereas the second Zn2+ ion plays solely a structural role.23 
Furthermore, chromatin and biomembranes appear to be stabilized by Zn2+ ions.27 Zinc 
has also been found to modulate neurotransmission,28-34 and more recently, studies on 
roles of zinc in apoptosis are growing rapidly.35-43 
 
1.1.2. Zinc Homeostasis 
The total amount of zinc in the adult body is maintained at an average of 1.4-2.3 
gram44 through intestinal uptake, fecal elimination, renal reabsorption, and distribution to 
cells.45 At the cellular level, the total zinc concentration averages 200-300 µM; however, 
the free intracellular zinc concentration in the cytosol is tightly regulated and presumably 
extremely low.46-49 The fact that zinc can be successfully distributed to a myriad of 
proteins while maintaining such low free zinc concentrations suggests a sophisticated 
cellular zinc regulatory system.  
Studies on the genetic disorder acrodermatitis enteropathica revealed that defects in 
the cellular zinc regulatory system can result in severe zinc deficiency.50,51 It is also 
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known that zinc deficiency causes various clinical conditions, such as growth 
retardation,52-54 immune system dysfunction,4-8 anorexia nervosa,55 and skin lesions56. 
Furthermore, zinc imbalance is related to various neurological diseases including 
Alzheimer's disease.32,33,57-61 Understanding zinc homeostasis at the molecular level is 
pivotal to unravel the mechanisms of these clinical conditions. 
 
1.1.2.1. Zinc Transporters 
A major component of the cellular zinc regulatory system are zinc transporters.62,63 
These are membrane proteins that are responsible for mediating zinc ion import and 
export into and from the cytoplasm.62,63 There are two families of zinc transporters: ZIP 
(zinc-iron related transporter proteins),64-66 which modulates the zinc ion import into the 
cytoplasm, and ZnT/CDF (cation diffusion facilitator proteins, only used for yeast), 
which modulates the zinc ion export from the cytoplasm.67-75 While the ZIP family of 
proteins and ZnT167-69 locate in the plasma membrane, other ZnT family of proteins 
locate only in the membranes of the intercellular compartments.70-75 The ZnT family of 
proteins share similar structure and membrane topology but many of them have their 
preferred tissues to be expressed.62,63 For example, while it’s widely distributed, there is 
more ZnT1 expressed in the tissues involved in zinc acquisition, such as small intestine 
(villus cells), renal tubular epithelium, and placenta.76 ZnT2 is expressed in liver, 
mammary gland, muscle, adipose, thymus, and spleen tissue70,76 and ZnT3 is found to be 
expressed in brain and testes.71 For more details, references 63 and 64 give 
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comprehensive reviews about zinc transporters. 
Since zinc transporters are membrane proteins that are only responsible for zinc 
trafficking across membranes, they cannot be proper “carriers” to directly deliver zinc to 
thousands of proteins all over the cell. Considering the extremely low free zinc 
concentration in the cytoplasm,46-49 direct insertion of free Zn2+ ion is clearly not a 
feasible proposal. In this regard, the existence and nature of such Zn2+-specific “carriers”, 
also referred to as metallochaperones, remains a highly elusive aspect in zinc 
homeostasis research. 
 
1.1.2.2 Metallothioneins (MTs) 
Metallothioneins are a family of cysteine-rich, low weight proteins that bind seven 
equivalent bivalent metal ions (mostly Zn2+) with very high affinity.77 In human 
hepatocytes, 5%-10% of the total zinc binds to MTs.78,79 In mammals, four MT isoforms 
have been found; MT-1 and MT-2 are expressed in all organs, whereas MT-3 and MT-4 
are found mainly in the brain and certain stratified tissues, respectively.80 In the cell, MTs 
mainly locate in the cytoplasm while some locate in the nuclei and lysosomes.81-83 One of 
the major functions of MTS is to detoxify heavy metals and reactive oxygen species 
(ROS).84 It’s observed that zinc induces the transcription of the MTS gene by activating 
the transcription factor MTF-1, which is known to activate the promoter of ZnT-1 gene.85 
Interestingly, despite of high zinc binding affinity of MTS, zinc transfer from Zn7-MT to 
apoproteins can be achieved by oxidizing the multiple cysteine residues and in vivo 
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experiment also approved the effective zinc transfer.86,87 Therefore, it has been proposed 
that MTs might be the missing piece in the zinc regulatory system;88,89 however, no direct 
proof has been established yet. 
 
1.1.2.3. Labile Zinc Pools 
Although the free zinc concentration in the cytoplasm is extremely low, a 
significant portion of intracellular zinc in eukaryotic cells can be readily removed by an 
extracellular chelator, suggesting the existence of a kinetically labile zinc pool. Estimates 
for the zinc concentration in this labile pool are only based on indirect measurements and 
vary from 10-5 to 10-12 M.67,90-93 The intracellular labile zinc pool appears to be located in 
intracellular vesicles (sometimes referred to as zincosomes), which have been shown to 
accumulate zinc if the extracellular zinc concentration is increased.94,95  
Despite the wealth of information available about zinc homeostasis, questions still 
remain about how zinc ions are delivered to proteins. Hence, it would be very helpful to 
understand the roles of MTs and labile zinc pools in the zinc regulatory system, a task 
that can only be solved by developing suitable methods that are capable of tracking zinc 
in live cells. 
 
1.2. Zinc-Selective Fluorescent Sensors 
To measure the total zinc concentration in cells, traditional methods such as atomic 
absorption spectroscopy (AAS) or inductively coupled plasma mass spectrometry 
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(ICP-MS) would be sufficient. Synchrotron X-ray fluorescence96 is a powerful technique 
to visualize the zinc distribution in cells with subcellular resolution; however, this 
methods requires chemically fixed specimens. For live cell imaging, magnetic resonance 
imaging (MRI) contrast agents seem to be a viable choice;97,98 however, the low spatial 
resolution99, typical around 1 mm3 for commercial medical instruments, renders this 
approach not suitable for subcellular studies. At present, zinc-responsive fluorescent 
sensors offer the most promising non-invasive method to visualize zinc trafficking in 
living cells. Although since the late 80’s, research activity in this field dramatically 
increased,100-104 there is at present still no probe available that would fulfill all 
requirements. 
To design a suitable zinc-selective fluorescent sensor, the properties of two 
components must be optimized independently: the fluorophore platform and the zinc 
binding group. While the fluorophore platform determines the photophysical properties 
of the sensor, the binding group will determine the zinc binding affinity and selectivity of 
the probe. 
 
1.2.1. First Generation Sensors and Fluorophore Platforms 
Currently, the majority of zinc-responsive sensors function based on any of the 
following three fundamental photophysical processes: 1) photo-induced electron transfer 
(PET), 2) photo-induced charge transfer (PCT), and 3) fluorescence resonance energy 
transfer (FRET).105 The design approach for the first generation sensors was based on a 
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“switch-on” mechanism, which means that the fluorescence emission is quenched in 
absence and largely enhanced in the presence of Zn2+ ions. As a consequence, the 
fluorescence intensity is directly proportional to the free Zn2+ concentration available in 











TSQ                  Zinquin 
1-1                    1-2 
Scheme 1-1. Selected sensors based on 8-aminoquinoline platform. 
 
 
One of the very first zinc-selective fluorescent sensors is 6-methoxy-8-p-toluene- 
sulfonamide quinoline 1-1 (TSQ).106 To improve its solubility in water as well as cellular 
retention, a carboxylic acid group was attached to give Zinquin 1-1 with overall improved 
performance  (Scheme 1-1).107 The solution chemistry of Zinquin with Zn2+ ions has 
been fully characterized in aqueous solution108 and the probe has been successfully 
applied to live cell imaging of labile zinc pools.35,37 Zinquin is now commercially 
available109 and has become one of the most popular zinc sensors. A few additional 
sensors have been reported that are based on the 8-aminoquinoline framework, including 
TFLZn110 and Danquin111. The fluorescein and rhodamine112 platforms were introduced 
 8 
later and offered significant improvements with a higher quantum yield and lower energy 
excitation. Depending on the attachment position of the Zn2+-chelating units, the sensors 
are named ZPs (1-3)113-116 and ZnAFs (1-4)117,118, respectively. (Scheme 1-2) Both 
sensors have been applied to live cell imaging studies and revealed similar staining 
















Zinpyr-1 (ZP1)               ZnAF-1 
1-3                        1-4 
Scheme 1-2. Selected sensors based on the fluorescein platform. 
 
Besides these two major families of Zn2+ responsive small molecule sensors, 
peptides or proteins based probes have been also reported that are based on FRET, 
including carbonic anhydrase,120 green fluorescent proteins (GFPs),121 and engineered 
copper chaperone domains.122 
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1.2.2. Binding Groups 
As mentioned above, the concentration of free zinc ions associated with labile pools 
has been estimated to range from 10-5 to 10-12 M.67,90-93 Conclusively, the zinc-responsive 
sensors should cover a wide dynamic range. Several binding groups (Scheme 1-3) have 
been already extensively utilized in zinc-selective sensors: 1,4,7,10-tetra-azacyclo- 
dodecane (cyclen, 1-5),123-126 sulfonamide (1-6),108 dipycolylamine (1-7)113-118 and 
2,2'-azane-diyldi-acetate (1-8).112,127 
The Kd of sensors containing chelating group of type 1-5 varies from 0.02 nM
120 to 
13.5 µM123, depending on the substituents R1R2R3. The sulfonamide 1-6 and quinoline 
together gives Zinquin a binding affinity of log K = 13.5.108 Group 1-8 gives Kd around 3 
µM for two derivatives. Synthetically, the structure of dipycolylamine 1-7 could be easily 
changed to tune the binding affinity. For example, by changing the length of the carbon 
linker, Kikuchi and coworkers successfully tuned the Kd value of their sensors in a very 
wide range (from 2.7 nM to 0.6 mM).128 
In Pearson's HSAB Classification System, Zn2+ ion is recognized as a borderline 
Lewis acid.129 By selecting borderline Lewis base, such as pyridine, aniline, and 
sulfonamide as binding groups, the zinc selectivity of the sensor against hard (Na+, K+, 
Mg2+, Ca2+, Mn2+, Cr3+ and Fe3+) and soft (Cu+, Ag+, Hg2+ and Cd2+) Lewis acids will be 
improved. To improve the selectivity against other bio-relevant borderline Lewis acids 
(Fe2+, Co2+, Ni2+ and Cu2+), designing the right coordination geometry of the zinc-sensor 
complex should be the way to go.130 Compared to Fe2+, Co2+, Ni2+ and Cu2+, Zn2+ bears 
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the special d10 electron configuration and is not subject to ligand field stabilization effects. 
Therefore, the less ligand field stabilization energy the coordination geometry could 
induce, the better zinc-selectivity the binding group with this geometry could have. The 
tetrahedral geometry, which induces less ligand filed stabilization energy than other 
common geometries do, will then be the preferred coordination geometry for zinc 
sensors. 
By evaluating these two points, we can conclude that neither binding group 1-5 nor 
1-8 is a good choice for zinc-selective purpose because amines and carboxylic acid 
groups are hard Lewis bases and the metal-cyclen 1-5 complex prefers the square planar 
geometry, which offers a large ligand field stabilization energy. 
Based on the same consideration, the dipycolylamine 1-7 should very zinc-selective 
because its zinc complex prefers tetrahedral geometry and pyridines are borderline bases. 
The sulfonamide group 1-6 is known to be borderline Lewis base. Since it is a 
monodentate ligand and cannot form a chelator alone, the zinc binding property of the 



















1-5                1-6                1-7                   1-8   
Scheme 1-3. Binding groups used in zinc-selective sensors. 
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1.2.3. Ratiometric Sensors 
For the first generation “turn-on” zinc-responsive sensors, the fluorescence intensity 
is not only dependent on the free metal ion concentration, but also on the total sensor 
concentration. In biological systems, the sensor concentration is typically not known 
since it is influenced by many factors, including membrane permeability, incubation time, 
temperature, and variations in cell size. Therefore, a quantitative interpretation of the 
fluorescence intensity distribution is complicated or impossible, and the free metal ion 
concentration cannot be reliably quantified with this type of sensor. To overcome this 
limitation, a new probe must be designed whose response is independent of the total 
sensor concentration. 
Ratiometric sensors were first proposed by Tsien and coworkers in the late 80’s in 
context of calcium sensing.131 If the fluorescence spectra shift upon binding metal ions, 
the ratio R of the fluorescence intensities at two different emission or excitation 
wavelengths λ1 and λ2 is directly related to the free metal ion concentration, according to 



















min)]([                     Eq. 1-1 
 
where Rmin and Rmax are the R values for the free sensor and its metal complex, 
respectively, both of which can be readily determined from in vitro measurements. 
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Similarly, the calibration procedure will also provide the instrument-dependent 
parameters Sapo and Sbnd. It is worthwhile noting that this equation is only valid for 
binding sensors that exhibit a 1:1 binding stoichiometry with the metal cation.  
The calcium sensor Fura-2 reported by Tsien and coworkers was later modified to a 
sensor with improved zinc selectivity, FuraZin.124 Currently, FuraZin (Scheme 1-4) is the 
only commercially available ratiometric zinc-selective fluorescent sensor.109 The 
ratiometric property of FuraZin can only be observed on the excitation side. To apply 
FuraZin for ratiometric live cell imaging, the microscopy will has to be equipped with 
two laser sources, which will increase the instrument expense a lot and limit the use of 
































FuraZin          ZnAF-R2          Zinbo-5          ZNP1    
1-9               1-10               1-11           1-12           13 





Some new ideas about ratiometric sensors have been proposed (Scheme 1-4), but 
none of them solve the problem. ZnAR-Rs 1-10 were designed, synthesized and applied 
in cultured macrophages to do ratiometric imaging.132 Benzoxazoles 1-11133 and 1-13134 
were inspired by the same proton transfer mechanism. The fluorescein based ZNP1 was 
proposed by Lippard.135  
The study of ZnAR-R2 has revealed the major difficulty that has hampered the 
development of the emission ratiometric sensor. While the excitation spectra of ZnAR-R2 
show large shift upon binding zinc, its peak emission stays almost the same.132 This fact 
suggests that the metal ion is ejected from the sensor at the excited state, which has been 
seen in a lot at sensors that is based on charge transfer and use the donor site for metal ion 
binding. To tackle this problem, a totally new design will be required. 
 
1.3. Thesis Objective 
The objective of this thesis is to find a ratiometric fluorophore platform with 
tunable affinity and good selectivity towards Zn2+. Such a probe would offer a powerful 
tool for investigating zinc trafficking in living cells. The development of such a sensor 
would thus help understanding zinc homeostasis and the origin of diseases related to zinc 
imbalance and deficiency. 
To fulfill these objectives, a fluorophore that undergoes emission shift upon binding 
Zn2+ must be first developed. Previous studies on benzoxazoles showed that inhibition of 
 14 
excited-state intramolecular proton-transfer is a promising mechanistic concept to 
achieve this key feature.128, 129 The picolylamine group offers good selectivity towards 
zinc and its binding affinity can be tuned via simple synthetic modifications. Therefore, 
with careful design, the combination of a benzazole fluorophore with picolylamine as 
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CHAPTER II 
ZINC(II)-SELECTIVE RATIOMETRIC FLUORESCENT SENSORS 
BASED ON INHIBITION OF EXCITED-STATE INTRAMOLECULAR 
PROTON TRANSFER 
2.1. Introduction 
Excited-state intramolecular proton transfer (ESIPT) has been observed in various 
kinds of molecules, such as salicylic acid1-5, 2-hydroxy benzophenone6, 
hydroxyflavones7-10, 1,5-dihydroxyxanthraquinone11, 2-hydroxy-4,5-naphthotropone12, 
benzazoles13-25 and 2-(2’-hydroxy-5’-methylphenyl) benzotriazole26-29, and has a wide 
range of applications.30-39 Generally, a pre-existing intramolecular hydrogen bond 
(between X and N in Scheme 2-1) is required for ESIPT. Upon photoexcitation, the 
proton covalently attached to the donor group (X) migrates to the acceptor group (N) and 
forms a more stable phototautomer (TB*). This phototautomer then gives a highly Stokes’ 
shifted emission and equilibrates back to the original ground state (TA). The excited state 
proton transfer is essentially barrierless and therefore a very fast process with reaction 
rates approaching the subpicosecond range.40-42 ESIPT can be disrupted by deprotonation 
or coordination of metal ions. The emission from the deprotonated species or metal 
complex (TM*) occurs then with normal Stokes shift, thus giving rise to a significant 




Scheme 2-1. Simplified Jablonski diagram illustrating the increase of the emission 
energy upon metal-cation-induced inhibition of excited-state intramolecular proton 
transfer. 
 
The interesting photophysical property of ESIPT sparked research in fluorescent 
sensor design; 37-39 however, its potential for the design of emission ratiometric 
cation-sensors had not been realized until several years ago. 43, 44 
By measuring the analyte concentration through the ratio of the luminescence 
intensities at two distinct wavelengths, ratiometric sensors have the advantage that their 
response is independent of dye concentration, pathlength, or instrument dependent 
parameters.45 Since the key photophysical requirement for the design of ratiometric 
probes relies on a significant spectral shift upon binding of the analyte, ESIPT represents 
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a promising design principle for developing such sensors.  
The photophysics of 2-(2’-hydroxyphenyl)benzazoles (I, Scheme 2-2) were already 
investigated as potential candidates for ratiometric sensors.43 However, in a polar solvent 
environment, these fluorophores equilibrate with a trans-rotamer that cannot undergo 
ESIPT. As a consequence, emission occurs mainly with normal Stokes shift in aqueous 
solution. To overcome this problem, 2-(2’-tosylaminophenyl)benzimidazole (II) was 
proposed because the sulfonamide lacks the electron lone pair to stabilize the 
trans-rotamer.44 Using this improved fluorophore platform as building block, a series of 
water soluble benzimidazole derivatives (III) were synthesized and characterized as 
potential ratiometric fluorescent sensors. To tune the binding affinity and optimize the 
selectivity towards Zn2+ ions, a chelating moiety (L) was introduced through modification 






















I (cis) I (trans)
II III  
Scheme 2-2 
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2.2. Results and Discussion 
2.2.1. Synthesis 
Using a modular approach, the synthesis of the modified fluorophores was 
accomplished with three key reactions (Scheme 2-3). Firstly, the condensation of the 
commercially available amine (2-1 or 2-(2’-aminophenyl)benzimidazole) with sulfonyl 
chloride 2-248 gave intermediate 2-3 (after MnO2 oxidation) or the unsubstituted ligand 
2-6a. Secondly, the copper(II)-mediated oxidative coupling of aldehyde 2-3 with 
2,3-diaminobenzyl alcohol46 2-4 or 1,2-phenylenediamine provided intermediate 2-5 
(after MnO2 oxidation), or unsubstituted ligand 2-6a as an alternative pathway. Thirdly, 
all three substituted ligands 2-7a, 2-8a and 2-9a were synthesized by means of reductive 
amination of aldehyde 2-5 with the corresponding amines. The water-soluble acids 2-6b, 
2-7b, 2-8b and 2-9b were finally obtained by hydrolysis with LiOH·H2O in aqueous 
methanol. 
2.2.2. Ground-State Tautomerism 
The NH-proton in benzimidazoles undergo fast annular tautomerization.46 Unlike 
the unsubstituted ligand 2-6a/b, ligands 2-7a/b-2-9a/b are involved in a nondegenerate 
prototropic equilibrium because the introduced binding moiety renders their tautomer 
pairs structurally and energetically different (Scheme 2-4). The 1H NMR spectra of all 
ligands show only one set of resonances for the benzimidazole protons, suggesting that 




















































































Scheme 2-3. a) pyridine, 0oC; b) MnO2, CH2Cl2, RT (53%, from 2-1); c) pyridine, (60%); d) Cu(OAc)2, EtOH, reflux (36%); e) MnO2, 
CH2Cl2, RT (86%); f) Cu(OAc)2, EtOH, reflux (20%); g) NaBH(OAc)3, Et2NH, 1,2-EtCl2 (76%); h) NaBH(OAc)3, 
N-2-picolyl-N-methylamine, 1,2-EtCl2 (97%); i) NaBH(OAc)3, N,N-2,2’-dipicolylamine, 1,2-EtCl2 (80%). 
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scale. For instance, although the proton resonances of ligand 2-7a in CD3OD undergo line 
broadening when cooled to –60oC (Figure 2-1), the tautomerization rate does not reach 
the slow-exchange limit that would provide the chemical-shift information for each 
tautomer and thus their concentration ratio. Therefore, this data set cannot be used to 
determine the equilibrium constant and activation barrier of the prototropic equilibrium. 
According to literature reports, the tautomerization equilibrium constants for 
4(7)-substituted benzimidazoles are very close to unity.47 This indicates that the relative 
stability of the N1(H) and N3(H) tautomer is almost identical, and that the stability 
difference between the annular tautomers of ligands 2-6-2-9 is primary controlled through 
steric factors and presumably very small. Conclusively, both tautomers are expected to be 
present in significant concentrations. The absorption and emission spectra discussed 

















Scheme 2-4. Nondegenerate prototropic equilibrium of the tautomer pairs of the 














Figure 2-2. Potentiometric titration curves for ligands 2-6b-2-9b in water (0.1 M KCl, 




Figure 2-3. Comparison of the UV-visible absorption (left) and normalized fluorescence 
emission spectra (right) of the species with protonated () and deprotonated (---) 
sulfonamide nitrogen atom in aqueous solution (0.1 M KCl, 25oC) for ligands a) 2-6b, b) 
2-7b, c) 2-8b, and d) 2-9b. The emission spectra were recorded at pH 7.2 () and 11.0 
(---). The Uv-visible traces were obtained through deconvolution of a series of spectra 




Figure 2-4. Calculated species distribution diagrams for ligands a) 2-6b, b) 2-7b, c) 2-8b, 
and d) 2-9b. 
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2.2.3. Protonation Equilibria 
Because the additional binding sites might also act as protonation sites, the 
protonation equilibria of these four ligands could be very complicated. To clarify possibly 
ambiguous pKa assignment, both potentiometric (Figure 2-2) and spectrophotometric 
titrations were performed. 
For ligand 2-6b and 2-7b, potentiometric titrations were sufficient to determine the 
pKa and their assignments. The observed two protonation steps for the titration of ligand 
2-6b (pKa=8.0 and 4.5) can be readily assigned to the nitrogen atom of sulfonamide 
moiety and the carboxylic acid moiety, respectively (Table 2-1). Ligand 2-7b showed an 
additional protonation equilibrium with pKa 10.1 for the tertiary-amine substituent, while 
the pKa for the carboxylic acid moiety was lowered to 3.7, presumably due to the 
presence of the additional cationic charge. For 2-8b and 2-9b, the pKa of the picolyl 
substituent (possibly around 7.3) 48,49 and sulfonamide moiety might fall into the same 
range and required therefore more careful studies for an unambiguous assignment. 
The carboxylic acid and picolyl substituent are decoupled from the fluorophore 
π-system and deprotonation should therefore not significant influence the absorption 
spectrum. However, deprotonation of the sulfonamide group is expected to give large 
spectral changes. Hence, spectrophotometric titrations should be well suited to determine 
the pKa of the sulfonamide group. 
The performed UV-vis titrations show that the pKa of sulfonamide (8.4 for 2-8b and 
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8.7 for 2-9b) is always higher than that of picolyl substituent (7.3 for 2-8b and 6.5 for 
2-9b). These titrations also give UV-vis spectra traces (deconvoluted by SPECFIT 
software package54, left in Figure 2-3) and absorption maxima (Table 2-1) of species with 
deprotonated or protonated sulfonamide moiety. 
Based on the information above, a species distribution diagram was calculated for 
each fluorophore (Figure 2-4). At neutral pH, 2-8b and 2-9b undergo very little 
deprotonated of the sulfonamide species (less than 1%), therefore, spectral interference of 
the sulfonamide anion on ratiometric Zn2+ measurements should be negligible. For 2-6b 
and 2-7b, there is about 10% of sulfonamide anion present at neutral pH due to the 
somewhat lower pKa’s, rendering the optimal pH range for reliable Zn
2+ analysis slightly 
lower. 
Upon excitation, each ligand gives a single clean emission band centered around 
460 nm with a quantum yield of 9 to 32% at neutral pH (Figure 2-3, right). These spectra 
are independent of the excitation wavelength, suggesting the presence of only one 
emissive species. The large Stokes shifts averaging around 11,000 cm-1 are clearly due to 
ESIPT.44 Upon deprotonation of the sulfonamide moiety, the ESIPT process is disrupted 
and results in a blueshifted, normal emission around 419 nm. Compared to 
2-(2’-hydroxyphenyl)- benzimidazoles, which show multiple emission bands under 
identical condition,17, 43 ligands 26b-2-9b exhibit uniform photophysical properties, thus 
further demonstrating that formation of the trans-rotamer is unfavorable even in aqueous 
solution.44
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Table 2-1. Protonation constants and photophysical data for ligands 2-6b, 2-7b, 2-8b, and 2-9b in aqueous solution.[a] 
 
Species/Equilibrium Data 2-6b 2-7b 2-8b 2-9b 
[LH-]/[H+][L2-] pK1 8.04±0.03 10.12±0.03 8.42±0.03 8.73±0.03 
[LH2]/[H
+][LH-] pK2 4.50±0.03 8.02±0.03 7.31±0.03 6.49±0.03 
[LH3
+]/[H+][LH2] pK3 n/a 3.73±0.05 3.33±0.05 4.05±0.03 
[LH4
2+]/[H+][LH3
+] pK4 n/a n/a n/a 2.84±0.05 
L2- absorption λmax [nm]
[b] 301 (15870) 304 (10120)[f] 303 (15170) 304 (12320) 
  329 (10920) 326 (7470)[f] 329 (10600) 332 (9220) 
 excitation λmax [nm]
[c] 296 299[f] 297 297 
 emission λmax [nm]
[c] 418 419[f] 419 419 
 Stokes’ shift (cm-1) 6470 6810[f] 6530 6250 
LH- absorption λmax [nm]
[b] 299 (12300) 306 (9360)[g] 305 (12850) 305 (10100) 
 excitation λmax [nm]
[d] 300 309[g] 309 308 
 emission λmax [nm]
[d] 460 469[g] 471 460 
 Stokes’ shift (cm-1) 11700 11360[g] 11550 11050 
 quantum yield[e] 0.23 0.32[g] 0.28 0.09 
 
[a] 0.1 M KCl, 25oC; [b] From deconvolution analysis, molar extinction coefficient [L mol-1cm-1] in parentheses; [c] pH 11.0, 0.1 M 
KCl; [d] pH 7.00, 10 mM PIPES, 0.1 M KCl; [e] Quinine sulfate in 1 N H2SO4 as standard; [f] Monoprotonated species LH
-; [g] 
Diprotonated species LH2. 
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Table 2-2. Protonation constants and photophysical data for ligands 2-6b, 2-7b, 2-8b, and 
2-9b in aqueous solution.[a] 
 
Data 2-6b 2-7b 2-8b 2-9b 
LogK[b] 4.50±0.04 3.09±0.04 9.23±0.04 12.10±0.04 
absorption λmax [nm]
[c] 327 318 297 334 
excitation λmax [nm] 294 299 300 338 
emission λmax [nm] 406 420 415 406 
Stokes’ shift (cm-1) 5950 7640 9570 5310 
Rmin F(400/500)
[d] 0.44 0.15 0.24 0.14 
Rmax F(400/500)
[d] 8.46 3.06 7.34 11.6 
Rmax/Rmin 19 20 30 82 
quantum yield[e] 0.22 0.23 0.17 0.21 
 
[a] 0.1M KClO4, 25
oC, 10mM PIPES, pH 7.20; [b] Apparent binding constant at pH 7.20; 
[c] From deconvolution analysis; [d] Ratio R of fluorescence emission intensities at 400 
and 500 nm; [e] Quinine sulfate in 1N H2SO4 as standard. 
 
 
2.2.4. Complexation Studies 
All zinc complexes of ligands 2-6b, 2-7b, 2-8b, and 2-9b yielded bright, blueshifted 
fluorescence emission in neutral buffer. The interaction of Zn2+ with each ligand was 
investigated by spectrophotometric methods (Table 2-2). The selectivity of all four 
ligands towards biologically important metal cations was also explored. While the 
coordination of Ca2+ and Mg2+ does not give visible changes of fluorescence emission, 
the coordination of paramagnetic transition-metal cations Mn2+, Co2+, Fe2+, Ni2+ and Cu2+ 
partially or completely quenches the emission. 
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Figure 2-5. UV-visible absorbance (left) and fluorescence emission spectra (right) of 
ligands a) 2-6b, b) 2-7b, c) 2-8b, and d) 2-9b as a function of added ZnII (excitation at the 
isosbestic point of the UV-visible traces, pH 7.20, 10 mM PIPES, 0.1 M KClO4). 
 
 40 
2.2.5. Absorption Spectra 
For ligand 2-6b, 2-7b, and 2-9b, the coordination of Zn2+ is associated with 
deprotonation of the sulfonamide group. Therefore, the UV-vis spectra of their zinc 
complexes are red-shifted, similar to the deprotonated species measured above. Upon 
addition of zinc triflate at neutral pH, a single isosbestic point was observed for each 
UV-vis spectra set (left, Figure 2-5). When ZnII concentration is above 10mM, ligand 
2-7b behaves differently (Figure 2-5b, dotted lines). The continuous increase of the 
absorbance over the entire wavelength range contradicts the presence of a 
stoichiometrically well-defined complex; this is possibly a result of precipitation and/or 
the formation of a coordination polymer. Interestingly, coordination of Zn2+ with ligand 
2-8b does not give a red-shifted absorption band, thus implying that the sulfonamide 
nitrogen atom is not deprotonated and presumably not involved in Zn2+ coordination. 
  
2.2.6 Emission Spectra 
Upon excitation at the wavelength of the absorption isosbestic point, each 
fluorophore 2-6b, 2-7b and 2-9b gives a set of emission spectra with a clear isosbestic 
point at various Zn2+ concentrations (Figure 2-5, right), suggesting a well defined 
equilibrium between free ligand and zinc complex. Interestingly, similar to the other three 
fluorophores, the zinc complex of ligand 2-8b gave also a blue-shifted, normal emission 
upon Zn2+ addition, indicating that ESIPT is still disrupted even without deprotonation of 
the sulfonamide nitrogen. As discussed in the introduction, the ESIPT process requires 
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the involvement of both, proton donor (sulfonamide nitrogen) and acceptor 
(benzimidazole nitrogen with one lone pair). Therefore, coordination of Zn2+ with either 
group could result in the inhibition of ESIPT. On basis of this understanding, 
coordination of Zn2+ with the benzimidazole nitrogen alone led to ESIPT inhition in case 
of ligand 2-8b. This hypothesis is further supported by the apparent Zn2+ binding affinity 
of logK = 9.2 (Table 2-2), which is much higher than the apparent binding affinity of 




 Binding Affinities 
The emission responses at various ZnII concentrations were analyzed by nonlinear 
least-squares fit method to determine the binding affinities. For ligands 2-6b and 2-7b, 
the binding affinities were directly obtained from mol-ratio plots with ZnII concentrations 
ranging from 10µM to 50mM. It was surprising to find that the affinity of 2-6b (logK = 
4.50) is higher than that of 2-7b (logK = 3.09), whose diethylamino moiety is a potential 
additionally zinc binding group. The proton equilibria data give us a hint about this 
confusing issue. With a relative high pKa (10.1), the coordination of the diethylamino 
group with Zn2+ is prohibited by protonation. The introduced positive charge from the 
protonation is very close to the binding sites and further lowers the affinity of ligand 2-7b. 
Both ligands bind ZnII with a 1:1 stoichiometry. 
For strong ZnII binding ligands 2-8b and 2-9b, metal buffers (ZnII/EGTA and 
ZnII/HEDTA, respectively) were utilized to determine their relatively high affinities. The 
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affinity of ligand 2-9b (logK = 12.1) is five log units higher than dipicolylaimie (logK = 
7.357). Combined with the absorption spectra showing the zinc coordination with 
sulfonamide group, this information convinces us that ligand 2-9b forms a pentadentate 
complex involving all five nitrogen-donor atoms. 
 
2.2.8. Ratiometric Measurements 
Ratiometric sensors determine metal concentration by the ratio R of the intensities 
at two different wavelengths λ1 and λ2.
45 When the binding is 1:1 stoichiometry, Equation 




















min][                                              (2-4) 
 
Rmin and Rmax are the limiting R values in the absence and at saturating level of Zn
II , 
respectively. Sapo and Sbnd are instrument-related factors and can be determined from the 
measurements of solution with known ZnII and sensors concentration. The parameter 








Figure 2-6. Change of the emission intensity ratio at 400 and 500 nm (λex= 320 nm) for 
ligands 2-6b-2-9b as a function of free ZnII (pZn = -log[ZnII free], pH 7.2, 10 mM PIPES, 







Figure 2-7. Emission intensity at 405 nm (λex = 320 nm) of ligands 2-6b, 2-8b, and 2-9b 
in response to various metal cations. Concentrations:2- 6b 10 µM, all M2+ 1 mM; 2-8b 10 
µm, CaII, MgII 1 mM, all other M2+ 10 µm; 2-9b 10 µM, CaII, MgII 1 mM, all other M2+ 
10 µM (pH 7.2, 10 mM PIPES, 0.1 M KClO4). 
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For ligands 2-6b-2-9b, the ratios of the emission intensities at 400 and 500 nm were 
determined at various ZnII concentrations (Figure 2-6, the ratio R is normalized for a 
better comparison). Nonlinear least-squares fit analysis using Equation (2-4) gives Rmax 
and Rmin values (Table 2-2). Compared to the commercial available ratiometric Ca
II 
sensor indo-1 (Rmax/Rmin = 21) and fura-2 (Rmax/Rmin = 45),
45 ligands 2-6b-2-9b exhibit 
decent Rmax/Rmin ratios (19-82). Because concentration measurements are only reliable 
between 20-80%,50 the dynamic range of sensors is restricted to one log units below or 
above their dissociation constants. Therefore, ligands 2-6b is suitable to measure free ZnII 
between 30 µM and 3 mM, and ligands 2-8b and 2-9b are good for concentration 
measurements between 0.1-10 nM and 0.2-20 pM, respectively. The dynamic range of 
ligand 2-7b overlaps a lot with that of ligand 2-6b and its binding stoichiometry is not 
conserved above 10mM. So this ligand was excluded from further investigation. 
 
2.2.9. Selectivity Towards Zn
II
 
The selectivity of each ligand 2-6b, 2-8b and 2-9b was investigated in two ways. 
Firstly, the emission intensity at the zinc complex emission maximum 405 nm was used 
as an indicator for the selectivity of the sensor response (Figure 2-7). While the 
millimolar concentrations of CaII and MgII cannot change the emission spectra, the 
paramagnetic transition metals MnII, CoII, FeII, NiII and CuII partially or completely 
quench the fluorescence. The response of a nonbiological metal CdII was also explored. 





Figure 2-8. Emission intensity ratios at 400 and 500 nm in response to various metal 
cations (pH 7.2, 10 mM PIPES, 0.1 M KClO4): a) 10 µM 2-6b, all M
2+ 1 mM; b) 10 µM 
2-8b, CaII, MgII 1 mM, all other M2+ 10 µM; c) 10 µM solution of 2-9b, CaII, MgII 1 mM, 
all other M2+ 10 µM. Binding competition measurements were acquired after 
equilibration for 3h (2-6b) and 24h (2-8b and 2-9b) with solutions containing equimolar 
concentrations of ZnII and the respective metal cation. 
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for each ligand, but only the response of 2-8b is as strong as that with ZnII. 
Secondly, to each metal cation, the ratio R of the emission intensities at 400 and 500 
nm was investigated with or without the presence of an equimolar amount of ZnII (Figure 
2-8). Except CuII, which actually quenches fluorescence completely, all biological metals 
do not interfere the response of ligand 2-8b and 2-9b to ZnII much. Compared to these 
two strong binding ligands, 2-6b shows worse selectivity, suggesting that the introduced 
binding moiety in 2-8b and 2-9b helps to increase the selectivity. The response to CdII is 
lower than that to ZnII, indicating that binding affinity of CdII is lower than that of ZnII.  
 
2.3. Conclusion 
To explore the potential of excited-state intramolecular proton transfer (ESIPT) for 
ZnII-selective emission ratiometric fluorescent sensors, ligands 2-6b-2-9b were 
synthesized and characterized. The ratiometric response was achieved via the spectra shift 
caused by the inhibition of ESIPT upon binding ZnII. The 2-(2’- 
arylsulfonamidophenyl)benzimidazole platform allows the introduction of additional 
binding groups to tune the binding affinity from picomolar to millimolar and improve the 
ZnII selectivity. However, to gain ratiometric property, these sensors have to be excited in 
UV range, which limits their application for fluorescence microscopy. Therefore, the 
future work will focus on tuning the excitation wavelength towards lower energy. 
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2.4. Experimental Section 
2.4.1. Materials and Reagents 
2-Aminobenzyl alcohol (Aldrich, 98%), 2-(2’-aminophenyl)-benzimidazole 
(Alfa-Aesar, 98%), phenol (Aldrich, 99%), ethyl bromoacetate (Aldrich, 98%), 
manganese dioxide (Aldrich, 99%), 1,2-phenylenediamine (Aldrich, 99%), copper acetate 
monohydrate (Aldrich, 98%), thionyl chloride (Aldrich, 99%), 2,2’-dipicolylamine (TCI, 
97%), N,N-diisopropylethyl amine (Aldrich, 99%), N-(2-hydroxyethyl)- 
ethylenediaminetriacetic acid (HEDTA, Aldrich, 99%), ethylenebis(oxyethylenenitrilo)- 
tetraacetic acid (EGTA, Aldrich, 97%). NMR: δ in ppm versus SiMe4 (0 ppm, 
1H, 400 
MHz). MS: selected peaks; m/z. Melting points are uncorrected. Flash chromatography: 
Merck silica gel (240-400 mesh). TLC: 0.25 mm, Merck silica gel 60 F254, visualizing at 
254 nm or with 2% KMnO4 solution.  
2.4.2. Synthesis 
2,3-Diaminobenzyl alcohol51 2-4 and ethyl 2-phenoxyacetate52 were synthesized 
following the published procedures.  
Ethyl (4-chlorosulfonylphenoxy)acetate (2-2):53 Chlorosulfonic acid (7.0 mL) was 
added dropwise to a solution of ethyl 2-phenoxyacetate (2 g, 11 mmol) in 
dichloromethane (50 mL) and cooled with ice. After stirring for 3h at RT, the reaction 
mixture was poured into ice-cold water (20 mL) and extracted two times with diethyl 
ether (40 mL). The combined organic extracts were dried with anhydrous MgSO4 and 
concentrated under reduced pressure to provide the sulfonyl chloride 2-2 as a yellowish 
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oil (2.40 g, 78% yield). 1H NMR (CDCl3, 400 MHz): δ=1.32 (t, J=7.1 Hz, 3H), 4.29 (q, 
J=7.1 Hz, 2 H), 4.73(s, 2 H), 7.04 (d, J=9.3Hz, 2H), 7.97 ppm (d, J=9.3Hz, 1H); MS (70 
eV): m/z (%): 278/280 (39/15) [M+], 243(100); EI-HRMS: m/z calcd (%) for [M+] 
C10H11ClO5S: 278.0016; found: 278.0049. 
Ethyl [4-(2-formylphenylsulfamoyl)phenoxy]acetate (2-3): A mixture of 2-1 (500 mg, 
4.06 mmol), 2 (1.4 g, 5.0 mmol), and pyridine (0.5 mL) in dichloromethane (5 mL) was 
stirred at RT for 2 h. The reaction mixture was quenched with water (50 mL) and 
extracted twice with dichloromethane. The combined organic extracts were dried with 
anhydrous MgSO4 and concentrated under reduced pressure to give ethyl 
[4-(2-hydroxymethylphenylsulfamoyl) phenoxy]acetate as a yellow oil (1.42 g). Without 
further purification, the product was dissolved in dichloromethane (10 mL) and stirred 
together with manganese dioxide (4.8 g) at RT overnight. The suspension was filtered 
through a pad of Celite and concentrated under reduced pressure. Recrystallization from 
ethyl acetate provided aldehyde 2-3 as a white solid (783mg, 53% yield). M.p. 83-85 oC; 
1H NMR (CDCl3, 400 MHz): δ=1.27 (t, J=7.1 Hz, 3H), 4.24 (q, J=7.1 Hz, 2 H), 4.62 (s, 
2H), 6.89 (d, J=8.7 Hz, 2 H), 7.15 (t, J=7.6 Hz, 1H), 7.49 (t, J=7.1 Hz, 1H), 7.58 (dd, 
J=7.4, 1.4 Hz, 1H), 7.66 (d, J=8.2 Hz, 1H), 7.81 (d, J=8.7 Hz, 2H), 9.81 (s, 1H), 10.75 
ppm (s, 1H); 13CNMR (CDCl3, 100 MHz): δ=14.6, 62.0, 65.6, 115.1, 118.0, 122.1, 123.2, 
129.7, 132.2, 136.0, 136.3, 140.0, 161.5, 167.9, 195.0 ppm; MS (70 eV): m/z (%): 363 
(34) [M+], 243(3 5), 120 (100); EI-HRMS: m/z calcd for [M+] C17H17NO6S: 363.0776; 
found: 363.0771; elemental analysis calcd (%) for C17H17NO6S (363.4): C 56.19, H 4.72, 
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N 3.85; found: C 56.26, H 4.64, N 3.93. 
Ethyl {4-[2-(4-formyl-1H-benzimidazol-2-yl)phenylsulfamoyl]phenoxy}-acetate (2-5): 
Acetic acid (0.280 mL), aldehyde 2-3 (1.11 g, 3.06 mmol) in MeOH (5 mL), and 
copper(II) acetate monohydrate (610 mg) in water (10 mL) were sequentially added with 
stirring to a solution of 2,3-diaminobenzyl alcohol 2-4 (300 mg, 2.17 mmol) in 
EtOH/H2O (20 mL, 1:1). The mixture was heated under reflux for 3h, filtered hot, and the 
residue washed with water. The precipitate was redissolved in a mixture of ethanol (12 
mL) and concd HCl (2.2 mL). After addition of Na2S·9H2O (1.05 g in 8 mL water) the 
mixture was heated under reflux for 1 h, cooled to RT, and filtered through a pad of 
Celite to remove the precipitated CuS. The filtrate was neutralized with aqueous NaHCO3 
and extracted three times with dichloromethane. The combined organic extracts were 
dried with MgSO4 and concentrated under reduced pressure. The crude product was 
purified on silica gel (hexanes/ethyl acetate 1:2-1:1) to provide the 
hydroxymethyl-substituted benzimidazole as a glassy, yellowish solid (378 mg, 36% 
yield). M.p. 54-56 oC; 1H NMR (CDCl3, 400 MHz) (note: tautomeric proton exchange 
broadens a few signals): δ=1.30 (t, J=7.1 Hz, 3H), 4.26 (q, J=7.1 Hz, 2H), 4.50 (s, 2 H), 
5.02 (s, 2H), 6.39 (d, J=8.7 Hz, 2H), 7.09 (br s, 1 H), 7.15 (t, J=7.6 Hz, 2H), 7.22 (d, 
J=7.6 Hz, 1 H), 7.33 (br s, 1 H), 7.32 (t, J=7.6 Hz, 2H), 7.49 (d, J=7.6 Hz, 1H), 7.67 (br s, 
1H), 7.73(d, J=7.6 Hz, 1H), 9.80 (br s, 1H), 9.99 ppm (br s, 1H); MS (70 eV): m/z (%): 
481 (65) [M+], 435 (27), 312 (31), 220 (100); EI-HRMS: m/z calcd (%) for [M+] 
C24H23N3O6S: 481.1308; found: 481.1297. 
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The above intermediate (482 mg, 1.0 mmol) was dissolved in dichloromethane (15 mL) 
and stirred with manganese dioxide (1.1 g) at RT overnight. The suspension was filtered 
through a pad of Celite and concentrated under reduced pressure. Recrystallization from 
diethylether provided aldehyde 2-5 as a glassy, yellow solid (415 mg, 86% yield). M.p. 
65-67 oC; 1H NMR (CDCl3, 400 MHz): δ=1.24 (t, J=7.1 Hz, 3H), 4.21 (q, J=7.1 Hz, 2 H), 
4.52 (s, 2 H), 6.65 (d, J=8.8 Hz, 2 H), 7.17 (t, J=8.0 Hz, 1H), 7.39 (td, J=8.8, 1.7 Hz, 1H), 
7.49 (t, J=8.0 Hz, 1H), 7.64 (d, J=9.3Hz, 2H), 7.68 (dd, J=8.8, 1.1 Hz, 1H), 7.79 (dd, 
J=8.5, 1.7 Hz , 2H), 8.11 (d, J=7.7 Hz, 1 H), 10.11 (s, 1 H), 10.87 (br s, 1 H), 12.35 ppm 
(s, 2H); 13C NMR (CDCl3, 100 MHz): d=14.5, 61.9, 65.3, 114.5, 115.6, 116.4, 121.0, 
121.3, 123.0, 123.8, 126.2, 126.9, 127.8, 129.3, 131.7, 132.2, 138.0, 149.0, 151.9, 160.9, 
167.9, 192.4 ppm; MS (70 eV): m/z (%): 479 (64) [M+], 415 (25), 378 (5), 328 (50), 236 
(100), 209 (11), 181 (9); EI-HRMS: m/z calcd (%) for [M+] C24H21N3O6S: 479.1151; 
found: 479.1145; elemental analysis calcd (%) for C24H21N3O6S (479.5): C 60.12, H 4.41, 
N 8.76; found: C 60.24, H 4.49, N 8.66. 
Ethyl {4-[2-(1H-benzimidazol-2-yl)phenylsulfamoyl]phenoxy}acetate (2-6a): A 
solution of 2-(2’-aminophenyl)benzimidazole (310 mg, 1.48 mmol) and 2-2 (500 mg, 
1.79 mmol) in pyridine (3mL) was stirred for 2 h. The reaction mixture was diluted with 
water (20 mL) and extracted twice with ethyl acetate (40 mL). The combined organic 
extracts were dried with MgSO4 and concentrated under reduced pressure. The crude 
product was purified by flash chromatography on silica gel (hexanes/ethyl acetate 2:1) to 
give ligand 2-6a as a yellowish solid (400 mg, 60% yield). M.p. 134-136 oC; 1H NMR 
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([D6]DMSO, 400 MHz): δ=1.12 (t, J=6.6 Hz, 3H), 4.08 (q, J=7.1 Hz, 2H), 4.77 (s, 2 H), 
6.92 (d, J=8.8 Hz, 2H), 7.19 (t, J=7.7 Hz, 1H), 7.28-7.31 (m, 2 H), 7.40 (t, J=7.7 Hz, 1 H), 
7.60 (d, J=8.8 Hz, 1 H), 7.64-7.67 (m, 4H), 8.02 (d, J=8.2 Hz, 1 H), 13.23 ppm (s, 2H); 
13C NMR (CDCl3, 100 MHz): δ=14.8, 61.5, 65.4, 115.7, 116.4, 119.2, 123.8, 124.0, 
128.0, 129.5, 131.5, 131.8, 151.0, 161.5, 168.5, 168.5 ppm; MS (70 eV): m/z (%): 451.1 
(44) [M+], 387.1 (14), 300.1 (40), 208.1 (100); EI-HRMS: m/z calcd (%) for [M+] 
C23H21N3O5S: 451.1202; found: 451.1189; elemental analysis calcd (%) for C23H21N3O5S 
(451.5): C 61.18, H 4.69, N 9.31; found: C 61.09, H 4.72, N 9.36. 
{4-[2-(1H-Benzimidazol-2-yl)phenylsulfamoyl]phenoxy}acetic acid (2-6b): Ethyl ester 
2-6a (170 mg, 0.38 mmol) was added to a solution of LiOH·H2O (350 mg) in a mixture 
of methanol (1 mL) and water (1 mL). The mixture was stirred at RT for 1 h, and the 
organic solvent subsequently removed under reduced pressure. The aqueous residue was 
acidified by the addition of 1m HCl and the product then extracted twice with ethyl 
acetate. The combined organic extracts were dried with MgSO4 and concentrated under 
reduced pressure to provide acid 2-6b as a yellowish solid (140 mg, 88% yield). For the 
photophysical studies a sample of the compound (10 mg) was further purified by 
semipreparative reversedphase HPLC (10×300 mm C18 column, CH3CN/H2O 
(0.01%TFA) 75:25-98:2); M.p. 140 oC (decomp); 1H NMR ([D6]DMSO, 400 MHz): 
δ=4.66 (s, 2H), 6.90 (d, J=8.8 Hz, 2 H), 7.19 (t, J=7.7 Hz, 1H), 7.28-7.31 (m, 2H), 7.40 (t, 
J=7.7 Hz, 1 H), 7.60 (d, J=8.8 Hz, 1 H), 7.65-7.67 (m, 4 H), 8.02 (d, J=8.2 Hz, 1 H), 
13.23 ppm (s, 2H); MS (70 eV): m/z (%): 423(20) [M+], 300 (17), 208 (100); EI-HRMS: 
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m/z calcd (%) for [M+] C21H17N3O5S: 423.0889; found: 423.0863.  
Ethyl {4-{2-{4-[(diethylamino)methyl]-1H-benzimidazol-2-yl}phenylsulfamoyl} 
phenoxy}acetate (2-7a): Diethyl amine (31 mL, 0.292 mmol) and sodium 
triacetoxyborohydride (66 mg, 0.313 mmol) were added to a solution of aldehyde 2-5 
(100 mg, 0.209 mmol) in 1,2-dichloroethane (15 mL). The reaction mixture was allowed 
to stir for 2.5 h under N2 and was then quenched by the addition of 1m aqueous NH4OH 
(3mL). The product was extracted twice with dichloromethane and the combined organic 
extracts were dried with MgSO4. The organic solvent was evaporated under reduced 
pressure and the residue purified by using flash chromatography on silica gel 
(dichloromethane/methanol/TFA 50:1:0.25-50:1:0.5) to provide ligand 2-7a as a glassy, 
pale yellow solid (85 mg, 76% yield). M.p. 54-56oC; 1H NMR (CDCl3, 400 MHz): 
δ=1.15 (t, J=7.1 Hz, 3H), 1.23 (t, J=7.1 Hz, 6H), 2.68 (q, J=6.9 Hz, 4 H), 4.01 (s, 2 H), 
4.20 (q, J=7.1 Hz, 2H), 4.52 (s, 2 H), 6.70 (d, J=8.8 Hz, 2 H), 7.08-7.13(m, 2 H), 7.20 (t, 
J=7.7 Hz, 1H), 7.30 (t, J=7.7 Hz, 1 H), 7.30 (t, J=8.2 Hz, 1 H), 7.63(br s, 1H), 7.67 (d, 
J=7.7 Hz, 1H), 7.70-7.74 (m, 3H), 9.44 (br s, 1H), 12.52 ppm (br s, 1H); 13C NMR 
(CDCl3, 100 MHz): δ=8.1, 10.5, 43.2, 52.2, 57.9, 61.4, 110.6, 112.7, 114.6, 116.3, 118.9, 
119.1, 119.6, 120.6, 122.3, 122.6, 125.4, 126.8, 128.6, 129.5, 134.0, 145.7, 156.8, 164.0 
ppm; MS (70 eV): m/z (%): 536 (1) [M+], 507 (52), 465 (100), 222 (100), 72 (25); 
EI-HRMS: m/z calcd (%) for [M+] C28H32N4O5S: 536.2093; found: 536.2065; elemental 
analysis calcd (%) for C28H32N4O5S·0.5H2O (545.7): C 61.63, H 6.10, N 10.27; found: C 
61.83, H 6.13, N 9.93. 
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{4-{2-{4-[(Diethylamino)methyl]-1H-benzimidazol-2-yl}phenylsulfamoyl}-phenoxy} 
acetic acid (2-7b): Ethyl ester 2-7a (22 mg, 0.041 mmol) was hydrolyzed as described 
for acid 2-6b to provide the free acid 2-7b (12 mg, 58%). M.p. 225-227 oC; 1H NMR 
(CD3OD, 400 MHz): δ=1.42 (t, J=7.1 Hz, 6H), 3.35 (q, J=7.4 Hz, 4H), 3.63 (br s, 1H), 
4.34 (s, 2H), 4.74 (s, 2H), 6.61 (d, J=8.2 Hz, 2 H), 7.24 (t, J=7.4 Hz, 1 H), 7.32 (d, J=7.7 
Hz, 2H), 7.34-7.45 (m, 3 H), 7.69 (t, J=6.9 Hz, 2H), 7.81 ppm (dd, J=8.7, 1.1 Hz, 1H); 
MS (70 eV): m/z (%): 509 (100) [M+1]+, 435 (5), 338 (15), 295 (44); ESI-TOF-HRMS: 
m/z calcd (%) for [M+1]+ C26H29N4O5S: 509.1859; found: 509.1884.  
Ethyl {4-{2-{4-[(methylpyridin-2-ylmethylamino)methyl]-1H-benzimidazol-2-yl} 
phenylsulfamoyl}phenoxy}acetate (2-8a): Prepared as described for 2-7a by reductive 
amination of aldehyde 2-5 (100 mg, 0.209 mmol) with methyl picolylamine54 (100 mg, 
0.819 mmol), providing 2-8a as a glassy, pale yellow solid (119 mg, 97% yield). M.p. 
56-58 oC; 1H NMR (CDCl3, 400 MHz): δ=1.22 (t, J=7.1 Hz, 3H), 2.29 (s, 3H), 3.74 (s, 
2H), 3.89 (s, 2H), 4.18 (q, J=7.1 Hz, 2 H), 4.41 (s, 2 H), 6.64 (m, 2 H), 7.03(d, J= 7.1 Hz, 
1H), 7.14-7.18 (m, 3H), 7.27 (d, J=7.7 Hz, 1 H), 7.33 (td, J=7.7, 1.7 Hz, 1 H), 7.65 (dd, 
J=7.7, 2.2 Hz, 1 H), 7.68-7.73(m, 3H), 7.78 (dd, J=8.2, 1.1 Hz, 1H), 8.18 (d, J=7.7 Hz, 1 
H), 8.43(d, J=4.4 Hz, 1H), 13.48 ppm (br s, 2H); 13C NMR (CDCl3, 100 MHz): δ=14.4, 
43.0, 58.8, 61.8, 63.1, 65.3, 114.5, 117.6, 118.2, 120.3, 122.1, 122.5, 122.8, 123.4, 123.6, 
123.9, 127.2, 129.4, 130.5, 132.8, 133.1, 137.3, 138.0, 143.0, 149.2, 150.5, 159.0, 160.6, 
167.9 ppm; MS (70 eV): m/z (%): 586 (100) [M+1]+, 344 (13), 293 (27); 
ESI-TOF-HRMS: m/z calcd (%) for [M+1]+ C31H32N5O5S: 586.2124; found: 586.2089; 
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elemental analysis calcd (%) for C31H31N5O5S (585.7): C 63.57, H 5.34, N 11.96; found: 
C 63.57, H 5.44, N 11.78. 
{4-{2-{4-[(Methylpyridin-2-ylmethylamino)methyl]-1H-benzimidazol-2-yl}phenyl- 
sulfamoyl}phenoxy}acetic acid (2-8b): Ethyl ester 2-8a (40 mg, 0.068 mmol) was 
hydrolyzed as described for acid 6b to give free acid 2-8b (23 mg, 61%). M.p. 133-135oC; 
1H NMR (CDCl3, 400 MHz): δ=2.47 (s, 3H), 3.63 (br s, 1H), 4.08 (s, 2H), 4.22 (s, 2 H), 
4.36 (s, 2H), 6.40 (d, J= 8.3Hz, 2 H), 7.06-7.18 (m, 4H), 7.28 (d, J=6.1 Hz, 2 H), 7.31 (d, 
J=7.7 Hz, 4H), 7.69 (d, J=6.7 Hz, 2H), 7.75 (d, J=7.1 Hz, 2 H), 8.55 ppm (d, J=4.4 Hz, 
1H); MS (70 eV): m/z (%): 558 (100) [M+1]+, 344 (5), 279, (19); ESI-TOF-HRMS: m/z 
calcd (%) for [M+1]+ C29H28N5O5S: 558.1811; found: 558.1846.  
Ethyl {4-{2-{4-[(bispyridin-2-ylmethylamino)methyl]-1H-benzimidazol-2-yl} 
phenylsulfamoyl}phenoxy}acetate (2-9a): Prepared as described for 2-7a by reductive 
amination of aldehyde 2-5 (40 mg, 0.083mmol) with 2,2’-dipicolylamine (22 mg, 0.11 
mmol), providing 2-9a as a glassy solid (44 mg, 80% yield). M.p. 65-67 8C; 1H NMR 
(CDCl3, 400 MHz): δ=1.23(t, J=7.1 Hz, 3H), 3.89 (s, 2 H), 3.91 (s, 4 H), 4.19 (q, J=7.1 
Hz, 2 H), 4.41 (s, 2H), 6.66 (d, J=9.3Hz, 2 H), 7.09-7.20 (m, 4H), 7.25 (d, J=7.6 Hz, 2H), 
7.36 (td, J=8.5, 1.4 Hz, 1H), 7.54 (td, J=7.6, 1.6 Hz, 2H), 7.72-7.77 (m, 3H), 7.81 (dd, 
J=8.2, 1.1 Hz, 1H), 8.17 (dd, J=7.9, 1.1 Hz, 1H), 8.40 (d, J=3.8 Hz, 2H), 13.20 (br s, 2H), 
14.11 ppm (s, 1H); 13C NMR (CDCl3, 400 MHz): δ=14.5, 56.5, 59.9, 61.9, 65.4, 114.6, 
118.6, 120.6, 122.3, 122.6, 123.0, 123.3, 123.6, 123.7, 126.9, 129.5, 130.6, 133.0, 133.3, 
137.1, 138.1, 143.0, 149.0, 150.6, 159.2, 160.7, 167.9 ppm; MS (70 eV): m/z (%): 662 (5) 
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[M+], 570 (100), 465 (13), 222 (40), 198 (53), 93 (78); EI-HRMS: m/z calcd (%) for [M+] 
C36H34N6O5S: 662.2311; found: 662.2276; elemental analysis calcd (%) for 
C36H34N6O5S·0.5H2O (671.8): C 64.37, H 5.25, N 12.51; found: C 64.76, H 5.13, N 
12.16. 
{4-{2-{4-[(Bispyridin-2-ylmethylamino)methyl]-1H-benzimidazol-2-yl}-phenylsulfa
moyl}phenoxy}acetic acid (2-9b): Ethyl ester 2-9a (22 mg, 0.033 mmol) was 
hydrolyzed as described for acid 2-6b to give free acid 2-9b (16 mg, 76%). For all 
photophysical studies a sample of the compound (10 mg) was further purified by 
semipreparative reversed-phase HPLC (10×300 mm C18 column, CH3CN/H2O 
(0.01%TFA) 75:25-98:2). M.p. 80-82 oC; 1H NMR (CDCl3, 400 MHz): δ=3.91 (s, 4H), 
3.99 (s, 2 H), 4.39 (s, 2 H), 6.50 (d, J=8.7 Hz, 2 H), 7.06 (d, J=7.1 Hz, 1H), 7.16 (t, J=7.6 
Hz, 4 H), 7.25 (s, 2H), 7.38 (t, J=7.6 Hz, 1H), 7.52 (d, J=8.7 Hz, 2H), 7.59 (td, J=7.6, 1.4 
Hz, 2H), 7.68 (d, J=7.6 Hz, 1H), 7.83(d, J=8.2 Hz, 1H), 8.00 (d, J=7.6 Hz, 1H), 8.40 ppm 
(d, J=4.9 Hz, 2H); FABMS (thioglycerol): m/z (%): 635 (100) [M+], 373 (62); 
FAB-HRMS: m/z calcd (%) for [M+H]+ C34H31N6O5S: 635.2077; found: 635.2119. 
 
2.4.3. Steady-state Absorption and Fluorescence Spectroscopy 
All sample stock solutions and buffer solutions were filtered through 0.2 mm Nylon 
membrane filters to remove interfering dust particles or fibers. UV/Vis absorption spectra 
were recorded at 25 oC by using a Varian Cary Bio50 UV/Vis spectrometer with 
constant-temperature accessory. Steady-state emission and excitation spectra were 
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recorded with a PTI fluorimeter and FELIX software. Throughout the titration the sample 
solution was stirred with a magnetic stirring device. For all titrations the path length was 
1 cm with a cell volume of 3.0 mL. All fluorescence spectra have been corrected for the 
spectral response of the detection system (emission correction file provided by the 
instrument manufacturer) and for the spectral irradiance of the excitation channel (by 
using a calibrated photodiode). Quantum yields were determined by using quinine sulfate 
dihydrate in 1.0 N H2SO4 (Φf  = 0.54 ± 0.03) as the fluorescence standard.
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2.4.4. Electrode Calibration in Aqueous Solution 
Measurements were performed with an Orion microcombination glass electrode. 
The electrode was calibrated for -log[H3O
+] by titration of a standardized HCl solution 
(Aldrich, 0.1N volumetric standard) with KOH (Aldrich, 0.1N volumetric standard) at 25 
oC and 0.1M ionic strength (KCl). The endpoint, electrode potential, and slope were 
determined by using Gran’s method56 as implemented in the software GLEE.57 The 
calibration procedure was repeated three times prior to each pKa value determination. The 
electrode potential was measured with the Corning pH/Ion Analyzer 355 and the emf 
measurements were reproducible with ±0.1 mV accuracy. 
 
2.4.5. Potentiometry 
All protonation constants reported in this study were determined from 
potentiometric titrations and additionally confirmed by spectrophotometric measurements. 
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Potentiometric titrations were carried out with a motorized burette (Dosimat, Metrohm, 
Switzerland) by adding a total of 40-100 aliquots of KOH (0.1M) to 10.0 mL of a 
solution of the corresponding ligand (0.5-1.0 mM) in KCl (0.1M) under a N2 atmosphere 
(solvent-vapor-saturated gas). Throughout the titration, the temperature was maintained at 
25±0.1 oC by circulating constant-temperature water through the water-jacket of the 
titration cell. For the potentiometric titration of ligands 2-7b, 2-8b, and 2-9b, the initial 
solution was further acidified by adding 1-3 molar equivalents of HCl (0.5m). The emf 
data were converted to -log[H3O
+] based on the electrode potential Eo and slope, which 
were determined as described above prior to each titration. The pKa values were obtained 
from nonlinear least-squares fit analysis of the potentiometric data.58 
 
2.4.6. Spectrophotometric Titrations 
The UV/Vis absorption spectra of the ligands were monitored for a series of 
solutions in which -log[H3O
+] was varied between 5 and 11. The emf of each solution 
was directly measured in the UV quartz cell (electrode diameter 3mm) and converted to 
-log[H3O
+] using the Eo and slope, as obtained from the electrode calibration procedure 
described above. The raw spectral and emf data were processed with nonlinear 
least-squares fit analysis using the SPECFIT software package.59 
 
2.4.7. Complex stability constants 
All reported stability constants K were measured at pH 7.2 (PIPES 10 mM, 0.1M 
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KClO4 ionic background) and refer to apparent stability constants.
60  
Determination of the apparent Zn
II
 affinity of ligands 2-6b and 2-7b: UV/Vis 
spectrophotometric titrations were performed with a 60µM solution (3.0 mL cell volume) 
of the corresponding ligand in PIPES buffer (10mM, pH 7.20, 0.1M KClO4) over the 
range of 4 logarithmic units of free ZnII. The recorded spectra were processed by 
nonlinear least-squares fit analysis using the SPECFIT software package.53 The resulting 









=                                  (2-1) 
 
in which [ZnL]=concentration of zinc-ligand complex, [Zn]=concentration of unbound 
ZnII, ([L]+[LH]+...[LHm])=concentration of all ligand species that do not involve Zn
II (at 
given conditions of pH 7.2, 0.1M KClO4, 25 
oC).54 
Determination of the apparent Zn
II
 affinity of ligand 2-8b and 2-9b: A series of 
PIPES-buffered solutions (10mM, pH 7.20, 0.1M KClO4) were prepared that contained 
HEDTA (HEDTA = N-(2-hydroxyethyl)ethylenediaminetriacetic acid, 10mM) or EGTA 
(EGTA = ethylenebis(oxyethylenenitrilo)tetraacetic acid, 10mM) and between 1-9mM of 
Zn(OTf)2. The concentration of free Zn
II was calculated using the program Hyss,61 based 
on the following published pKa and logK values for HEDTA, pK1 = 9.87, pK2 = 5.38, pK3 
= 2.62, pK4 = 1.60, logK(ZnL) = 14.6 (25 
oC, µ = 0.1), and EGTA, pK1 = 9.40, pK2 = 
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8.79, pK3 = 2.70, logK(ZnL) = 12.6 (25 
oC, µ = 0.1).62 According to Martell and Smith,56 
the tabulated pKa data must be corrected upward by 0.11 to account for 0.1M ionic 
strength. This correction is necessary because the tabulated pKa values are determined on 
the basis of the concentration and not the activity of the hydronium ions. For the 
calculation of the free ZnII concentrations, the published pKa values of HEDTA and 
EGTA were therefore corrected by 0.11. Ligands 2-8b or 2-9b were dissolved in 3.0 mL 
of the corresponding buffer solutions up to a final concentration of 10 µM. After a 24 h 
equilibration time, the fluorescence intensity at 400 and 500 nm was determined. The 
experimental data were analyzed by a nonlinear least-squares fit algorithm with the 
following formalisms: By assuming a 1:1 metal-to-ligand stoichiometry, the following 
relationship [Eq. (2-2)] was found between the free ZnII concentration, apparent 










min][                                                    (2-2) 
 
in which Fmin = fluorescence intensity of free ligand, Fmax = fluorescence intensity of 
ZnII-bound ligand.  
Using Equation (2-2) the emission intensity F can be expressed as a function of free ZnII 












=                                                 (2-3) 
 
Nonlinear least-squares fit analysis of the experimental intensities versus the 
calculated free ZnII concentrations allowed for the determination of Fmax, Fmin, and Kd. 
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CHAPTER III 
EXCITED STATE INTRAMOLECULAR PROTON TRANSFER IN 2-(2’- 
ARYLSULFONAMIDOPHENYL)BENZIMIDAZOLE DERIVATIVES: 
THE EFFECT OF DONOR AND ACCEPTOR SUBSTITUENTS 
3.1. Introduction 
The study of 2’-(sulfonamidophenyl)benzimidazole derivatives in Chapter 2 
revealed their great potential as emission ratiometric zinc(II)-selective fluorescence 
sensors. However, these fluorophores need to be excited at UV range to gain ratiometric 
property and the optical setting of standard fluorescence microscopes prohibits the 
transmission of light at wavelength below 350 nm. Thus, in order to use these sensors for 
biological imaging applications, their peak absorption has to be shifted toward lower 
energy, which can be achieved by decreasing the HOMO-LUMO gap of the fluorophore 
π-system. 
In our previous work, the orbital surfaces of the HOMO and LUMO orbitals of 
2-(2’-tosylaminophenyl)benzimidazole (TPBI) were calculated by quantum chemical 
methods (Figure 3-1).1 These results showed that the LUMO density at position 4’ is 
significantly higher than the HOMO density, and conversely, the HOMO density at 
position 6(5) is much higher than the LUMO density. On basis of these data it should be 
possible to decrease HOMO-LUMO energy difference by either introducing an electron 
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withdrawing group at position 4’ (and thus stabilizing the LUMO more than the HOMO) 
or by introducing an electron donating group at position 6 (thus destabilizing the HOMO 











     
 
Figure 3-1. Molecular orbital surfaces of the HOMO and LUMO responsible for the 
lowest energy transition in the UV-vis spectrum of 
2-(2′-tosylaminophenyl)benzimidazole (TPBI) (CI-ZINDO calculation).1 
 
By selecting methoxy and dimethylamino groups as electron-donating substituents 
and cyano and thiazolyl groups as electron-withdrawing groups, a series of water-soluble 
2-(2’-arylsulfonamidophenyl)benzimidazole derivatives were synthesized containing 
structural modification at the 4’, 5’ and 6(5) position.  Detailed photophysical studies 
were then performed to experimentally determine the effect of donor and acceptor 
substituents on the absorption and emission properties of this compound class. Since the 
corresponding Zn(II) complexes are expected to exhibit similar absorption and emission 
spectra compared to the fully deprotonated species L2-, the discussion of the 
photophysical properties will focus entirely on the deprotonated species as substitute. 
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3.2. Results and Discussion 
3.2.1. Synthesis 
Sulfonyl chloride 3-10 was synthesized as described in Chapter 2 following a 
modified published procedure.2 There are two key steps for the synthesis of all 
derivatives (Scheme 3-1): 1) the condensation reaction of the aniline and sulfonyl 
chloride to form the sulfonamide moiety, and 2) the oxidative coupling reaction of the 
corresponding benzaldehyde with phenylenediamine to install the benzimidazole ring 
system. Depending on the order of these two steps, two distinct routes (A and B) could be 
principally used for the synthesis of the target fluorophores. Since the nitro-benzaldehyde 
precursors (3-1a-e) are readily accessible or commercially available, fluorophores 3-3a-e 
were synthesized according to route A. Thus, in the first step, benzimidazoles 3-2a-e 
were synthesized, followed by hydrogenation to form the aniline intermediates 3-3a-e. 
Coupling with sulfonyl chloride2 3-10 concluded then the synthesis for the products 
3-4a-e. Conversely, the aniline precursors (3-7i-l) were the preferred starting materials for 
route B; therefore, installation of the sulfonamide was performed first (3-8i-l), followed 
by MnO2 oxidation of the alcohol to the aldehydes 3-9i-l and the coupling reaction to 
form the benzimidazoles (3-4i-l). In case of fluorophores 3-4f-h, the nitro-benzaldehydes 
(3-1f-g) were first hydrogenated to anilines (3-6f-g, route B), followed by installation of 
the sulfonamide (3-9f-g) and coupling to form the desired benzimidazoles (3-4f-h). 
Hydrolysis of the ethyl esters was performed under mild conditions with lithium 





























































































































R1 = H, R2 = H
R1 = CN, R2 = H
R1 = 2-thiazolyl, R2 = H
R1 = OCH3, R2 = H
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3.2.2. Protonation Equilibria 
As previously described in Chapter 2, deprotonation of the sulfonamide group is 
associated with a bathochromic shift in the absorption spectra and a hypsochromic shift in 
the fluorescence spectra. To study the effects of substituents without being misled by 
pH-dependent changes, the UV-vis and fluorescence emission spectra were therefore 
measured at well-defined protonation states. Hence, the protonation equilibria of each 
compound were first analyzed by means of spectrochemical UV-vis titrations with 
–log[H3O
+] ranging between 5 and 11. The absorption spectra of the fully deprotonated 
L2- and monoprotonated species HL- were then obtained from deconvolution of the 
UV-vis traces over the entire spectral range using a non-linear least-squares fitting 
procedure. 
The determined pKa values are shown in Table 3-1 and all spectral data are listed in 
Table 3-2. The pKa1 is associated with a large shift in the absorption spectrum, and thus 
can be assigned to deprotonation of the sulfonamide group. In contrast, pKa2 gives rise to 
only small absorption change and must be therefore associated with deprotonation of the 
carboxylic acid group, which is electronically decoupled from the conjugated π-system of 
the fluorophore. Due to the presence of the dimethylamino substituent, compound 3-5g 
has an additional protonation equilibrium with pKa at 8.0, thus resulting in different pKa 
assignments. 
As evident from Table 3-1, the pKa value of the sulfonamide group varies from 6.7 
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to 9.3 and strongly depends on the nature of the substituent and its attachment position. 
The explanation of this observation requires careful evaluation of the resonance 
stabilization and inductive effects of the substituents and can be readily quantified by 
Hammett’s free energy relationship (Figure 3-2).2 The acidity constant of the derivatives 
with two substituents (3-5c and 3-5h) show the influence of both groups; however, the 





Figure 3-2 Linear dependence of the sulfonamide acidity (pKa1) on Hammett’s σ 




Table 3-1. Protonation Constants of Benzimidazole Derivatives 3-5a-3-5l in Aqueous Solutiona 
 
 substituents    [L2-]/[L]tot 





+]d  [%]e 
3-5a
f
 H H H 8.04 ± 0.03 4.46 ± 0.08 7.0 4 
3-5b CN H H 6.75 ± 0.02 n.d.g 5.2 3 
3-5c CN H OCH3 6.88 ± 0.03 n.d.g 5.2 3 
3-5d 2-thiazolyl H H 7.30 ± 0.01 n.d.g 6.0 3 
3-5e OCH3 H H 7.60 ± 0.01 4.79 ± 0.03 6.2 3 
3-5f H OCH3 H 8.34 ± 0.01 4.53 ± 0.06 6.5 <1 
3-5g H N(CH3)2 H 9.33 ± 0.05 8.01 ± 0.02h 6.7 <1 
3-5h H OCH3 CN 7.96 ± 0.02 5.51 ± 0.1 6.7 5 
3-5i H H CN 7.63 ± 0.02 5.21 ± 0.1 6.5 6 
3-5k H H OCH3 7.95 ± 0.02 4.91 ± 0.1 6.5 3 
3-5l -OCH2O- H 7.98 ± 0.01 4.65 ± 0.02 6.3 1 
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[a] 0.1 M KCl, 25 oC. [b] Ka1 = [L
2-][H+]/[LH-]. [c] Ka2 = [LH
-][H+]/[LH2]. [d] Proton concentration used for photophysical 
characterization of LH-. [e] Residual concentration of fully deprotonated L2-. [f] Data from ref 2. [g] Spectral deconvolution 
insufficient for accurate determination. [h] Protonation of the carboxylate group occurs at pKa3 = 4.81 ± 0.05. 
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Table 3-2. Photophysical Data of Benzimidazole Derivatives 3-5a-3-5l in Aqueous Solutiona 
 
 monoprotonated species (LH-)  deprotonated species (L2-)    
 






















 300 460 11,590 0.23 329 418 6470 0.26 315 42 
3-5b 319 483 (404) 10,640 0.37 355 447 5800 0.70 341 36 
3-5c 341 481 8540 0.46 362 452 5500 0.34 350 29 
3-5d 331 484 (403) 9550 0.41 361 475 6650 0.42 352 9 
3-5e 305 432 9640 0.17g 329 396 5140 0.06 314 36 
3-5f 298 497 13,440 0.14 334 444 7420 0.27 322 53 
3-5g 273 568 (448) 14,760h <0.01 348 505 8930 0.08 296 63 
3-5h 306 534 13,950 0.03 340 480 8580 0.02 326 54 
3-5i 307 489 12,120 0.25 333 452 7910 0.29 320 37 
3-5k 316 452 9520 0.13 333 416 5990 0.29 320 36 
3-5l 314 459 10,060 0.04 340 423 5770 0.04 326 36 
 
[a] 0.1 M KCl, 25 oC. [b] From deconvolution analysis. [c] At the proton concentration as indicated in Table 3-1; excitation at 
isosbestic point. [d] pH 10.8, 0.1 M KCl. [e] Difference of peak emission wavelength of species LH- and L2-. [f] Data from ref 2. [g] 
Excitation at 370 nm increases the quantum yield to 0.35. [h] Based on excitation spectrum acquired at 650 nm.
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It is known that 1H-benzimidazole derivatives undergo rapid annular 
tautomerization in solution. 2, 4 With the introduction of substituent R3, the N1(H)/N3(H) 
prototropic equilibrium will lead to a nondegenerate tautomer pair (Scheme 3-2). The 
equilibrium constant KT is directly related to the concentration ratio of two tautomers and 
can be used to calculate their stability difference (∆GT = -RT lnKT). 
Temperature dependent 1H NMR spectroscopy was used to investigate the effect of 
the electron-withdrawing group 5(6)-cyano (3-4i, Figure 3-3) and the electron-donating 
group 5(6)-methoxy (3-4k) on the energy difference of the two tautomers. While the 
tautomerization rate does not reach the slow-exchange limit in protic solvents2, the 
solution in acetone-d6 gives two-sets of well-resolved signals at –60
oC. For compound 
3-4i, the equilibrium constant (KT = 1.43 ± 0.008) of two tautomers can be calculated 
through the integration intensity ratio of C4(H) and C7(H) resonances at 8.43 and 8.11 
ppm, which also gives the free energy difference of two tautomers (∆GT = 0.63 ± 0.01 kJ 
mol-1)  
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To find out which of the two tautomers is more stable in solution, 2D NOESY NMR 
experiments were performed at –80o in acetone-d6 (Figure 3-4). This temperature is 
sufficiently low to slow down the exchange kinetics and thus to yield two well-separated 
benzimidazole NH resonances. Since the N1(H) proton is in NOE contact with the proton 
C7(H), it is straight forward to assign the corresponding singlet of the proton C7(H) to 
the 6-substituted species. By comparing the integrations of the proton C7(H) of 
6-substituted species and the proton C4(H) of 5-substituted species, the concentration 
ratio of two tautomers was calculated. As shown in Figure 3-4a, for the cyano-substituted 
derivative 3-4i, the 5-substituted species is more stable, a finding that is consistent with 
recent quantum chemical calculation results.5 For the methoxy-substituted derivative 
3-4k, unlike 3-4i, the 6-subsituted species is actually more stable (KT = 0.66 ± 0.01, ∆GT 
= 0.66 ± 0.01 KJ mol-1), indicating that the resonance effect of the substituent is the major 




Figure 3-3. Variable temperature 1H NMR spectra 5(6)-cyano-substituted benzimidazole 




Figure 3-4. Two-dimensional 500 MHz 1H-1H NOESY spectra of (a) 3-4i (left) and (b) 3-4k (right) in acetone-d6 at -80
oC. The dashed 
lines indicate the correlation signals for the benzimidazole proton N1(H) of each tautomer. For both derivatives, N1(H) shows NOE 
contact with the C7(H) singlet of the 6-substituted tautomer, while the 5-substituted tautomer shows an NOE contact with C(7)H 
appearing as a doublet (atom numbering shown in Scheme 3-2).
 80 
 
3.2.4. Substituent Effects on Photophysical Properties 
3.2.4.1 Effect of Donor Substitution 
The deconvoluted UV-vis spectra and measured emission spectra of the three 
methoxy-substituted derivatives are shown on Figure 3-5. For all three derivatives, the 
deprotonation of the sulfonamide group is associated with a bathochromic shift in the 
absorption spectra. The structural modification did not significantly affect the absorption 
spectrum of the fully deprotonated species L2-; however, more significant changes were 
observed for the monoprotonated species HL-. In this case, the absorption spectrum is 
stronger influenced by substitution on the benzimidazole ring (3-5k), resulting in a (λmax 
16 nm red-shifted absorption maximum compared to the unsubstituted parent fluorophore 
3-5a, while substitution on the central benzene ring resulted only in small shifts (λmax 
red-shifted 5 nm for 3-5e, blue-shifted 2nm for 3-5f). 
For all derivatives, the deprotonation of the sulfonamide group is associated with a 
hypsochromic shift in the emission spectra due to the disruption of the ESIPT process. 
Interestingly, the emission maxima of these fluorophores strongly depended on the 
substituent position, with the deprotonated species L2- being equally affected compared to 
the monoprotonated species HL-. While the emission spectra of the 6-substituted 
derivative 3-5k are similar to the parent fluorophore 3-5a, the 4’- and 5’-substituted 
derivatives 3-5e and 3-5f give significantly red- (28nm) and blue-shifted (37nm) 
emissions. The origin of this unexpected divergent spectral shift will be further discussed 
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in detail in Chapter 4. 
3.2.4.1.1. Ground-State Proton Transfer 
For 4’-substituted derivative 3-5e, an additional low-energy absorption band at 360 
nm was observed, which is most likely due to formation of a prototropic imino tautomer 
present in the ground-state equilibrium.6 Excitation spectra acquired over the entire 
emission energy range consistently showed a similar low-energy band, thus supporting 
this hypothesis. The emission spectrum measured with excitation at 350 nm were also 
similar to those acquired with excitation below 350 nm. These data further support that 
the low-energy absorption band originates from a ground-state intramolecular proton 
transfer species. 
 
3.2.4.1.2. Effect of Donor Strength 
Stronger donors including 5’-dimethylamino (5-3g) and 4’,5’-methylenedioxy (5-3l) 
were introduced on the central benzene ring of the fluorophore. Compared to 5’-methoxy 
derivative 3-5f, fluorophore 5-3g showed largely red-shifted emissions (Table 3-2) for 
both monoprotonated HL- (71 nm shift) and deprotonated L2- species (62 nm shift). 
Considering that 4’-methoxy (3-5e) and 5’-methoxy (3-5f) showed opposite effects on the 
emission maxima, it’s not very surprising that 4’,5’-methylenedioxy group does not 
change the peak emission wavelength much. Interestingly, both 5-3g and 5-3l showed 
very low quantum yield (<0.01 and 0.04, respectively), indicating that the strong donor 





Figure 3-5. Effect of donor substituents: deconvoluted UV-vis absorption spectra (left) 
and fluorescence emission spectra (right) of compounds (a) 3-5a, (b) 3-5e, (c) 3-5f, and 
(d) 3-5k in aqueous solution (0.1 M KCl, 25 oC). UV-vis traces for the species with 
protonated (-) and deprotonated (- - -) sulfonamide group were obtained through 
deconvolution analysis of a series of spectra with -log[H3O
+] ranging between 6 and 10. 
Emission spectra were acquired with excitation at the isosbestic point and were recorded 
near neutral pH as specified in Table 3-1 (-) and at pH 11 (- - -) without further 
deconvolution. The four vertical grid lines are added as a guide to the eye indicating the 




Figure 3-6. Effect of acceptor substituents: deconvoluted UV-vis absorption spectra (left) 
and fluorescence emission spectra (right) of compounds (a) 3-5b, (b) 3-5i, (c) 3-5d, and 
(d) 3-5c in aqueous solution (0.1 M KCl, 25 oC). UV-vis traces for the species with 
protonated (-) and deprotonated (- - -) sulfonamide group were obtained through 
deconvolution analysis of a series of spectra with -log[H3O
+] ranging between 6 and 10. 
Emission spectra were acquired with excitation at the isosbestic point and were recorded 
near neutral pH as specified in Table 1 (-) and at pH 11 (- - -) without further 
deconvolution. The four vertical grid lines are intended as a guide to the eye indicating 
the position of the peak absorption and emission of parent compound 3-5a. 
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 Scheme 3-3 
As shown in Figure 3-6, the introduction of the electron-withdrawing group resulted 
in red-shifted absorption and emission spectra. For example, compared to the parent 
compound 3-5a, fluorophore 3-5b revealed a 19 nm and 26 nm shift in the absorption 
spectra for HL- and L2-, respectively, and a 23 nm and 29 nm shift in the emission spectra. 
Since the thiazolyl ring extends the fluorophore π-system, the absorption and emission 
spectra are even more red-shifted for derivative 3-5d. 
Interestingly, a high-energy emission band (404 nm and 403 nm, respectively) is 
observed for the monoprotonated species of derivative 3-5b and 3-5d. Dual fluorescence 
emission is not unusual for ESIPT fluorophores, and could be principally due to the 
presence of a rotamer (Scheme 3-3, Nt) that cannot undergo ESIPT,
7 or radiative decay 
from a polarized, local excited state8. Detailed photophysical studies revealed uniform 
excitation spectra regardless of the emission wavelength, suggesting that only one species 
gives rise to both emission peaks. Furthermore, quantum chemical calculation suggested 
that the cis-rotamer Nc is strongly favored over the trans-rotamer Nt in case of 
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2’-sulfonamidophenyl-substituted benzimidazoles.1 Therefore, the dual emission is most 
likely not due to the existence of a additional ground-state rotamer, but might originate 
from competition between radiative relaxation of a local excited state and formation of 
the proton-transfer phototautomer. 
 
3.2.4.3. Effect of Donor-Acceptor Double Substitutions 
As discussed in the introductory paragraph, 4’-cyano-6-methoxy-derivative 3-5c 
was expected to yield further red-shifted absorption and emission spectra, a prediction 
that was indeed confirmed by photophysical studies (Figure 3-6d). Compared to the 
parent fluorophore 3-5a, the compound 3-5c revealed a strongly red-shift absorption (41 
nm shift for HL-; 33 nm shift for L2-) and emission maximum (21 nm for HL-; 34 nm for 
L2-). The spectral blue-shift caused by deprotonation of the sulfonamide group is 29 nm. 
This change should be sufficient for reliable ratiometric concentration measurements. The 
quantum yield of 3-5c (0.46 for HL-; 0.34 for L2-) is also much higher than that of 3-5a 
(0.23 for HL-; 0.26 for L2-). 
An additional double substituted derivative 3-5h was also synthesized and 
characterized (Table 3-2). The 5’-methoxy-6-cyano substituents led to a largely 
red-shifted emission spectra, but yielded a very low quantum yield with no substantial 




In this chapter, the substituent effects on 2-(2’-arylsulfonamidophenyl)- 
benzimidazole platform was systematically investigated. Both the nature of substituents 
and the substitution positions showed very strong influence on the photophysical and 
protonation properties of the derivatives. While differences in the protonation equilibria 
were readily explained using Hammett’s free energy relationship, the substituents effects 
on their photophysical properties appeared more complicated. For some derivatives, a 
ground-state proton-transfer species was found to cause an additional band in the 
absorption spectrum. Also, the radiative relaxation of the local excited state was believed 
to be the reason of the additional emission peak in some derivatives’ spectra. Most 
importantly, the absorption and emission maximums strongly depend on the substituents. 
This effect was utilized to achieve the red-shifted absorption. As predicted by theoretical 
calculations, fluorophore 3-5c was found to have decent absorbance beyond 350 nm. 
Although its pKa value of the sulfonamide group is still low (6.88), it should be possible 
to further adjust it by introducing suitable substituents on the arylsulfonamido moiety. 
Furthermore, the substituent effects on emission spectra shift will be investigated in 
details in chapter 4. 
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3.4. Experimental Section 
3.4.1. Synthesis 
Benzimidazole derivatives 3-4a and 3-5a, (4-chlorosulfonyl-phenoxy)acetic acid 
ethyl ester 3-10, and 2-(4-(N-(2-formylphenyl) sulfamoyl)phenoxy)acetic acid ethyl ester 
3-9i were synthesized as previously describe.9 Compounds 
4-cyano-2-nitrobenzaldehyde10 (3-1b), 5-methoxy-2-nitrobenzaldehyde11 (3-1f), 
4-methoxy-2-nitrobenzaldehyde12 (3-1e), and 4-bromo-2-nitrobenzaldehyde13 were 
synthesized according to published procedures. NMR: δ in ppm versus SiMe4 (0 ppm, 
1H, 
400 MHz; 0 ppm, 13C, 100 MHz). Note: due to the presence of prototropic exchange 
equilibria, benzimidazole hydrogens are in many cases broadened (indicated as “br”) or 
not resolved. Similarly, 13C resonances for C3a(7a), C4(7), and C5(6) of the 
benzimidazole ring were either broadened or absent. For variable temperature NMR 
experiments, the actual sample temperature was determined by means of a calibration 
curve using neat methanol as chemical-shift thermometer.14 Two-dimensional NOESY 
1H-1H NMR spectra were acquired in acetone-d6 at 193 K with a 500 MHz spectrometer 
(300 ms mixing time). Structural assignments were confirmed with 2D COSY 
experiments acquired at the same temperature (Figure 3-7 and Figure 3-8). MS: selected 
peaks; m/z. Melting points are uncorrected. Flash chromatography (FC): silica gel 
(240-400 mesh). 
2-Nitro-4-(thiazol-2-yl)benzaldehyde (3-1d). A solution of 4-bromo-2-nitrobenzalde-
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hyde6 (310 mg, 1.3 mmol), 2-(tributylstannyl)-thiazole (500 mg, 410 µL, 1.3 mmol), and 
Pd(PPh3)4 (50 mg, 0.043 mmol) in DMF (10 mL) was degassed and then heated at 80°C 
overnight. After cooling to room temperature, the reaction mixture was diluted with 
CH2Cl2, washed with deionized water, and concentrated under reduced pressure. The 
residual crude product was purified on silica gel (FC, EtOAc/hexanes, 1:3) providing 340 
mg (1.45 mmol, quantitative yield) of thiazole 3-1d as a yellow solid. Mp 101-103 °C; 1H 
NMR (CDCl3, 400 MHz) δ 7.55 (d, J = 3.1 Hz, 1H), 8.01 (d, J = 3.2 Hz, 1H), 8.06 (d, J = 
8.0 Hz, 1H), 8.34 (dd, J = 8.0 Hz, 1.7 Hz, 1H), 8.71 (d, J = 1.7 Hz, 1H), 10.45 (s, 1H); 
13C NMR (CDCl3, 100 MHz) δ 121.6, 122.0, 130.4, 130.87, 130.91, 138.6, 144.8, 150.1, 
163.8, 187.3; IR (KBr) 3121, 3106, 2926, 1691, 1526, 1506, 1348, 1141, 824, 770, 736 
cm-1; MS (70 eV) m/z 234 ([M+], 11), 204 (100), 176 (25), 159 (27); EI-HRMS calcd for 
C10H6N2O3S 234.0099, found 234.0078. 
5-(Dimethylamino)-2-nitrobenzaldehyde (3-1g). A mixture of 5-fluoro-2-nitrobenz-
aldehyde (100 mg, 0.59 mmol), dimethylamine hydrochloride (77 mg), and anhydrous 
K2CO3 (245 mg) in DMSO (2 mL) was heated at 105°C for 2 h. After cooling to room 
temperature, the reaction mixture was diluted with water, and the precipitated product 
was extracted twice with diethylether (40 mL). The combined organic extracts were dried 
with anhydrous MgSO4, filtered, and concentrated under reduced pressure, providing 92 
mg (0.47 mmol, 80% yield) of compound 3-1g as a yellow solid. Mp 124-126 °C; 1H 
NMR (CDCl3, 400 MHz) δ 3.16 (s, 6H), 6.72 (dd, J = 9.3, 3.0 Hz, 1H), 6.91 (d, J = 3.0 
Hz, 1H), 8.11 (d, J = 9.3 Hz, 1H), 10.51 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 40.3, 
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110.0, 112.7, 127.4, 135.0, 136.2, 153.3, 190.0; IR (KBr) 2902, 1701, 1600, 1573, 1295, 
1261, 1231, 1198, 886, 811 cm-1; MS (70 eV) m/z 194.1 ([M+], 100), 164.1 (18), 136.3 
(100), 119.1 (32), 105.1 (18); EI-HRMS calcd for [M+] C9H10N2O3 194.0691, found 
194.0674. 
General Procedure A: Synthesis of Benzimidazole Derivatives through Oxidative 
Coupling with Benzoquinone. An equimolar solution of the corresponding aldehyde and 
phenylenediamine (0.5 mmol) in EtOH (2 mL) was heated under reflux until all starting 
material was converted to the imine intermediate (ca. 1.5 h). After addition of 
1,4-benzoquinone (119 mg, 1.10 mmol) the reaction mixture was heated at reflux until 
the imine intermediate was completely converted to the benzimidazole product (typically 
30-60 min). The reaction mixture was then cooled to room temperature, diluted with 
saturated aqueous NaHCO3, and the product was extracted twice with ethyl acetate. The 
combined organic extracts were dried with anhydrous MgSO4, filtered, and concentrated 
under reduced pressure. The crude product was purified by FC on silica to give the 
analytically pure benzimidazole. 
4-(1H-Benzimidazol-2-yl)-3-nitrobenzonitrile (3-2b). Starting from 200 mg of 
aldehyde 3-1b (0.12 mmol) and 1,2-phenylenediamine (129 mg, 1.19 mmol), 
benzimidazole derivative 3-2b was obtained in 43% yield (FC, EtOAc/hexanes, gradient 
1:2 to 1:1). Mp 209-211 °C; 1H NMR (CD3OD, 400 MHz) δ 7.33 (m, 2H), 7.64 (br, 2H), 
8.06 (d, J = 8.2 Hz, 1H), 8.20 (dd, J = 8.2, 1.6 Hz, 1H), 8.53 (d, J = 1.6 Hz, 1H); 13C 
NMR (acetone-d6, 100 MHz) δ 115.7, 117.2, 124.5 (br), 129.5, 130.1, 133.7, 137.1, 147.5, 
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150.0; IR (KBr) 3198, 3097, 3072, 2236, 1560, 1535, 1425, 1354, 787, 747 cm-1; MS (70 
eV) m/z 264.1 ([M+], 100), 247.1 (65), 234.1 (26); EI-HRMS calcd for [M+] C14H8N4O2 
264.06473, found 264.06592. 
4-(5(6)-Methoxy-1H-benzimidazol-2-yl)-3-nitrobenzonitrile (3-2c). Starting from 200 
mg of aldehyde 3-1b (0.12 mmol) and 4-methoxybenzene-1,2-diamine (165 mg, 1.19 
mmol), benzimidazole derivative 3-2c was obtained in 30% yield (FC, EtOAc/hexanes, 
gradient 1:2 to 1:1). Mp 75-77 °C; 1H NMR (CD3OD, 400 MHz) δ 3.86 (s, 3H), 6.95 (dd, 
J = 8.9, 2.4 Hz, 1H), 7.09 (br, 1H), 7.52 (d, J = 8.7 Hz, 1H), 8.02 (d, J = 8.0 Hz, 1H), 
8.16 (dd, J = 8.0, 1.6 Hz, 1H), 8.49 (d, J = 1.6 Hz, 1H); 13C NMR (acetone-d6, 100 MHz) 
δ 55.9, 114.0, 114.2, 117.1, 128.5, 128.7, 131.9, 136.0, 145.3, 149.6, 157.9; IR (KBr) 
3074, 2946, 2234, 1617, 1540, 1269, 1198, 1157, 1025, 1001, 831 cm-1; MS (70 eV) m/z 
294.1 ([M+], 100); EI-HRMS calcd for [M+] C15H10N4O3 294.07529, found 294.07582. 
2-(2-Nitro-4-thiazol-2-yl-phenyl)-1H-benzimidazole (3-2d). Starting from 28 mg of 
aldehyde 3-1d (0.12 mmol) and 1,2-phenylenediamine (15 mg, 0.14 mmol), 
benzimidazole derivative 3-2d was obtained in 31% yield (FC, EtOAc/hexanes, 1:1). Mp 
120-122 °C; 1H NMR (CD3OD/CDCl3 1:1, 400 MHz) δ 7.29-7.35 (m, 2H), 7.61-7.68 (br, 
2H), 7.69 (d, J = 3.2 Hz, 1H), 7.96 (d, J = 8.1 Hz, 1H), 8.00 (d, J = 3.2 Hz, 1H), 8.33 (dd, 
J = 8.1, 1.8 Hz, 1H), 8.65 (d, J = 1.8 Hz, 1H); 13C NMR (CD3OD/CDCl3, 100 MHz) δ 
122.1, 123.0, 123.9 (br), 126.9, 130.8, 133.5, 136.5, 144.9, 148.2, 150.0, 165.6; IR (KBr) 
3120, 3091, 1534, 1518, 1474, 1448, 1433, 1369, 1354, 1276, 771, 746 cm-1; MS (70 eV) 
m/z 322 ([M+], 50), 292 (100), 129 (57), 57(52), 40.9 (37); EI-HRMS calcd for [M+] 
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C16H10N4O2S 322.0525, found 322.0496. 
2-(4-Methoxy-2-nitro-phenyl)-1H-benzimidazole (3-2e). Starting from 410 mg of 
aldehyde 3-1e (2.26 mmol) and 1,2-phenylenediamine (257 mg, 2.37 mmol), benz-
imidazole derivative 3-2e was obtained in 82% yield (FC, EtOAc/hexanes, gradient 1:4 to 
1:2). Mp 178-180 °C; 1H NMR (CD3OD, 400 MHz) δ 3.96 (s, 3H), 7.25-7.29 (m, 2H), 
7.38 (dd, J = 8.6, 2.6 Hz, 1H), 7.58 (br, 2H), 7.65 (d, J = 2.6 Hz, 1H), 7.74 (d, J = 8.6 Hz, 
1H); 13C NMR (DMSO-d6, 100 MHz) δ 56.3, 109.6, 115.9, 117.8, 122.1 (br), 131.6, 
147.1, 149.7, 160.1; IR (KBr) 2844, 1628, 1531, 1500, 1449, 1430, 1304, 1272, 1238, 
1027, 755 cm-1; MS (70 eV) m/z 269 ([M+], 90), 239.1 (100), 196 (32), 110.1 (77); 
EI-HRMS calcd for [M+] C14H11N3O3 269.0800, found 269.0816. 
3-Amino-4-(1H-benzimidazol-2-yl)benzonitrile (3-3b). A solution of nitro-substituted 
benzimidazole intermediate 3-2b (102 mg, 0.39 mmol) in 5 mL of methanol was 
hydrogenated at room temperature under ambient pressure in the presence of Pd on 
activated carbon as catalyst (25 mg, 5 wt % Pd). After completion of the reaction (TLC), 
the catalyst was filtered off through a pad of Celite, and the filtrate was concentrated 
under reduced pressure providing 85 mg (0.36 mmol, 94% yield) of amine 3-3b as a 
yellow solid. Mp 88-90 °C; 1H NMR (CD3OD, 400 MHz) δ 6.92 (dd, J = 8.2, 1.6 Hz, 1H), 
7.12 (d, J = 1.6 Hz, 1H), 7.22-7.25 (m, 2H), 7.58 (br, 2H), 7.79 (d, J = 8.2 Hz, 1H); 13C 
NMR (CD3OD, 100 MHz) δ 114.0, 116.0, 119.1, 119.7, 120.1, 129.0, 149.2, 151.9; IR 
(KBr) 3305 (br), 3060, 2228, 1617, 1586, 1577, 1454, 1437, 1334, 1267, 766, 741 cm-1; 
MS (70 eV) m/z 234.1 ([M+], 100); EI-HRMS calcd for [M+] C14H10N4 234.0906, found 
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234.0907. 
3-Amino-4-(1H-benzimidazol-2-yl)benzonitrile (3-3c). Synthesized from 3-2c as 
described for 3-3b, 53% yield. Mp 193-195 °C; 1H NMR (CD3OD, 400 MHz) δ 3.83 (s, 
3H), 6.87 (dd, J = 8.8, 2.7 Hz, 1H), 6.93 (dd, J = 8.2, 1.6 Hz, 1H), 7.07 (d, J = 2.2 Hz, 
1H), 7.12 (d, J = 1.6 Hz, 1H), 7.49 (d, J = 8.8 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H); 13C 
NMR (CD3OD, 100 MHz) δ 56.2, 97.6, 113.3, 113.5, 116.2, 117.3, 119.0, 119.9, 128.7, 
135.4, 139.3, 148.9, 151.6, 157.9; IR (KBr) 3296, 2224, 1631, 1610, 1590, 1453, 1434, 
1338, 1263, 1199, 1158, 832 cm-1; MS (70 eV) m/z 264 ([M+], 100), 249.1 (52), 167 (28), 
147.9 (78), 129 (90); EI-HRMS calcd for [M+] C15H12N4O 264.1011, found 264.1014. 
2-(1H-Benzimidazol-2-yl)-5-thiazol-2-yl-phenylamine (3-3d). Synthesized from 3-2d 
as described for 3-3b, 88% yield. Mp dec>230 °C; 1H NMR (CD3OD, 400 MHz) δ 
7.12-7.16 (m, 2H), 7.21 (dd, J = 8.2, 1.8 Hz, 1H), 7.37 (d, J = 1.8 Hz, 1H), 7.47- 7.52 (m, 
2H), 7.53 (d, J = 3.3 Hz, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.79 (d, J = 3.3 Hz, 1H); 13C 
NMR (CD3OD, 100 MHz) δ 114.2, 114.7, 115.1 (br), 115.3, 120.1, 123.0, 128.9, 135.1, 
139.9 (br), 143.6, 148.3, 152.3, 169.4; IR (KBr) 3321, 2500, 1617, 1452, 1286, 1262, 
1138, 1060, 868, 806, 730, 658 cm-1; FAB-MS (thioglycerol) m/z 293 ([M+], 100), 237 
(13); FAB-HRMS calcd for [M+] C16H13N4S 293.0861, found 293.0876. 
2-(4-Methoxy-2-amino-phenyl)-1H-benzimidazole (3-3e). Synthesized from 3-2e as 
described for 3-3b, 99% yield (FC, hexanes/EtOAc, gradient 3:1 to 2:1). Mp 140-143 °C; 
1H NMR (DMSOd6, 400 MHz) δ 3.74 (s, 3H), 6.27 (dd, J = 8.7, 2.4 Hz, 1H), 6.37 (d, J = 
2.4 Hz, 1H), 7.11-7.18 (m, 2H), 7.32 (br, 2H), 7.45 (d, J = 7.3 Hz, 1H), 7.59 (d, J = 7.3 
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Hz, 1H), 7.76 (d, J = 8.7 Hz, 1H), 12.47 (s, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 54.8, 
99.2, 102.7, 103.7, 110.3, 117.6, 121.0, 121.7, 128.4, 133.2, 142.8, 149.6, 149.7, 152.4, 
160.9; IR (KBr) 3201, 1627, 1614, 1502, 1447, 1431, 1251, 1214, 1026, 735 cm-1; MS 
(70 eV) m/z 239 ([M+], 100), 210 (7), 196 (32); EI-HRMS calcd for [M+] C14H13N3O 
239.1058, found 239.1056. 
2-(4-(N-(2-(1H-Benzimidazol-2-yl)-5-cyanophenyl)sulfamoyl)-phenoxy)acetic Acid 
Ethyl Ester (3-4b). To a solution of amine 3-3b (35 mg, 0.149 mmol) in anhydrous 
pyridine (2 mL) was added (4-chlorosulfonyl-phenoxy)-acetic acid ethyl ester2 3-10 (50 
mg, 0.179 mmol). After stirring at room temperature for 18 h, the reaction mixture was 
poured into aqueous 1 M HCl (20 mL), and the product was extracted twice with ethyl 
acetate. The combined organic extracts were dried with anhydrous MgSO4, filtered, and 
concentrated under reduced pressure. The crude product was purified on silica gel 
(EtOAc/hexanes, gradient 1:3 to 1:1) providing 25 mg (0.053 mmol, 35%) of 
sulfonamide 3-4b as a tan solid. Mp 208-210 °C; 1H NMR (CDCl3, 400 MHz) δ 1.34 (t, J 
= 7.1 Hz, 3H), 4.31 (q, J = 7.1 Hz, 2H), 4.65 (s, 2H), 6.45 (d, J = 9.0 Hz, 2H), 7.34-7.40 
(m, 4H), 7.43 (dd, J = 8.1 Hz, 1.6 Hz, 1H), 7.50 (br, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.83 
(br, 1H), 8.05 (d, J = 1.5 Hz, 1H), 9.93 (s, 1H), 12.18 (s, 1H); 13C NMR 
(CDCl3/acetone-d6, 100 MHz) δ 13.7, 61.2, 64.7, 112.9, 114.2, 117.4, 119.9, 122.3, 123.3 
(br), 125.9, 126.9, 128.7, 131.2, 137.6, 147.9, 160.6, 167.4; IR (KBr) 3313, 3068, 2983, 
2232, 1757, 1595, 1497, 1403, 1277, 1226, 1155, 1095, 555 cm-1; MS (70 eV) m/z 476.1 
([M+], 39), 412.1 (35), 325.1 (37), 233.1(100); EI-HRMS calcd for [M+] C24H20N4O5S 
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476.1154, found 476.1156. 
2-(4-(N-(5-Cyano-2-(5(6)-methoxy-1H-benzimidazol-2-yl)phenyl)sulfamoyl)- 
phenoxy)acetic Acid Ethyl Ester (3-4c). Synthesized from amine 3-3c as described for 
3-4b, 43% yield. Mp 83-85 °C; 1H NMR (CD3OD) δ 1.20 (t, J = 7.1 Hz, 3H), 3.87 (s, 
3H), 4.17 (q, J = 7.1 Hz, 2H), 4.65 (s, 2H), 6.81 (d, J = 9.0 Hz, 2H), 6.97 (dd, J = 8.9, 2.4 
Hz, 1H), 7.11 (d, J = 2.3 Hz, 1H), 7.49 (dd, J = 8.2, 1.6 Hz, 1H), 7.57 (d, J = 8.9 Hz, 1H), 
7.64 (d, J = 9.0 Hz, 2H), 7.92 (d, J = 8.2 Hz, 1H), 7.98 (d, J = 1.5 Hz, 1H); 13C NMR 
(DMSO-d6/CDCl3, 100 MHz) δ 13.6, 55.1, 60.7, 64.5, 111.9, 113.1 (br), 114.2, 117.4, 
119.6, 121.2, 125.5, 127.0, 128.3, 130.9, 137.0, 147.4, 156.4, 160.4, 166.9; IR (KBr) 
3400, 2980, 2231, 1759, 1595, 1496, 1400, 1273, 1200, 1158, 1095, 828, 554 cm-1; MS 
(70 eV) 506.1 ([M+], 47), 263.1 (100); EI-HRMS m/z calcd for [M+] C25H22N4O6S 
506.1260, found 506.1281. 
(4-(2-(1H-Benzimidazol-2-yl)-5-thiazol-2-yl-phenylsulfamoyl)-phenoxy)acetic Acid 
Ethyl Ester (3-4d). Synthesized from amine 3-3d as described for 3-4b, yield 68% (FC, 
EtOAc/hexanes, 1:1). Mp 202-204 °C; 1H NMR (CD3OD/CDCl3 1:1, 400 MHz) δ 1.23 (t, 
J = 7.1 Hz, 3H), 4.20 (q, J = 7.1 Hz, 2H), 4.59 (s, 2H), 6.76 (d, J = 9.0 Hz, 2H), 7.30-7.36 
(m, 2H), 7.57 (d, J = 3.3 Hz, 1H), 7.64-7.71 (m, 2H), 7.74 (d, J = 9.0 Hz, 2H), 7.77 (dd, J 
= 8.3, 1.8 Hz, 1H), 7.91 (d, J = 3.3 Hz, 1H), 7.93 (d, J = 8.3 Hz, 1H), 8.29 (d, J = 1.7 Hz, 
1H); 13C NMR (CD3OD/CDCl3 1:1, 100 MHz) δ 14.2, 62.2, 65.5, 115.1, 119.0, 119.3, 
120.8, 121.9, 123.8, 128.1, 129.9, 132.2, 135.3, 138.6, 144.2, 150.3, 161.7, 168.0, 169.1; 
IR (KBr) 2923, 2852, 2265, 1775, 1758, 1594, 1577, 1497, 1406, 1330, 1151, 654, 573, 
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555 cm-1; MS (70 eV) m/z 534 ([M+], 48), 470 (13), 383 (24), 291 (100); EI-HRMS calcd 
for [M+] C26H22N4O5S2 534.1032, found 534.1023. 
(4-(2-(1H-Benzimidazol-2-yl)-5-methoxy-phenylsulfamoyl)-phenoxy)acetic Acid 
Ethyl Ester (3-4e). Synthesized from amine 3-3e as described for 3-4b, 36% yield (FC, 
hexanes/EtOAc, gradient 2:1 to 1:1). Mp 75-77 °C; 1H NMR (CDCl3, 400 MHz) δ 1.28 (t, 
J = 7.1 Hz, 3H), 3.71 (s, 3H), 4.25 (q, J = 7.1 Hz, 2H), 4.57 (s, 2H), 6.53 (d, J = 8.9 Hz, 
2H), 6.57 (d, J = 2.5 Hz, 1H), 7.20 (d, J = 2.5 Hz, 1H), 7.22-7.26 (m, 2H), 7.42 (d, J = 8.7 
Hz, 1H), 7.50 (br, 2H), 7.52 (d, J = 8.9 Hz, 2H), 7.75 (br, 1H), 9.88 (br, 1H); 13C NMR 
(CDCl3, 100 MHz) δ 14.2, 29.8, 55.5, 61.9, 64.8, 106.8, 110.5, 110.7 (br), 111.0, 114.0, 
118.9 (br), 122.9 (br), 127.4, 128.9, 131.3, 132.8 (br), 138.7, 142.2 (br), 149.8, 160.4, 
161.0, 168.2; IR (KBr) 3367, 2925, 1754, 1596, 1582, 1497, 1409, 1274, 1200, 1143, 
1094, 1082, 585 cm-1; MS (70 eV) m/z 481 ([M+], 46), 330 (21), 238 (100); EI-HRMS 
calcd for [M+] C24H23N3O6S 481.1308, found 481.1297. 
Imidazole derivatives 3-4f-l were synthesized according to procedure A. 
4-(2(1H-Benzimidazol-2-yl)-4-methoxy-phenylsulfamoyl)-phenoxy-acetic Acid Ethyl 
Ester (3-4f). Starting from 50 mg of aldehyde 3-9f (0.13 mmol) and 
1,2-phenylenediamine (15 mg, 0.13 mmol), benzimidazole 3-4f was obtained in 74% 
yield (FC, EtOAc/hexanes, gradient 1:4 to 1:2). Mp 76-78 °C; 1H NMR (CDCl3, 400 
MHz) δ 1.38 (t, J = 7.1 Hz, 3H), 3.83 (s, 3H), 4.36 (q, J = 7.1 Hz, 2H), 4.65 (s, 2H), 6.13 
(d, J = 8.9, 2H), 6.89 (d, J = 2.9 Hz, 1H), 6.95 (d, J = 8.9 Hz, 2H), 6.97 (dd, J = 8.9, 2.9 
Hz, 1H), 7.29-7.34 (m, 2H), 7.43 (br, 1H), 7.71 (d, J = 8.9, 1H), 7.78 (br, 1H), 9.76 (s, 
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1H), 10.68 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 14.2, 55.6, 62.0, 64.4, 111.2 (br), 
112.0, 113.3, 115.6, 119.1 (br), 122.4, 122.6 (br), 123.5 (br), 126.8, 128.5, 129.4, 130.0, 
133.2 (br), 133.6, 149.1, 157.0, 160.0, 168.7; IR (KBr) 3338, 2936, 1757, 1735, 1595, 
1502, 1325, 1279, 1214, 1158, 1094, 831, 566 cm-1; MS (70 eV) m/z 481 ([M+], 38), 238 
(100); EI-HRMS calcd for [M+] C24H23N3O6S 481.1307, found 481.1320. 
2-(4-(N-(2-(1H-Benzimidazol-2-yl)-4-(dimethylamino)phenyl)-sulfamoyl)phenoxy)- 
acetic Acid Ethyl Ester (3-4g). Starting from 131 mg of aldehyde 3-9g (0.32 mmol) and 
1,2-phenylenediamine (26 mg, 0.20 mmol), benzimidazole 3-4g was obtained in 50% 
yield (FC, EtOAc/hexanes, gradient 1:3 to 1:1). Mp 82-84 °C; 1H NMR (CD3OD, 400 
MHz) δ 1.17 (t, J = 7.1 Hz, 3H), 2.89 (s, 6H), 4.13 (q, J = 7.1 Hz, 2H), 4.43 (s, 2H), 6.40 
(d, J = 8.8 Hz, 2H), 6.73 (dd, J = 9.3, 2.7 Hz, 1H), 6.97 (d, J = 3.3 Hz, 1H), 7.20-7.26 (m, 
4H), 7.48 (d, J = 9.3 Hz, 1H), 7.55 (br, 2H); 13C NMR (CDCl3, 100 MHz) δ 14.2, 40.4, 
61.8, 64.3, 109.7, 113.2, 114.1, 122.5, 122.6 (br), 125.1, 126.8, 128.5, 130.0, 148.1, 150.1, 
159.8, 168.6; IR (KBr) 3318, 2981, 2904, 2806, 1752, 1735, 1595, 1510, 1497, 1279, 
1215, 1158, 1094 cm-1; MS (70 eV) m/z 494.2 ([M+], 18), 251.2 (100); EI-HRMS calcd 
for [M+] C25H26N4O5S 494.1624, found 494.1615. 
2-(4-(N-(2-(5(6)-Cyano-1H-benzimidazol-2-yl)-4-methoxyphenyl)sulfamoyl)- 
phenoxy)acetic Acid Ethyl Ester (3-4h). Starting from 72 mg of aldehyde 3-9f 
(0.183mmol) and 3,4-diaminobenzonitrile (26 mg, 0.20 mmol), benzimidazole 3-4h was 
obtained in 53% yield (FC, EtOAc/hexanes, gradient 1:3 to 1:1). Mp 72-74 °C; 1H NMR 
(CD3OD, 400 MHz) δ 1.23 (t, J = 7.1 Hz, 3H), 3.85 (s, 3H), 4.19 (q, J = 7.1 Hz, 2H), 
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4.57 (s, 2H), 6.57 (d, J = 9.0 Hz, 2H), 7.07 (dd, J = 9.0, 2.9 Hz, 1H), 7.29-7.34 (m, 3H), 
7.60 (dd, J = 8.3, 1.5 Hz, 1H), 7.65 (d, J = 9.0 Hz, 1H), 7.72 (br, 1H), 8.06 (br, 1H); 13C 
NMR (acetone-d6, 400 MHz) mixture of two tautomers (ratio 2:3) δ 14.4, 56.0, 61.6, 65.5, 
106.5, 107.0, 112.6, 113.4, 114.9, 116.8, 118.2, 118.5, 119.3, 119.9, 120.6, 124.3, 124.8, 
126.7, 127.5, 129.5, 129.6, 131.5, 131.6, 132.1, 132.2, 133.8, 137.0, 142.6, 145.8, 153.4, 
154.1, 157.2, 161.7, 168.3; IR (KBr) 3283, 2936, 2223, 1752, 1735, 1594, 1503, 1318, 
1293, 1214, 1159, 1094, 832 cm-1; MS (70 eV) m/z 506.1 ([M+], 47), 263.1 (100); 
EI-HRMS calcd for [M+] C25H22N4O6S 506.1260, found 506.1251. 
2-(4-(N-(2-(5(6)-Cyano-1H-benzimidazol-2-yl)phenyl)sulfamoyl)-phenoxy)acetic 
Acid Ethyl Ester (3-4i). Starting from 150 mg of aldehyde 3-9i (0.41 mmol) and 
3,4-diaminobenzonitrile (60 mg, 0.41 mmol), benzimidazole 3-4i was obtained in 50% 
yield (FC, EtOAc/hexanes, gradient 1:2 to 1:1). Mp 169-171 °C; 1H NMR (CD3OD, 400 
MHz) δ 1.21 (t, J = 7.1 Hz, 3H), 4.17 (q, J = 7.1 Hz, 2H), 4.61 (s, 2H), 6.72 (d, J = 9.0 
Hz, 2H), 7.22 (ddd, J = 8.5, 7.5, 1.1 Hz, 1H), 7.44 (ddd, J = 8.5, 7.5, 1.5 Hz, 1H), 7.54 (d, 
J = 9.0 Hz, 2H), 7.58 (dd, J = 8.4, 1.5 Hz, 1H), 7.73 (br, 1H), 7.75 (dd, J = 8.3, 1.0 Hz, 
1H), 7.82 (d, J = 7.9, 1.4 Hz, 1H), 8.02 (br, 1H); 13C NMR (CD3OD, 100 MHz) δ 14.1, 
61.1, 64.9, 105.1 (br), 113.2 (br), 115.7, 119.5, 119.9, 124.0, 127.0 (br), 128.2, 129.2, 
131.2, 132.0, 136.7 (br), 137.5, 141.4 (br), 144.5 (br), 153.4 (br), 161.2, 168.2; IR (KBr) 
3332, 2985, 2220, 1758, 1740, 1594, 1496, 1315, 1154, 1095, 921, 572 cm-1; MS (70 eV) 
m/z 476.2 ([M+], 36), 412.1 (32), 325.1 (34), 233.1 (100); EI-HRMS calcd for [M+] 
C24H20N4O5S 476.1154, found 476.1135. 
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2-(4-(N-(2-(5(6)-Methoxy-1H-benzimidazol-2-yl)phenyl)sulfamoyl)phenoxy)acetic 
Acid Ethyl Ester (3-4k). Starting from 200 mg of aldehyde 3-9i (0.55 mmol) and 
1,2-diamino-4-methoxybenzene (80 mg, 0.58 mmol), benzimidazole 3-4k was obtained 
in 60% yield (FC, EtOAc/hexanes, gradient 1:3 to 1:1). Mp 72-74 °C; 1H NMR (CD3OD, 
400 MHz) δ 1.19 (t, J = 7.1 Hz, 3H), 3.85 (s, 3H), 4.16 (q, J = 7.1 Hz, 2H), 4.58 (s, 2H), 
6.69 (d, J = 9.0 Hz, 2H), 6.91 (dd, J = 8.8, 2.4 Hz, 1H), 7.09 (d, J = 2.2 Hz, 1H), 7.16 
(ddd, J = 8.5, 7.8, 1.2 Hz, 1H), 7.33 (ddd, J = 8.3, 7.4, 1.5 Hz, 1H), 7.49-7.54 (m, 3H), 
7.69-7.75 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 14.0, 55.6, 61.8, 64.7, 113.0 (br), 
114.1, 116.1, 118.2, 121.5, 124.1, 126.2, 128.9, 130.2, 131.2, 136.8, 149.4 (br), 156.8 (br), 
160.6, 168.4; IR (KBr) 3325, 2938, 1752, 1497, 1333, 1283, 1200, 1160, 1148, 1094, 570 
cm-1; MS (70 eV) m/z 481.2 ([M+], 38), 238 (100); EI-HRMS calcd for [M+] 
C24H23N3O6S 481.13076, found 481.13063. 
2-(4-(N-(6-(1H-Benzimidazol-2-yl)benzo[1,3]dioxol-5-yl)sulfamoyl)phenoxy)acetic 
Acid Ethyl Ester (3-4l). Starting from 51 mg of aldehyde 3-9l (0.12 mmol) and 
1,2-phenylenediamine (14 mg, 0.12 mmol), benzimidazole 3-4l was obtained in 44% 
yield (FC, EtOAc/hexanes, gradient 1:3 to 1:1). Mp 168-170 °C; 1H NMR (acetone-d6, 
400 MHz) δ 1.17 (t, J = 7.1, 3H), 4.15 (q, J = 7.1 Hz, 2H), 4.70 (s, 2H), 6.09 (s, 2H), 6.80 
(d, J = 8.6 Hz, 2H), 7.28-7.31 (m, 2H), 7.32 (s, 1H), 7.40 (s, 1H), 7.50 (br, 1H), 7.60 (d, J 
= 8.6 Hz, 2H), 7.76 (br, 1H), 11.78 (br, 1H); 13C NMR (acetone-d6, 100 MHz) δ 14.4, 
61.7, 65.7, 102.8, 103.2, 106.6, 111.2, 112.0, 115.4, 119.4, 123.4, 124.3, 129.9, 132.0, 
132.8, 134.7, 143.1, 145.4, 150.5, 151.6, 162.1, 168.7; IR (KBr) 3372, 2922, 1731, 1597, 
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1499, 1482, 1429, 1328, 1279, 1250, 1161, 1098, 1037, 916, 769 cm-1; MS (70 eV) m/z 
495 ([M+], 32), 252 (100); EI-HRMS calcd for [M+] C24H21N3O7S 495.1100, found 
495.1089. 
General Procedure B: Hydrolysis of Esters 3-4 to Acids 3-5. A solution of the 
corresponding ester (0.085 mmol) and LiOH · H2O (87 mg) in 1.5 mL of 
MeOH/water/THF (1:1:2) was heated at reflux for 3 h. After removing the organic 
solvents under reduced pressure, the residue was acidified with aqueous HCl (1 M) until 
the acid precipitated. The product was filtered off, washed with water, and dried in 
vacuum to give the free acid. 
2-(4-(N-(2-(1H-Benzimidazol-2-yl)-5-cyanophenyl)sulfamoyl)-phenoxy)acetic Acid 
(3-5b). From 3-4b, 92% yield. Mp >210 °C (dec); 1H NMR (CD3OD, 400 MHz) δ 4.60 (s, 
2H), 6.80 (d, J = 8.9 Hz, 2H), 7.33-7.38 (m, 2H), 7.51 (dd, J = 8.2 Hz, 1.3 Hz, 1H), 7.62 
(d, J = 8.9 Hz, 2H), 7.65-7.69 (m, 2H), 7.97 (d, J = 8.2 Hz, 1H), 8.00 (d, J = 1.4 Hz, 1H); 
13C NMR (DMSO-d6, 100 MHz) δ 65.7, 111.7, 114.5, 115.1, 118.7, 121.0, 121.5, 122.6, 
128.1, 128.5, 131.3, 133.6, 137.5, 143.0, 150.2, 160.4, 170.2; IR (KBr) 3071, 2922, 2851, 
2233, 1735, 1594, 1581, 1570, 1497, 1401, 1333, 1274, 1155, 1094, 566, 552 cm-1; 
ESI-MS m/z 449.0918 ([M + H]+); ESIHRMS calcd for [M + H]+ C22H17N4O5S 449.0914, 
found 449.0913. 
2-(4-(N-(5(6)-Cyano-2-(5-methoxy-1H-benzoimidazol-2-yl)-phenyl)sulfamoyl)pheno-
xy)acetic Acid (3-5c). From 3-4c, 85% yield. Mp 112-115 °C; 1H NMR (CD3OD, 400 
MHz) δ 3.89 (s, 3H), 4.61 (s, 2H), 6.82 (d, J = 9.0 Hz, 2H), 6.98 (dd, J = 8.9 Hz, 2.4 Hz, 
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1H), 7.12 (d, J = 2.4 Hz, 1H), 7.51 (dd, J = 8.2 Hz, 1.6 Hz, 1H), 7.58 (d, J = 9.1, 1H), 
7.62 (d, J = 9.0 Hz, 2H), 7.92 (d, J = 8.2 Hz, 1H), 8.00 (d, J = 1.3 Hz, 1H); 13C NMR 
(DMSO-d6, 100 MHz) δ 55.6, 64.9, 96.7, 111.8, 113.6, 114.9, 118.1, 120.1, 121.2, 126.0, 
128.0, 128.6, 130.8, 137.9, 148.1, 156.6, 161.1, 169.3; IR (KBr) 2924, 2851, 2231, 1735, 
1636, 1594, 1570, 1496, 1405, 1272, 1157, 1094, 833, 554 cm-1; MS (70 eV) m/z 478 
([M+], 8), 263.1 (100); EI-HRMS calcd for [M+] C23H18N4O6S 478.0947, found 
478.0946. 
(4-(2-(1H-Benzimidazol-2-yl)-5-thiazol-2-yl-phenylsulfamoyl)-phenoxy)acetic Acid 
(3-5d). From 3-4d, 71% yield. Mp >300 °C; 1H NMR (CD3OD, 400 MHz) δ 4.43 (s, 2H), 
6.73 (d, J = 9.0 Hz, 2H), 7.30-7.36 (m, 2H), 7.58 (d, J = 9.0 Hz, 2H), 7.64-7.71 (m, 3H), 
7.78 (dd, J = 8.1, 1.8 Hz, 1H), 7.89-7.95 (m, 2H), 8.33 (d, J = 1.7 Hz, 1H); 13C NMR 
(DMSO-d6, 100 MHz) δ 66.0, 114.9, 115.9, 117.5, 121.5, 123.1, 128.6, 130.9, 134.4, 
139.0, 144.3, 150.2, 161.7, 166.0, 169.6; IR (KBr) 3401 (br), 1612, 1595, 1577, 1496, 
1426, 1324, 1247, 1162, 1095, 1065, 576 cm-1; FAB-MS (thioglycerol) m/z 507 ([M+], 
24), 349.1 (26), 327 (28), 311 (62), 279 (58), 237 (100); FAB-HRMS calcd for [M+] 
C24H19N4O5S2 507.0797, found 507.0835. 
(4-[2-(1H-Benzimidazol-2-yl)-5-methoxy-phenylsulfamoyl]-phenoxy)acetic Acid 
(3-5e). From 3-4e, 88% yield. Mp 128-131 °C; 1H NMR (CD3OD, 400 MHz) δ 3.72 (s, 
3H), 4.52 (s, 2H), 6.67 (dd, J = 8.8, 2.5 Hz, 1H), 6.73 (d, J = 8.9 Hz, 2H), 7.09 (d, J = 
2.5 Hz, 1H), 7.22-7.26 (m, 2H), 7.54-7.58 (m, 4H), 7.67 (d, J = 8.8 Hz, 1H); 13C NMR 
(CD3OD, 100 MHz) δ 56.0, 65.9, 107.8, 111.3, 111.8, 115.35, 115.42, 124.1, 129.8, 
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130.0, 132.2, 137.9, 139.8, 151.5, 162.5, 162.6, 171.9; IR (KBr) 2934, 1735, 1629, 1611, 
1594, 1581, 1497, 1302, 1261, 1230, 1155, 1092 cm-1; MS (70 eV) m/z 454 ([M + H+] 
100); ESI-TOF-HRMS calcd for [M + H+] C22H20N3O6S 454.1067, found 454.1097. 
2-(4-(N-(2-(1H-Benzimidazol-2-yl)-4-methoxyphenyl)sulfamoyl)-phenoxy)acetic 
Acid (3-5f). From 3-4f, 96% yield. Mp 187-190 °C; 1H NMR (DMSO-d6, 400 MHz) δ 
3.81 (s, 3H), 4.64 (s, 2H), 6.82 (d, J = 8.9 Hz, 2H), 7.06 (dd, J = 9.0, 2.8 Hz, 1H), 
7.29-7.34 (m, 2H), 7.54 (d, J = 8.9 Hz, 2H), 7.59 (d, J = 8.9 Hz, 1H), 7.59 (d, J = 2.9 Hz, 
1H), 7.68 (br, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 55.6, 64.5, 109.4, 111.9, 114.5, 
114.6, 116.8, 117.6, 121.4, 123.3 (br), 128.5, 130.0, 130.6, 149.9, 155.2, 160.6, 169.1; IR 
(KBr) 3067, 2928, 2853, 2736, 1735, 1594, 1582, 1500, 1330, 1233, 1159, 1095, 835 
cm-1; MS (70 eV) m/z 453 ([M+], 18), 238 (100); EI-HRMS calcd for [M+] C22H19N3O6S4 
53.0994, found 453.1009. 
2-(4-(N-(2-(1H-Benzimidazol-2-yl)-4-(dimethylamino)phenyl)-sulfamoyl)phenoxy)ac
etic Acid (3-5g). From 3-4g, 67% yield. Mp >230 °C; 1H NMR (CD3OD, 400 MHz) δ 
2.93 (s, 6H), 4.28 (s, 2H), 6.58 (d, J = 9.3 Hz, 2H), 6.81 (d, J = 7.7 Hz, 1H), 7.23-7.32 
(m, 5H), 7.43 (d, J = 8.8 Hz, 1H), 7.59-7.63 (m, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 
41.4, 67.6, 112.0, 113.8, 116.7, 118.2, 120.5, 121.0, 127.6, 128.6, 143.1, 153.8, 159.7, 
171.0; IR (KBr) 3436, 1686, 1648, 1444, 1384, 1212, 1140, 846, 804, 726 cm-1; MS (70 
eV) m/z 466.1 ([M+], 9), 252.2 (100), 238.1 (100), 184 (44), 125 (46); EI-HRMS calcd 
for [M+] C23H22N4O5S 466.1311, found 466.1326. 
2-(4-(N-(2-(5(6)-Cyano-1H-benzimidazol-2-yl)-4-methoxyphenyl)sulfamoyl)- phen-
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oxy)acetic Acid (3-5h). From 3-4h, 49% yield. Mp 236-239 °C; 1H NMR (DMSO-d6, 
400 MHz) δ 3.85 (s, 3H), 4.54 (s, 2H), 6.57 (d, J = 9.0 Hz, 2H), 7.08 (dd, J = 9.0, 2.9 Hz, 
1H), 7.30 (d, J = 9.0 Hz, 2H), 7.32 (d, J = 2.9 Hz, 1H), 7.61 (dd, J = 8.4, 1.5 Hz, 1H), 
7.65 (d, J = 9.0 Hz, 1H), 7.73 (br, 1H), 8.05 (br, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 
55.6, 64.6, 104.8, 112.4, 114.4, 117.6, 119.5, 122.5, 126.3, 128.5, 130.0, 130.2, 152.8, 
155.5, 160.7, 169.1; IR (KBr) 3293 (br), 3078, 2927, 2224, 1735, 1592, 1502, 1339, 1240, 
1158, 1095, 835, 570 cm-1; ESI-MS m/z 479.10 ([M + H+]); ESI-HRMS calcd for [M + 
H+] C23H19N4O6S 479.1020, found 479.1053. 
2-(4-(N-(2-(5(6)-Cyano-1H-benzimidazol-2-yl)phenyl)sulfamoyl)-phenoxy)acetic 
Acid (3-5i). From 3-4i, 68% yield. Mp 279-281 °C; 1H NMR (DMSO-d6, 400 MHz) δ 
4.69 (s, 2H), 6.92 (d, J = 8.9 Hz, 2H), 7.26 (td, J = 7.4, 1.0 Hz, 1H), 7.50 (td, J = 7.4, 1.4 
Hz, 1H), 7.63-7.62 (m, 4H), 7.81 (br, 1H), 8.05 (d, J = 7.8 Hz, 1H), 8.24 (br, 1H), 12.71 
(br, 1H); 13C NMR (DMSO-d6, 100 MHz) δ 64.6, 104.8, 114.8, 115.3, 119.0, 119.5, 
123.5, 126.3, 126.4, 127.9, 128.8, 130.5, 131.6, 137.1, 153.0, 161.0, 169.2; IR (KBr) 
3300, 2923, 2220, 1741, 1594, 1581, 1492, 1339, 1251, 1160, 1095, 576 cm-1; MS (70 eV) 
m/z 448 ([M+], 10), 234.1 (100); EI-HRMS calcd for [M+] C22H16N4O5S 448.0841, found 
448.0867. 
2-(4-(N-(2-(5(6)-Methoxy-1H-benzimidazol-2-yl)phenyl)sulfamoyl)phenoxy)acetic 
Acid (3-5k). From 3-4k, 90% yield. Mp 133-135 °C; 1H NMR (CD3OD, 400 MHz) δ 
3.83 (s, 3H), 4.53 (s, 2H), 6.68 (d, J = 9.0 Hz, 2H), 6.91 (dd, J = 8.8, 2.4 Hz, 1H), 7.08 (d, 
J = 2.3, 1H), 7.17 (td, J = 7.6, 1.2 Hz, 1H), 7.33 (td, J = 7.5, 1.5 Hz, 1H), 7.46-7.51 (m, 
 103
3H), 7.61 (dd, J = 9.2, 1.0 Hz, 1H), 7.71 (dd, J = 7.9, 1.4 Hz, 1H); 13C NMR (CD3OD, 
100 MHz) δ 56.2, 65.9, 97.5, 114.2, 115.3, 116.9, 119.9, 123.1, 125.6, 128.1, 130.0, 
131.3, 132.2, 133.6, 137.8, 138.3, 150.6, 158.3, 162.4, 171.8; IR (KBr) 3068, 2943, 1636, 
1595, 1492, 1403, 1332, 1302, 1274, 1233, 1155, 824, 573 cm-1; MS (70 eV) m/z 453.2 
([M+], 26), 238 (100); EI-HRMS calcd for [M+] C22H19N3O6S 453.0995, found 453.1032. 
2-(4-(N-(6-(1H-Benzimidazol-2-yl)benzo[1,3]dioxol-5-yl)sulfamoyl)phenoxy)acetic 
Acid (3-5l). From 3-4l, 81% yield. Mp >128 °C (dec); 1H NMR (CD3OD, 400 MHz) δ 
4.34 (s, 2H), 6.00 (s, 2H), 6.57 (d, J = 9.0 Hz, 2H), 7.18 (s, 1H), 7.22 (s, 1H), 7.23-7.28 
(m, 2H), 7.35 (d, J = 9.0 Hz, 2H), 7.55-7.58 (m, 2H); 13C NMR (DMSO-d6, 100 MHz) δ 
67.0, 101.6, 102.6, 106.6, 110.6, 114.9, 115.0, 123.2, 128.8, 130.0, 133.5, 144.3, 149.5, 
151.0, 162.3, 171.1; IR (KBr) 3068, 2923, 1595, 1503, 1484, 1256, 1226, 1157, 1037 
cm-1; MS (70 eV) 467 ([M+], 18), 252.1 (100); EI-HRMS m/z calcd for [M+] 
C22H17N3O7S 467.0787, found 467.0791. 
4-(2-Formyl-4-methoxy-phenylsulfamoyl)-phenoxy]acetic Acid Ethyl Ester (3-9f). A 
solution of 5-methoxy-2-nitrobenzaldehyde4 3-1f (250 mg, 1.38 mmol) in methanol (15 
mL) was hydrogenated at atmospheric pressure in the presence of Pd on activated carbon 
(10 wt %, 50 mg) as catalyst. After completion of the reaction (3 h) the reaction mixture 
was filtered through a pad of Celite and concentrated under reduced pressure. The crude 
amine 3-6f was immediately dissolved in anhydrous pyridine (4 mL), and ethyl 
(4-chlorosulfonyl-phenoxy)-acetate2 3-10 (770 mg, 2.76 mmol) was added. The mixture 
was stirred at room temperature for 3 h, diluted with water (10 mL), and extracted twice 
 104
with ethyl acetate (20 mL). The combined organic extracts were dried with MgSO4 and 
concentrated under reduced pressure. The residue was purified on silica gel (FC, gradient 
hexanes/EtOAc, 2:1 to 1:1) providing 243 mg of aldehyde 3-9f as a tan solid (0.62 mmol, 
45%). Mp 133-135 °C; 1H NMR (CDCl3, 400 MHz) δ 1.28 (t, J = 7.1 Hz, 3H), 3.81 (s, 
3H), 4.25 (q, J = 7.1 Hz, 2H), 4.62 (s, 2H), 6.87 (d, J = 8.9 Hz, 2H), 7.05 (d, J = 3.0 Hz, 
1H), 7.09 (dd, J = 9.0, 3.3 Hz, 1H), 7.67 (d, J = 9.0 Hz, 1H), 7.73 (d, J = 8.9, 2H), 9.73 
(s, 1H), 10.19 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 14.2, 55.7, 61.7, 65.2, 114.6, 119.2, 
121.0, 121.9, 123.4, 129.2, 131.7, 132.6, 155.5, 160.9, 167.6, 194.3; IR (KBr) 2924, 1735, 
1654, 1593, 1580, 1497, 1271, 1163, 1149, 1095 cm-1; MS (70 eV) m/z 393 ([M+], 5), 
241 (11), 129 (100); EI-HRMS calcd for [M+] C18H19NO7S 393.0882, found 393.0869. 
2-(4-(N-(4-(Dimethylamino)-2-formylphenyl)sulfamoyl)phenoxy)acetic Acid Ethyl 
Ester (3-9g). A solution of 2-nitro-5-dimethylamino-benzaldehyde 3-1g (255 mg, 1.3 
mmol) in methanol (50 mL) was hydrogenated at room temperature and ambient pressure 
in the presence of Pd on activated carbon as catalyst (60 mg, 5 wt % Pd). After 
completion of the reaction (TLC), the catalyst was filtered off through a pad of Celite, 
and the solvent was evaporated under reduced pressure. The crude amine (227 mg) was 
immediately dissolved in pyridine (3 mL), and (4-chlorosulfonylphenoxy)-acetic acid 
ethyl ester14 10 (462 mg, 1.66 mmol) was added. After stirring for 2 h at room 
temperature, the reaction mixture was poured into 1 M aqueous HCl (10 mL), and the 
product was extracted twice with ethyl acetate. The combined organic extracts were dried 
with MgSO4, filtered, and concentrated under reduced pressure. The crude product was 
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recrystallized from diethyl ether to give 146 mg (0.36 mmol) of aldehyde 3-9g as a tan 
solid (28% total yield). Mp 85-87 °C; 1H NMR (CDCl3, 400 MHz) δ 1.27 (t, J = 7.1 Hz, 
3H), 2.94 (s, 6H), 4.25 (q, J = 7.1 Hz, 2H), 4.61 (s, 2H), 6.80 (d, J = 3.3 Hz, 1H), 6.84 (d, 
J = 9.3 Hz, 2H), 6.88 (dd, J = 8.8, 3.3 Hz, 1H), 7.57 (d, J = 8.8 Hz, 1H), 7.67 (d, J = 8.8 
Hz, 2H), 9.70 (s, 1H), 9.85 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 14.1, 40.5, 61.6, 65.1, 
114.4, 118.1, 119.0, 121.7, 124.1, 128.1, 129.1, 131.8, 147.1, 160.7, 167.6, 195.1; IR 
(KBr) 3206, 2987, 2812, 1762, 1663, 1591, 1507, 1364, 1204, 1152, 1094, 921, 563 cm-1; 
MS (70 eV) m/z 406.2 ([M+], 68), 163.1 (100), 135.1 (100); EI-HRMS calcd for [M+] 
C19H22N2O6S 406.1199, found 406.1197. 
2-(4-(N-(6-Formylbenzo[1,3]dioxol-5-yl)sulfamoyl)phenoxy)acetic Acid Ethyl Ester 
(3-9l). A solution of 6-nitropiperonal (1.0 g, 5.12 mmol) in ethanol (30 mL) was 
hydrogenated at room temperature and ambient pressure in the presence of Pd on 
activated carbon (200 mg, 5% Pd) as catalyst. After completion of the reaction (2 h), the 
catalyst was filtered through a pad of Celite, and the filtrate was concentrated under 
reduced pressure providing 885 mg of crude 3-7l as a yellow solid. A solution of crude 
amine 3-7l (885 mg) and (4-chlorosulfonyl-phenoxy)acetic acid ethyl ester2 3-10 (1.79 
g, 6.4 mmol) in 22 mL of pyridine was stirred at room temperature for 48 h. The mixture 
was poured into 1 N HCl and extracted twice with ethyl acetate. The combined organic 
extracts were dried with anhydrous MgSO4, filtered, and concentrated under reduced 
pressure. The crude product was purified by silica FC (EtOAc/hexanes, gradient 1:2 to 
1:1) to give 584 mg of intermediate 3-8l as a yellowish solid. A mixture of intermediate 
 106
8l (576 mg, 1.41 mmol) and MnO2 (1.6 g, 18.4 mmol) in 5 mL of CH2Cl2 was stirred 
overnight at room temperature. The reaction mixture was filtered through a pad of Celite 
and concentrated under reduced pressure to give aldehyde 3-9l as a pale yellow solid (378 
mg, 0.928 mmol, 18% yield over three steps). Mp 166-168 °C; 1H NMR (CDCl3, 400 
MHz) δ 1.28 (t, J = 7.1 Hz, 3H), 4.26 (q, J = 7.1 Hz, 2H), 4.64 (s, 2H), 6.04 (s, 2H), 6.90 
(d, J = 9.0 Hz, 2H), 6.91 (s, 1H), 7.27 (s, 1H), 7.79 (d, J = 9.0 Hz, 2H), 9.57 (s, 1H), 
11.07 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 14.3, 61.8, 65.2, 99.6, 102.5, 112.8, 114.8, 
115.9, 129.3, 131.8, 137.9, 143.5, 153.7, 161.1, 167.7, 192.2; IR (KBr) 2913, 1735, 1641, 
1594, 1487, 1361, 1283, 1245, 1225, 1151, 1093, 1038, 574 cm-1; MS (70 eV) 407 ([M+], 
37), 164 (100); EI-HRMS m/z calcd for [M+] C18H17NO8S 407.0675, found 407.0662. 
 




H COSY experiments 
See Figure 3-7 and 3-8. 
3.4.3. Electrode Calibration in Aqueous Solution 
Measurements were performed with an Orion microcombination glass electrode. 
The electrode was calibrated for -log[H3O
+] by titration of a standardized HCl solution 
(Aldrich, 0.1 N volumetric standard) with KOH (Aldrich, 0.1 N volumetric standard) at 
25 oC and 0.1M ionic strength (KCl). The endpoint, electrode potential, and slope were 
determined by using Gran’s method15 as implemented in the software GLEE.16 The 
calibration procedure was repeated three times prior to each pKa value determination. The 
electrode potential was measured with the Corning pH/Ion Analyzer 355 and the emf 
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Figure 3-7. 2D 1H-1H COSY NMR spectrum of 3-4i at –80°C in acetone-d6. Top: 
overview spectrum. Bottom: Connectivity within the central aromatic ring and the 
benzimidazole moiety of the two tautomeric species is shown to the right. 
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Figure 3-8. 2D 1H-1H COSY NMR spectrum of 3-4k at –80°C in acetone-d6. Top: 
overview spectrum. Bottom: Connectivity within the central aromatic ring and the 
benzimidazole moiety of the two tautomeric species is shown to the right. 
 110 
3.4.4. Spectrophotometric Titrations 
The UV/Vis absorption spectra of the ligands were monitored for a series of 
solutions in which -log[H3O
+] was varied between 5 and 11. The emf of each solution 
was directly measured in the UV quartz cell (electrode diameter 3mm) and converted to 
-log[H3O
+] using the Eo and slope, as obtained from the electrode calibration procedure 
described above. The raw spectral and emf data were processed with nonlinear 
least-squares fit analysis using the SPECFIT software package.17 
 
3.4.5. Steady-state Absorption and Fluorescence Spectroscopy 
All sample stock solutions and buffer solutions were filtered through 0.2 mm Nylon 
membrane filters to remove interfering dust particles or fibers. UV/Vis absorption spectra 
were recorded at 25 oC by using a Varian Cary Bio50 UV/Vis spectrometer with 
constant-temperature accessory. Steady-state emission and excitation spectra were 
recorded with a PTI fluorimeter and FELIX software. Throughout the titration the sample 
solution was stirred with a magnetic stirring device. For all titrations the path length was 
1 cm with a cell volume of 3.0 mL. All fluorescence spectra have been corrected for the 
spectral response of the detection system (emission correction file provided by the 
instrument manufacturer) and for the spectral irradiance of the excitation channel (by 
using a calibrated photodiode). Quantum yields were determined by using quinine sulfate 
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CHAPTER IV 
EXCITED STATE INTRAMOLECULAR PROTON TRANSFER IN 2-(2’- 
ARYLSULFONAMIDOPHENYL)BENZIMIDAZOLE DERIVATIVES: 
INSIGHTS INTO THE ORIGIN OF DONOR SUBSTITUENT-INDUCED 
EMISSION ENERGY SHIFTS 
4.1. Introduction 
The systematic studies on substituent effects on the photophysical properties of 
2-(2’-arylsulfonamidophenyl)benzimidazole fluorophores described in Chapter 3 
revealed that the peak emission energies of the methoxy substituted derivatives 4-2 and 
4-3 (Chart 4-1) strongly depended on the substituent attachment position while their 
absorption spectra show very little shift. This observation implies that the substituent 
might influence the fluorescence emission properties of this compound class with 
unexpected complexity. Since the peak emission energy represents a key property of 
fluorescence sensors, it would be worthwhile investigating the origin of this effect to gain 
further insights for rationally tuning and ultimately optimizing the ESIPT sensor 
properties. 
Principally, the observed substituent effects on the fluorescence emission energy 
could be due different polarization of the excited state, specific solute-solvent interactions, 
or perhaps a differential stabilization of the frontier orbital energies depending on the 
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attachment position of the substituents. Solute-solvent interactions could be based on 
simple isotropic dielectric effects, or alternatively, non-isotropic hydrogen-bonding 
interactions with the fluorophore. The latter may be of particular importance since all 
photophysical measurements were performed in aqueous buffer solution, a very polar 
solvent environment that offers potentially strong hydrogen-bonding interactions. For 
example, methoxy and sulfonyl groups may undergo hydrogen bonding interactions 
through their oxygen lone-pair electrons. In addition, because an intramolecular 
proton-transfer process is the key photophysical feature of the investigated systems, 
hydrogen-bonding interactions might play a central role in understanding the observed 

























In order to evaluate the importance of these factors, detailed solvatochromic studies 
were performed with the methoxy-substituted 4-2 and 4-3. Furthermore, to explore 
whether the hydrogen-bonding of the methoxy substituent is important to the 
photophysical properties of 4-2 and 4-3, two additional derivatives of 2-(2’-arylsulfon-
amidophenyl)benzimidazoles with a pyrrole rather than methoxy substituent as donor 
group (4-4 and 4-5) were synthesized and characterized. In pyrrole, the nitrogen lone-pair 
electrons are integral part of an aromatic ring-system and therefore not readily available 
for hydrogen-bonding interactions with the solvent. 
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The procedures for the synthesis of parent compound 4-1, sulfonyl chloride 4-14, 
and the methoxy-substituted derivatives 4-2 and 4-3 were already described in Chapters 2 
and 3, respectively.1,2 The pyrrole-substituted derivatives 4-4 and 4-5 were synthesized 
using a similar approach, which included copper-mediated oxidative coupling of the 
corresponding nitro-benzaldehydes (4-8 and 4-9) with o-phenylenediamine to form 
benzimidazoles 4-10 and 4-11, respectively, followed by reduction of the nitro group and
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Table 4-1: Protonation Constants and Photophysical Data of Benzimidazole Derivatives 4-1b-4-5b in Aqueous Solutiona 
 
Species Data 4-1bb 4-2b 4-3b 4-4b 4-5b 
pKa1 [L
2-][H+]/[LH-] 8.04 ± 0.03 8.34 ± 0.02 7.60 ± 0.01 7.69 ± 0.01 7.28 ± 0.01 
pKa2 [LH
-][H+]/[LH2] 4.50 ± 0.04 4.54 ± 0.05 4.79 ± 0.01 4.32 ± 0.05 4.44 ± 0.02 











 excitationd λmax(nm) 296 297 330 337 (sh) 310 
 emissiond λmax(nm) 418 444 396 438 404 
 quantum yielde 0.26 0.27 0.06 0.32 0.32 
 Stokes shift (cm-1) 6470 7420 5140 6660 4660 
LH- absorptionc λmax(nm) 299 (1.23) 298 (1.00) 305 (1.57) 270 (2.36) 316 (1.72) 
     303 (sh)  
 excitation λmax(nm) 300 295 308 n/a 321 
 emission λmax(nm) 460 497 437 485 444 
 Stokes shift (cm-1) 11,700 13,430 9640 12,380 9120 
 quantum yielde 0.23 0.14 0.17 0.16 0.13 
LH2 absorptionc λmax(nm) 290 (1.31) 292 (1.07) 303 (1.69) 272 (2.35) 316 (1.79) 
 
[a] 0.1 M KCl, 25 °C. [b] Data from ref 1. [c] From deconvolution analysis, molar extinction coefficient [104 L mol-1 cm-1] in 
parentheses. [d] pH 11.20, 0.1 M KCl. [e] Quinine sulfate in 1 N H2SO4 as standard. 
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reaction of the anilines 4-12 and 4-13 with sulfonyl chloride1 4-14 to give the final 
fluorophores 4-4 and 4-5. The precursors 4-8 and 4-9 were synthesized via 
palladium-catalyzed amination of bromo-benzene 4-6 and 4-7, respectively. The ethyl 
esters 4-1a through 4-5a were used for solvatochromic studies in organic solvents, while 
the corresponding carboxylic acids 4-1b through 4-5b were used for the photophysical 
characterization in aqueous solution. The hydrolysis of the corresponding ethyl esters was 
accomplished under mild conditions with lithium hydroxide in a methanol-water-THF 
solvent mixture. 
 
4.2.2. Protonation Equilibria 
The protonation equilibria of each compound was investigated by UV-vis titration 
with –log[H3O
+] ranging between 5 to 11. The absorption spectra of deprotonated species 
L2- and monoprotonated species HL- were deconvoluted from UV-vis traces obtained 
from the spectrophotometric titrations. The pKa values obtained from non-linear 
least0squares fitting procedures and all spectral data are listed in Table 4-1. The pKa1 is 
associated with a large bathochromic shift of the absorption maximum, and can be 
therefore readily assigned to deprotonation of the sulfonamide group. In contrast, pKa2 
results only in small absorption changes and can be therefore assigned to deprotonation of 
the carboxylic acid group, which is electronically decoupled from conjugated π-system of 
the fluorophore. 
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As evident from Table 4-1, the pKa values of the derivatives containing the electron 
donating substituent in the para-position relative to the sulfonamide group (4-2b: 8.34, 
4-4b: 7.69) are higher than those of the meta-substituted derivatives (4-3b: 7.60, 4-5b: 
7.28). This observation can be readily rationalized by weighing the contributions of 
substituent resonance stabilization and inductive effects as already discussed in Chapter 3. 
Furthermore, the pKa values of the pyrrole-substituted derivatives 4-4b and 4-5b are 
significantly lower compared to their methoxy-substituted analogs, suggesting that the 
pyrrole ring acts primarily as σ-acceptor rather than π-donor moiety in the ground state. 
 
4.2.3. UV-vis Spectra 
While the methoxy substituents have no significant effect on the absorption spectra, 
the 4-pyrrolyl-substituted derivative 4-4b revelaed an additional strong absorption band 
centered around 270 nm (Figure 4-1), thus indicating significant electronic interactions 
between pyrrole ring and fluorophore π-system. For 5-pyrroly-substituted derivative 4-5b, 
the peak absorptions are significantly red-shifted (HL-: 316 nm, L2-: 340 nm) compared to 
the parent compound 4-1b (HL-: 299 nm, L2-: 329 nm), but the shape of the absorption 
spectra are qualitatively quite similar. Interestingly, an additional low-energy band 
centered around 365 nm was observed for both 4-3b and 4-5b, which is presumably due 




Figure 4-1. Deconvoluted UV-vis absorption spectra (left) and normalized fluorescence 
emission spectra (right) of fluorophore: (a) 4-1b, (b) 4-2b, (c) 4-3b, (d) 4-4b, and (e) 
4-5b in aqueous solution (0.1 M KCl, 25 oC). UV-vis traces for the species with 
protonated (-) and deprotonated (---) sulfonamide group were obtained through 
deconvolution of a series of spectra with pH ranging between 6 and 10. The emission 
spectra were directly recorded at pH 6.0 (-) and 11.0 (---) without deconvolution analysis 
(excitation at the isosbestic point). 
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4.2.4. Fluorescence Spectra 
For all derivatives, deprotonation of the sulfonamide group is associated with a 
hypsochromic shift in the emission spectra due to disruption of the ESIPT process. 
However, compared to parent compound 4-1b, the peak emissions of the 5-substituted 
derivatives 4-2b and 4-4b are red-shifted while those of the 4-substituted derivatives 4-3b 
and 4-5b were blue-shifted.  
As outlined in Section 4.1, differences in the strength of hydrogen-bonding 
interactions of the methoxy substituents might be a key contributor to the divergent peak 
emission shifts. If the methoxy group would act primarily as a strong π-donor, one of the 
two oxygen lone pairs would be involved in π-conjugation with the fluorophore ring 
system, while the other lone pair would be available for hydrogen bonding interactions 
with the solvent. However, if hydrogen-bonding interaction with the second lone pair 
outweighs resonance stabilization, the methoxy group would rotate out of plane and thus 
acting solely as σ-acceptor. As discussed above, the pyrrole-substituted derivatives 4-4b 
and 4-5b showed qualitatively the same trends in the emission spectra compared to the 
methoxy-substituted analogs 4-2b and 4-3b. Because the pyrrolyl group does not have a 
lone pair available for hydrogen bonding, these data strongly suggest that 
hydrogen-bonding interactions of the methoxy group are not critical for the interpretation 
of the divergent emission energy shifts. Having excluded this possibility, detailed 
solvatochromic shift studies were performed to further explore the origin of the peculiar 
substituent effects on the fluorescence emission. 
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4.2.5. Solvatochromic Shift Studies 
Solvatochromic shift measurements in a set of solvents with varying polarity 
represent a powerful approach to probe the extent and nature of solvent-solute 
interactions. The technique has been widely used as a major tool to investigate the 
photophysical properties of fluorophores, and is particularly suitable to determine 
changes in dipole moments between ground and excited state, and to probe the 
importance of ground and excited state hydrogen bonding interactions with solvent 
molecules.3 Several theoretical and empirical approaches have already been established to 
explore these complex interactions, including the Onsager’s reaction field model,4 
Reichardt’ empirical solvent polarity scale ET(30),
9 and Kamlet-Taft’s empirical solvent 
index.5 
For the following solvatochromic shift studies, the absorption and emission spectra 
of the ethyl ester derivatives of all five fluorophores were recorded in a set of 14 organic 
solvents. In aqueous buffer, the corresponding carboxylic acid derivatives were used. At 
neutral pH, the acid moiety is fully dissociated, thus significantly increasing the solubility 
of the fluorophores in aqueous solution. A compilation of all solvent parameters and peak 
energies is provided in Appendix A.  
The normalized absorption and emission spectra shown Figure 4-2 illustrate the 
trends in solvatochromic shifts for the methoxy-substituted derivatives 4-2 and 4-3, as 
well as the unsubstituted parent compound 4-1. All fluorophores showed minor changes 
in their peak absorption, suggesting very small dipole moment changes between the 
 123
ground and Frank-Condon excited state. Furthermore, with increasing solvent polarity, 
the peak absorption energy underwent a small blue-shift, an observation that is consistent 
with a decrease of the molecular dipole moment upon photoexcitation. Interestingly, 
protic solvents revealed a stronger solvatochromic shift than would be expected solely 
based on their polarity (dielectric constant), suggesting that hydrogen-bonding 
interactions are at least partially responsible for the degree of emission shift and cannot 
be entirely ignored in this system. For a more detailed solvatochromic shift analysis, all 
three approaches mentioned above were utilized to further investigate the origin of the 








Figure 4-2. Normalized UV-vis absorption (left) and fluorescence emission spectra (right, 
excitation at peak absorption energy) for derivatives (a) 4-1a, (b) 4-2a, and (c) 4-3a, in 
selected organic solvents illustrating the solvatochromic shift behavior (solvent legend : 
no. 1 1,4-dioxane, no. 6 ethylacetate, no. 10 butyronitrile, no. 11 acetonitrile, no. 13 
ethanol). For comparison, the fluorescence emission spectra of the water-soluble 
compounds 4-1b, 4-2b, and 4-3b in aqueous buffer (pH 6.0, 0.1 M KCl) have been also 
included (dashed traces).  
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4.2.5.1. Onsager’s Reaction Field Model 
This model treats the solvent as homogeneous, polarizable medium and assumes the 
solute is located in a cavity of defined size surrounded by solvent molecules. The 
permanent dipole moment of the solute will then polarize the solvent molecules in close 
proximity and thus induce an opposing dipole moment that will electrostatically interact 
with the solute, thus resulting in a net stabilization. 10 If the dipole moment of the solute 
changes upon photoexcitation, the ground and excited state will be differently stabilized, 
which gives rise to the solvatochromic shift behavior. Therefore, this model is used to 
analyze the solvatochromic shift mainly caused by isotropic electrostatic solute-solvent 
interactions based on equation 4-1.6 
 
























As shown in Figure 4-3, for derivatives 4-1, 4-2 and 4-3, linear regression analysis 
of peak emission energies versus Onsager’s solvent polarity parameters f yielded a good 
correlation in case of all nonprotic solvents, while protic solvents, such as butanol, 
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ethanol, methanol and water revealed emission energies significantly outside of the linear 
regression range. Most importantly, all derivatives showed a similar pattern, suggesting 
that the substituent attachment position is not responsible for the deviation observed in 
protic solvents. If only nonprotic solvents are considered, a relatively flat slope is 
obtained from the regression analysis, indicating very little dipole moment changes 
between the ground and excited-states of all three derivatives. Conclusively, given the 
lack of significant solvatochromic shifts, dipole moment changes upon photoexcitation 
are not the primary reason for the divergent emission shifts observed in donor-substituted 
derivatives. Nevertheless, it is noteworthy that hydrogen-bonding interactions appear to 
promote some of the solvatochromic shift behavior; however, the overall influence is 
significantly smaller compared to the emission energy shift observed for the para vs 






Figure 4-3. Correlation of the peak emission energies of derivative 4-1a, 4-2a, and 4-3a 
with the solvent polarity parameter f (ε,n). The plotted linear regression line does not 
include acetonitrile (no. 11) and any protic solvents (nos. 12-15). The solvent numbering 
scheme and values for f (ε,n) are given in Table A-1 provided with the Appendix A. 
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4.2.5.2. Reichardt’s ET(30) Solvent Scale 
This is an empirical approach based on the negative solvatochromism of an 
N-phenolate betaine dye.9 Because the betaine dye is known to exhibit stronger spectral 
shifts in solvents with hydrogen-bonding donor properties, Reichardt’s ET
N(30) solvent 
scale already includes specific solvent acidity effects, which can be directly interpreted as 
the hydrogen-bond donating property of the solvent. As illustrated with Figure 4-4 and 
the data compiled in Table 4-2, for all derivatives, linear regression analysis with peak 
emission energies versus Reichardt’s ET
N(30) solvent scale gives a good correlation over 
the entire range of solvents, including the carboxylic acids 4-1b-4-5b measured in 
aqueous buffer. This result further confirmed that the hydrogen-bond interaction with 
solvent molecules plays an important role in the solvatochromic shift behavior of this 
fluorophore system. Interestingly, the calculated slopes for all derivatives are similar, 
indicating again that the substituent attachment position is not important for the observed 
solvatochromic shift. However, the calculated intercepts from the linear regression of the 
4-substituted derivatives 4-3 and 4-5 are larger than that of the parent compound 4-1, 
while those of the 5-substituted derivatives 4-2 and 4-4 are smaller, suggesting that the 
origin of the divergent emission shift might be due to differences in the electronic 




Figure 4-4. Linear regression analysis of the solvatochromic emission shifts according to 
Reichardt's ET
N(30) empirical solvent polarity scale. (a) Linear correlation of the peak 
emission energies of the methoxy-substituted compounds 4-2a and 4-3a. (b) Linear 
correlation for compounds 4-4a and 4-5a. For ease of comparison, the data for the 




Table 4-2: Fitted Parameters for the Regression Analysis of the Solvatochromic Peak Fluorescence Emission Shifts According to the 
ET(30) Empirical Solvent Model
a 
 
parameter  4-1a 4-2a 4-3a 4-4a 4-5a 
slope [cm-1] 1605 ±148 1882 ± 147 1941 ± 166 1597 ± 127 1803 ± 145 
intercept [cm-1] 20,140 ± 68 18,222 ± 68 21,114 ± 76 18,966 ± 58 20,658 ± 67 
correlation coeff 0.949  0.962  0.956  0.961  0.960 
 
[a] Linear regression includes all 15 solvents listed in Appendix A. 
 
Table 4-3: Fitted Parameters for the Multiple Regression Analysis of the Solvatochromic Peak Fluorescence Emission Shifts 
According to the Kamlet-Abboud-Taft Empirical Solvent Model 
 
parameter  4-1a 4-2a 4-3a 4-4a 4-5a 
dielectric interactions (s, [cm-1]) 369 ± 198 580 ± 262 386 ± 208 304 ± 182 388 ± 212 
H-bonding donor (a, [cm-1]) 842 ± 91 910 ± 121 977 ± 96 824 ± 84 904 ± 98 
H-bonding acceptor (b, [cm-1]) 224 ± 199 540 ± 263 322 ± 209 349 ± 183 330 ± 214 
υ0 [cm
-1] 20,221 ± 163  18,131 ± 216 21,215 ± 171 19,010 ± 150 20,727 ± 175 
correlation coeff r  0.976 0.968 0.980 0.977  0.976 
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4.2.5.3. Kamlet-Abboud-Taft’s Solvent Index (KAT) 
KAT solvent index is a comprehensive empirical approach, which covers a wide 
range of solvent properties, such as dielectric effects, hydrogen-bonding properties, 
acidity and basicity as shown expressed by equation 4-2.  
 
βαπνν ⋅+⋅+⋅+= bas *0             Eq. 4-2 
 
where π* is a measure for the dipolarity and polarizability of the solvent, α and  
refer to the solvent’s ability to act as hydrogen-bond donor and acceptor, respectively. A 
multiple linear regression analysis of the emission energy (ν ) versus three parameters π*, 
α and β will give s, a, and b as the corresponding fitted parameters as well as the 
absorption or emission energy in vacuum (ν0). A compilation of the corresponding 
solvent parameters for each of the 15 solvents used in the regression analysis is provided 
in Appendix A Table A-1.7 
As evident from the data listed in Table 4-3, multiple linear regression analysis 
yielded good correlations for all the derivatives. It is immediately apparent, that the fitted 
parameter a is significantly larger than the other two solvent parameters, thus indicating 
that hydrogen-bonding interactions of the solvent dominate the solvatochromic shift 
behavior of this compound class. Interestingly, the emission energies in vacuum of 
4-substituted derivatives 4-3 and 4-5 are higher than that of the parent compound 4-1 
while those of the 5-substituted derivatives 4-2 and 4-4 are lower. This result further 
 132
confirms that the origin of donor substituent-induced emission energy shifts is most likely 
due to differences in their electronic structure induced by the different attachment 
positions of the donor substituents. 
There are principally several hydrogen-bonding acceptors on the fluorophore 
framework available: the oxygen atoms of the sulfonamide moiety, the sp2 hybridized 
benzimidazole nitrogen, as well as the oxygen atom of –OR2 moiety and the methoxy 
substituent (Chart 4-1). Above studies already demonstrated that hydrogen-bonding 
interactions with the methoxy group have little influence on the solvatochromic shift 
behavior. Because the benzimidazole nitrogen is already occupied with formation of the 
intramolecular sulfonamide hydrogen-bond, possible moieties that may undergo 
hydrogen bonding interactions with solvent molecules and thus cause the observed 
solvatochromic shifts are reduced to the oxygen atoms of the sulfonamide group or the 
oxygen atom of the –OR2 substituent. Moreover, previous studies on 
2-(2'-tosylaminophenyl)benzimidazole revealed a similar solvatochromic shift behavior 
as observed for above derivatives.8 Therefore, potential hydrogen bonding candidates of 
the fluorophore framework are further reduced to the oxygen atoms of the sulfonamide 
moiety, which, due to its close proximity, would be expected to have some influence on 
the excited state proton transfer process. 
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Table 4-4: Experimental and Calculated Vertical Excitation and Emission Energies (eV) 
for 4-1c-4-3c. 
 
Parameter 4-1c 4-2c 4-3c 
Excitation [eV] 
INDO-SCI 4.12 4.11 4.09 
f
a 0.355 0.360 0.492 
Mge [D]
b 4.8 4.8 5.6 
exptc 4.13 4.20 4.07 
Emission [eV] 
INDO-SCI 2.61 2.52 2.66 
f
a 0.447 0.462 0.429 
Mge [D]
b 6.7 6.9 6.5 
exptc 2.70 2.49 2.84 
gas-phase fitd 2.51 2.25 2.63 
 
[a] Oscillator strength. [b] Transition dipole moment. [c] Measured in aqueous solution, 
0.1 M ionic strength (KCl). [d] Extrapolated gas-phase values from Kamlet-Abboud-Taft 
empirical solvent model. 
 
 
Table 4-5: HFCIS/3-21+G(d,p)//INDO-SCI Computed Ground and Excited State Dipole 
Moments and Their Differences for 4-1c-4-3c. 
 
Parameter 4-1c 4-2c 4-3c 
Gas Phase 
µg [D] 13.4 14.4 15.2 
µe [D] 11.1 12.8 12.7 
µ∆ [D] -2.2 -1.6 -2.5 
Solution Phase (MeOH) 
µg [D] 15.6 16.9 17.4 
µe [D] 13.2 15.0 15.1 
µ∆ [D] -2.4 -1.9 -2.4 
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4.3. Quantum Chemical Calculations 
Quantum chemical calculations were carried out to investigate the substituent 
effects on emission shifts. In this case, methoxy-substituted compounds were preferred 
since they show more pronounced emission shifts than the corresponding 
pyrrole-substituted compounds. To simplify the calculations, the carboxymethyl 
substituent (OCH2-COOR’) was replaced by a methoxy group. Therefore, the molecules 
used in all calculations were 4-1c, 4-2c and 4-3c (Chart 4-1).  
The calculated photophysical data are shown in Table 4-4 and 4-5. Consistent with 
the solvatochromic analysis, the dipole moment change upon excitation is small for all 
derivatives. The HOMO and LUMO isosurface diagram (Figure 4-5) shows that while the 
5-position on the central benzene ring contributes strongly to the HOMO but weakly to 
the LUMO, the 4-position contributes strongly to the LUMO but weakly to the HOMO. 
Therefore, the electron-donating group methoxy on 5-position increases the HOMO 
energy and does not affect LUMO energy, thus decreasing the HOMO-LUMO gap and 
resulting in a red-shifted emission. The methoxy group in the 4-position results therefore 





Figure 4-5. Energy level diagram for the frontier orbitals of the phototautomer of 




In this chapter, solvatochromic shift analysis and theoretical calculations were 
performed to investigate the photophysical properties of the ESIPT fluorophores, in 
particular the effect of substituents on the fluorescence emission. Both, experimental and 
theoretical studies showed that the dipole moment change upon excitation is small for 
2-(2’-arylsulfonamidophenyl)benzimidazole fluorophores. The observed negative 
solvatochromic shift is dominated by hydrogen-bonding in protic solvents through the 
oxygen atoms of the sulfonamide moiety. The origin of the substituent effects on the 
emission shift is solely due to the HOMO-LUMO energy difference, whereas different 
hydrogen-bonding modes of methoxy group on central benzene ring can be excluded. 
These studies provide a detailed understanding of the photophysical properties of ESIPT 
fluorophores and may also offer further guidelines for rationally tuning their properties. 
 
4.5. Experimental Section 
4.5.1. Synthesis.  
Sulfonyl chloride 4-14 and fluorophores 4-1a/b, 4-2a/b, and 4-3a/b were 
synthesized following published procedures.2 NMR: δ in ppm vs SiMe4 (0 ppm, 
1H, 400 
MHz), br = exchange broadened signal. MS: selected peaks; m/z. Melting points are 
uncorrected. Flash chromatography (FC): Merck silica gel (240-400 mesh). TLC: 0.25 
mm, Merck silica gel 60 F254, visualizing at 254 nm or with 2% KMnO4 solution. 
2-Nitro-5-pyrrol-1-yl-benzaldehyde (4-8). In a Schlenck tube 2-nitro-5-bromobenz-
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aldehyde9 (4-6, 500 mg, 2.17 mmol), freshly distilled pyrrole (133 mg, 1.97 mmol, 0.137 
mL), palladium acetate (4.4 mg, 0.02 mmol), xantphos (34 mg, 0.059 mmol), and 
potassium carbonate (817 mg, 5.91 mmol) were mixed in 5 mL of o-xylene. The mixture 
was degassed and the tube refilled with argon. After heating at 120 °C overnight, the 
mixture was cooled to room temperature, washed with water, and extracted with EtOAc. 
The combined organic extracts were dried over anhydrous MgSO4 and concentrated 
under reduced pressure. The residue was purified on silica gel (FC, EtOA-hexanes, 2:9) 
providing 367 mg (1.7 mmol, 78% yield) of 4-8 as a yellow solid: mp 74-76 °C. Rf 0.47 
(EtOAc-hexanes, 2:9); 1H NMR (CDCl3, 400 MHz) δ 6.46 (t, J = 2.2 Hz, 2H), 7.22 (t, J 
= 2.2 Hz, 2H), 7.69 (dd, J = 8.9, 2.6 Hz, 1H), 7.89 (d, J = 2.6 Hz, 1H), 8.27 (d, J = 8.9 
Hz, 1H), 10.53 (s, 1H); MS (70 eV) m/z 216 ([M+], 100), 186 (31), 158.1 (23), 141.1 (52), 
130 (30), 115.1 (38); EI-HRMS calculated for [M+] C11H8N2O3 216.05349, found 
216.05407. 
 
2-(2-Nitro-5-pyrrol-1-yl-phenyl)-1H-benzimidazole (4-10). A mixture of aldehyde 4-8 
(200 mg, 0.925 mmol), o-phenylenediamine (120 mg, 1.11 mmol), acetic acid (0.08 mL, 
1.4 mmol), and copper(II) acetate monohydrate (183 mg, 0.92 mmol) in 20 mL of 
ethanol-water (1:1) was refluxed overnight. The reaction mixture was cooled to room 
temperature and quenched by addition of 10 mL of concentrated aqueous NH4OH. The 
mixture was extracted with EtOAc, and the combined organic extracts were dried 
(MgSO4) and concentrated under reduced pressure. The residue was purified on silica gel 
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(FC, EtOAc:hexanes, 1:3), affording 85 mg (0.28 mmol, 30% yield) of benzimidazole 
derivative 4-10 as a tan solid: mp >210 °C dec; Rf 0.18 (EtOAc-hexanes, 1:3); 
1H NMR 
(DMSO-d6, 400 MHz) δ 6.39 (t, J = 2.2 Hz, 2H), 7.27 (br, 2H), 7.64 (br, 2H), 7.64 (t, J = 
2.2 Hz, 2H), 7.97 (dd, J = 8.9, 2.5 Hz, 1H), 8.150 (d, J = 8.9 Hz, 1H), 8.154 (d, J = 2.5 
Hz, 1H), 13.02 (s, 1H); MS (70 eV) m/z 304.1 ([M+], 100), 287.1 (83), 262.1 (23), 257 
(12), 155.1 (15), 141 (15); EI-HRMS calculated for [M+] C17H12N4O2 304.0960, found 
304.1004. 
2-(1H-Benzimidazol-2-yl)-4-pyrrol-1-ylphenylamine (4-12). A solution of 4-10 (80 mg, 
0.26 mmol) in 8 mL of ethanol was hydrogenated at atmospheric pressure in the presence 
of Pd on activated carbon (5 wt %, 13 mg) as catalyst. Upon completion of the reaction 
(TLC) the mixture was filtered through a pad of Celite and concentrated under reduced 
pressure, affording 60 mg (0.22 mmol, 84% yield) of amine 4-12 as a tan solid: mp 
163-165 °C; Rf 0.65 (EtOAc-hexanes, 1:2); 
1H NMR (DMSO-d6, 400 MHz) δ 6.24 (t, J = 
2.2 Hz, 2H), 6.91 (d, J = 8.7 Hz, 1H), 7.21-7.23 (m, 2H), 7.25 (t, J = 2.2 Hz, 2H), 7.37 
(dd, J = 8.7, 2.5 Hz, 1H), 7.56-7.64 (m, br, 2H), 8.00 (d, J = 2.5 Hz, 1H); MS (70 eV) m/z 
274.1 ([M+], 100), 246.1 (8), 137 (9); EI-HRMS calculated for [M+] C17H14N4 274.1219, 
found 274.1208. 
{4-[2-(1H-Benzimidazol-2-yl)-4-pyrrol-1-ylphenylsulfamoyl]phenoxy}acetic acid 
ethyl ester (4-4a). A solution of amine 4-12 (54 mg, 0.20 mmol) and ethyl (4-chloro-
sulfonylphenoxy) acetate1 (4-14, 66 mg, 0.24 mmol) in anhydrous pyridine (1 mL) was 
stirred for 2 h at room temperature. The reaction mixture was diluted with aqueous HCl 
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(1 M, 5 mL) and extracted twice with EtOAc (10 mL). The combined organic extracts 
were dried with MgSO4 and concentrated under reduced pressure. The crude product was 
purified on silica gel (FC, EtOAc-hexanes, 1:2), providing 45 mg (0.087 mmol, 44% 
yield) of 4-4a as a tan solid: mp >106 °C dec; Rf 0.25 (EtOAc-hexanes, 1:2); 
1H NMR 
(CDCl3, 400 MHz) δ 1.23 (t, J = 7.1 Hz, 3H), 4.17 (q, J = 7.1 Hz, 2H), 4.65 (s, 2H), 6.21 
(d, J = 8.9 Hz, 2H), 6.36 (t, J = 2.1 Hz, 2H), 7.06-7.12 (m, 4H), 7.32-7.37 (m, 2H), 
7.40-7.47 (m, 3H), 7.81 (br, 1H), 7.83 (d, J = 9.5 Hz, 1H), 9.98 (s, br, 1H), 11.20 (s, br, 
1H); MS (70 eV) m/z 516.1 ([M+], 48), 273.1 (100); EI-HRMS calculated for [M+] 
C27H24N4O5S 516.1467, found 516.1417. 
{4-[2-(1H-Benzimidazol-2-yl)-4-pyrrol-1-ylphenylsulfamoyl]phenoxy}acetic Acid 
(4-4b). Ester 4-4a (40 mg, 0.077 mmol) was dissolved in THF (1.5 mL), and a solution of 
LiOH·H2O (97 mg) in MeOH-water (1:1, 3 mL) was added. The resulting mixture was 
heated under reflux for 4 h and then cooled to room temperature. After removal of the 
organic solvent under reduced pressure, the reaction mixture was diluted with water (2 
mL). Aqueous HCl (1 M) was added until the product started to precipitate. The product 
was filtered off, washed with little water, and dried in vacuum, affording 38 mg (0.082 
mmol, 99%) of acid 4-4b as a tan solid: mp >130 °C dec; Rf 0.44 (MeOH-CH2Cl2, 1:3); 
1H NMR (DMSO-d6, 400 MHz) δ 4.68 (s, 2H), 6.31 (t, J = 2.2 Hz, 2H), 6.92 (d, J = 9.0 
Hz, 2H), 7.33-7.37 (m, 2H), 7.41 (t, J = 2.2 Hz, 2H), 7.67-7.70 (m, 4H), 7.72 (br, 2H), 
8.26 (s, 1H), 13.22 (br, 2H); MS (70 eV) m/z 488.1 ([M+], 23), 273.1 (100), 299 (79); 
EIHRMS calculated for [M+] C25H20N4O5S 488.1154, found 488.1141. 
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2-Nitro-4-pyrrol-1-yl-benzaldehyde (4-9). 2-Nitro-4-bromobenzaldehyde10 (4-7, 250 
mg, 1.09 mmol) was converted to pyrrole derivative 4-9 as described for the synthesis of 
4-8, yielding 102 mg (0.47 mmol, 43% yield) of 4-9 as a yellow solid: mp 113-115 °C; Rf 
0.18 (EtOAc-hexanes, 1:9); 1H NMR (CDCl3, 400 MHz) δ 6.47 (t, J = 2.0 Hz, 2H), 7.22 
(t, J = 2.0 Hz, 2H), 7.76 (dd, J = 8.5, 2.2 Hz, 1H), 8.07 (d, J = 2.2 Hz, 1H), 8.09 (d, J = 
8.5 Hz, 1H), 10.40 (s, 1H); MS (70 eV) m/z 216.1 ([M+], 100), 186.1 (64), 141 (78), 
130.1 (50), 115.1 (42); EI-HRMS calculated for [M+] C11H8N2O3 216.0535, found 
216.0544. 
2-(2-Nitro-4-pyrrol-1-yl-phenyl)-1H-benzimidazole (4-11). Aldehyde 4-9 (102 mg, 
0.47 mmol) was converted to benzimidazole derivative 4-11 as described for 4-10, 
providing 114 mg (0.37 mmol, 80% yield) of 4-11 as a yellow solid: mp >200 °C (dec); 
Rf 0.26 (EtOAc-hexanes, 1:2); 
1H NMR (DMSO-d6, 400 MHz) δ 6.37 (t, J = 2.0 Hz, 2H), 
7.23-7.26 (m, 2H), 7.58-7.62 (m, 2H), 7.65 (t, J = 2.0 Hz, 2H), 8.07 (d, J = 8.5 Hz, 1H), 
8.13 (dd, J = 8.5, 2.4 Hz, 1H), 8.31 (d, J = 2.4 Hz, 1H), 13.06 (s, br, 1H); MS (70 eV) 
m/z 304.1 ([M+], 100), 287.1 (18), 141 (15). EI-HRMS calculated for [M+] C17H12N4O2 
304.0960, observed 304.0937. 
2-(1H-Benzimidazol-2-yl)-5-pyrrol-1-yl-phenylamine (4-13). Nitrocompound 4-11 
(110 mg, 0.36 mmol) was reduced to amine 4-13 as described for the synthesis of 4-12, 
yielding 76 mg of 4-13 (0.28 mmol, 77% yield) as a tan solid: mp 253-255 °C; Rf 0.67 
(EtOAc-hexanes, 1:1); 1H NMR (DMSO-d6, 400 MHz) δ 6.28 (t, J = 2.1 Hz, 2H), 6.90 
(dd, J = 8.5 Hz, 2.4 Hz, 1H), 6.98 (d, J = 2.4 Hz, 1H), 7.16-7.23 (m, 2H), 7.34 (t, J = 2.1 
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Hz, 2H), 7.45 (s, br, 2H), 7.50 (d, br, J = 7.6 Hz, 1H), 7.64 (d, br, J = 7.6 Hz ,1H), 7.92 
(d, J = 8.6 Hz, 1H), 12.69 (s, 1H); MS (70 eV) m/z 274.1 ([M+], 100), 246.1 (12); 
EI-HRMS calculated for [M+] C17H14N4 274.1219, found 274.1211. 
{4-[2-(1H-Benzimidazol-2-yl)-5-pyrrol-1-yl-phenylsulfamoyl]phenoxy}acetic Acid 
Ethyl Ester (4-5a). Amine 4-13 (20 mg, 0.073mmol) was reacted with ethyl 
(4-chlorosulfonylphenoxy)acetate3 4-14 as described above for the synthesis of 4-4a, 
affording 25 mg (0.048 mmol, 66% yield) of 4-5a as a tan solid: mp 193-195 °C; Rf 0.55 
(EtOAc-hexanes, 3:2); 1H NMR (CDCl3, 400 MHz) δ 1.30 (t, J = 7.1 Hz, 3H), 4.27 (q, J 
= 7.1 Hz, 2H), 4.60 (s, 2H), 6.32 (t, J = 2.1 Hz, 2H), 6.62 (d, J = 8.9 Hz, 2H), 6.88 (t, J 
= 2.1 Hz, 2H), 7.05 (dd, J = 8.5, 2.1 Hz, 1H), 7.18 (d, J = 2.1 Hz, 1H), 7.23-7.26 (m, 2H), 
7.50 (d, J = 8.9 Hz, 2H), 7.52-7.55 (m, 2H), 7.65 (d, J = 8.6 Hz, 1H); MS (70 eV) m/z 
516.1 ([M+], 28), 365.1 (9), 274.1 (100), 273 (50), 212.1 (28); EI-HRMS calculated for 
[M+] C27H24N4O5S 516.1467, found 516.1460. 
{4-[2-(1H-Benzimidazol-2-yl)-5-pyrrol-1-ylphenyl-sulfamoyl]phenoxy}acetic Acid 
(4-5b). Ethyl ester 4-5a (10 mg, 0.019 mmol) was hydrolyzed as described for the 
synthesis of 4-4b, yielding 10 mg (0.082 mmol, 99% yield) of acid 4-5b as a tan solid: 
mp >190 °C (dec); Rf 0.53 (MeOH-CH2Cl2, 1:3); 
1H NMR (DMSO-d6, 400 MHz) δ 4.69 
(s, 2H), 6.35 (t, J = 2.1 Hz, 2H), 6.96 (d, J = 9.0 Hz, 2H), 7.31-7.37 (m, 4H), 7.51 (dd, J 
= 8.3, 1.6 Hz, 1H), 7.65-7.73 (m, 3H), 7.75 (d, J = 8.9 Hz, 2H), 8.13 (d, J = 8.8 Hz, 1H), 
13.40 (s, br, 2H); FAB-MS (thioglycerol) m/z 489 ([M+], 13), 327 (25), 274.1 (18), 273 
(17), 237 (100); EI-HRMS calculated for [M+] C25H21N4O5S 489.1233, found 489.1268. 
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4.5.2. Electrode Calibration in Aqueous Solution 
Measurements were performed with an Orion microcombination glass electrode. 
The electrode was calibrated for -log[H3O
+] by titration of a standardized HCl solution 
(Aldrich, 0.1 N volumetric standard) with KOH (Aldrich, 0.1 N volumetric standard) at 
25oC and 0.1M ionic strength (KCl). The endpoint, electrode potential, and slope were 
determined by using Gran’s method11 as implemented in the software GLEE.12 The 
calibration procedure was repeated three times prior to each pKa value determination. The 
electrode potential was measured with the Corning pH/Ion Analyzer 355 and the emf 
measurements were reproducible with ±0.1 mV accuracy. 
 
4.5.3. Spectrophotometric Titrations 
The UV/Vis absorption spectra of the ligands were monitored for a series of 
solutions in which -log[H3O
+] was varied between 5 and 11. The emf of each solution 
was directly measured in the UV quartz cell (electrode diameter 3mm) and converted to 
-log[H3O
+] using the Eo and slope, as obtained from the electrode calibration procedure 
described above. The raw spectral and emf data were processed with nonlinear 
least-squares fit analysis using the SPECFIT software package.13 
 
4.5.4. Steady-state Absorption and Fluorescence Spectroscopy 
All sample stock solutions and buffer solutions were filtered through 0.2 µm Nylon 
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membrane filters to remove interfering dust particles or fibers. UV/Vis absorption spectra 
were recorded at 25oC by using a Varian Cary Bio50 UV/Vis spectrometer with 
constant-temperature accessory. Steady-state emission and excitation spectra were 
recorded with a PTI fluorimeter and FELIX software. Throughout the titration the sample 
solution was stirred with a magnetic stirring device. For all titrations the path length was 
1 cm with a cell volume of 3.0 mL. All fluorescence spectra have been corrected for the 
spectral response of the detection system (emission correction file provided by the 
instrument manufacturer) and for the spectral irradiance of the excitation channel (by 
using a calibrated photodiode). Quantum yields were determined by using quinine sulfate 
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CHAPTER V 
EXCITED STATE INTRAMOLECULAR PROTON TRANSFER (ESIPT) 
IN 2-(2’-SULFONAMIDOPHENYL)BENZIMIDAZOLE DERIVATIVES: 
IMPACT OF EXTENDED π-CONJUGATION 
5.1. Introduction 
As outlined in Chapter 3, in order to utilize ESIPT sensors for biological imaging 
applications, the peak absorption wavelength should be greater than 350 nm. Besides 
taking advantage of substituent-induced absorption shifts as discussed in Chapter 3, 
extension of the π-conjugated aromatic system of the fluorophore might serve as 
promising alternative approach. 
In principle, the more p-orbitals are participating in a π-conjugated system, the 
more discrete π-orbitals are involved in bonding.1 As a consequence, the HOMO-LUMO 
energy gap generally decreases with increasing size of a conjugated π-system, an effect 
that has utilized on structurally related 2-(o-hydroxyaryl)benzazole ESIPT systems.2 
More interestingly, it was found that in these systems, the photophysical properties 
depended not only on the size of the π-conjugated system, but also on the relative 
position of the annulated ring-extension. 
To explore the effect of extended π-conjugation on the photophysical properties of 
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2-(2’-sulfonamidophenyl)benzimidazoles fluorophores, three derivatives 5-1, 5-2 and 5-3 
were synthesized which contained a ring extension annulated to three different positions 
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5.2. Results and Discussion 
5.2.1. Synthesis 
The precursors 5-43, 5-54 and 5-153 were synthesized following published 
procedures. The individual synthetic routes were chosen based on the commercial 
availability of the starting materials. Since the synthesis of derivative 5-1 was best started 
from naphthylamine 5-5, the aryl-sulfonamide moiety was installed prior to the formation 
of the benzimidazole ring. The alcohol 5-6 was obtained through reduction of 5-5 with 
lithium aluminum hydride, and then reacted with sulfonylchloride 5-15 to form the 
sulfonamide intermediate 5-7. After mild oxidation of the primary alcohol with MnO2, 
the resulting aldehyde 5-8 was subjected to copper-mediated condensation with 
o-phenylenediamine, providing the final product 5-1a with 6% yield. The disappointingly 
low yield of the coupling step is presumably due to the significant stability but low 
solubility of the formed copper complex in the workup process. For compound 5-2a and 
5-3a, the corresponding nitro-substituted arylaldehyde precursors are commercially 
available. Hence, the benzimidazole ring was installed prior to formation of the 
aryl-sulfonamide moiety. The yield for the copper-mediated coupling reaction could be 
markedly improved by using ammonium hydroxide to remove the copper salts during the 
work up procedure. Finally, the hydrolysis of the carboxylate esters was accomplished 





































































































.Table 5-1: Protonation Constants and Photophysical Data.[a] 
 
Species/equilibrium Data 5-1b 5-2b[f] 5-3b 5-4b[g] 
[H+][LH-]/[LH2] pKa
1 4.73±0.05 4.75±0.03 n.d.[h] 4.46±0.03 
[H+][L2–]/ [LH–] pKa
2 8.06±0.005 7.62±0.06 7.94±0.005 8.04±0.03 









 excitation λmax (nm)
[c] 319  294 346 296 
 emission λmax (nm)
[c] 480  436 456 418 
 Stokes shift (cm–1) 10223 7552 6889 6470 
 quantum yield[e] 0.30 0.12 0.35 0.26 




321 (11772) 336 (5358) 299 (12300) 
 excitation λmax (nm)
[d] 304 292 334 300 




471 487 460 
 Stokes' Shift (cm–1) 6466, 13797  9921 9228 11700 
 quantum Yield[e] 0.09 0.10 0.29 0.23 
 brightness (εϕ, Lmol–1cm–1) 1620 1177 1340 2829 
 
[a] 0.1M KCl, 25°C. [b] from deconvolution analysis; molar extinction coefficient [Lmol–1cm–1] in parentheses; [c] pH = 11.0, 0.1M KCl; 
[d] pH = 6.5 (5-1b), 6.2 (5-2b), or 6.3 (5-3b), 10 mM PIPES, 0.1 M KCl; [e] quinine sulfate in 1 N H2SO4 as standard; 
[f] contaminated 
by photoreaction products; [g] data taken from reference 2; [h] spectral deconvolution insufficient for accurate determination.
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5.2.2. Protonation Equilibria 
As already discussed in chapter 3 and 4, deprotonation of the sulfonamide group is 
typically associated with a bathochromic shift in the peak absorption and a hypsochromic 
shift in the fluorescence emission. To study the impact of the extended π-conjugated 
system without being misled by pH-dependent absorption changes, the UV-vis and 
fluorescence emission spectra were therefore acquired at well-defined protonation states. 
Hence, the protonation equilibria of each compound were analyzed by means of 
spectrochemical UV-vis titrations with –log[H3O
+] ranging between 5 and 11. The 
absorption spectra of the fully deprotonated L2- and monoprotonated species HL- were 
then obtained by means of deconvolution based on non-linear least-squares fitting of the 
UV-vis traces over the entire spectral range (Figure 5-1). 
As evident from Table 5-1, the pKa values of the sulfonamide group depended 
strongly on the annulation position of the π-system extension. While derivative 5-1b 
(8.06) and 5-3b (7.94) gave a surprisingly similar pKa compared to the unsubstituted 
parent molecule 5-4b (8.04), derivative 5-2b revealed significantly lower pKa of 7.62, 




5.2.3. Photophysical Studies in Aqueous Solution. 
5.2.3.1. UV-vis Spectra.  
For the monoprotonated species HL-, extension of π-conjugated system led to 
red-shifted absorption for all derivatives. The bathochromic shift was strongest for 
derivative 5-3b (37 nm), followed by 5-2b (22 nm) and 5-1b (15 nm). The absorption 
band shifts of 5-1b and 5-2b are consistent with the results previously observed for 
2-(o-hydroxyaryl)benzazoles.2 For the deprotonated species L2-, the absorption maxima 
follow the same trend (5-3b: 347 nm, 5-2b: 328 nm, 5-1b: 322 nm); however, compared 
to parent compound 5-4b (329nm), the absorption spectra of 5-1b and 5-2b L2- are 
actually slightly blue-shifted. The extinction coefficient of 5-1b HL- is the highest 
(18,000 Lmol–1cm–1), followed by 5-4b (12,300 Lmol–1cm–1), 5-2b (11,800 Lmol–1cm–1), 
and 5-3b (5,360 Lmol–1cm–1).  
 
5.2.3.2. Fluorescence Steady-State Spectra.  
Compared to parent compound 5-4b (460nm), the ESIPT emission band of the 
monoprotonated species HL- is red-shifted for all three derivatives. While the emission 
shift of 5-2b (471 nm) and 5-3b (487 nm) follow the same order as observed in their 
absorption spectra, the peak emission of derivative 5-1b is significantly more red-shifted 
to 554 nm, an observation that is consistent with what the nodal-plane model recently 
proposed in the literature.2 Since the deprotonation of the sulfonamide nitrogen disrupts 





Figure 5-1: Deconvoluted UV-vis absorption spectra (left) and fluorescence emission 
spectra (right) of compounds (a) 5-4b, (b) 5-1b, (c) 5-2b, and (d) 5-3d in aqueous 
solution (0.1 M KCl, 25oC). UV-vis traces for the species with monoprotonated (—) and 
deprotonated (---) sulfonamide group were obtained through deconvolution analysis of a 
series spectra with –log[H3O
+] ranging between 5-11. Emission spectra were acquired 
with excitation at the isosbestic point and were recorded near pH as specified in Table 5-1 
and at pH 11 without further deconvolution. The four vertical grid lines are intended as a 




all derivatives. The emission maxima still follow the same trend (5-4b: 418 nm, 5-2b: 
436 nm, 5-3b: 456 nm, 5-1b: 480 nm) as observed for the corresponding ESIPT emission 
bands.  
Interestingly, the mono-protonated species of 5-1b revealed an additional 
high-energy emission band centered around 394 nm. As discussed in chapter 3, dual 
emission is not uncommon in ESIPT fluorophores, and can be attributed either to a 
rotamer that cannot undergo excited state proton transfer5,6 or a competing radiative 
decay from a polarized local excited state7. A contour plot of the emission intensities 
revealed uniform excitation spectra regardless of the emission wavelength, suggesting 
that only one species is responsible for both emission bands (Figure 5-2). Furthermore, 
the quantum chemical calculation indicated that the cis-rotamer is thermodynamically 
favored in case of 2’-sulfonamidophenyl-substituted benzimidazoles.8 Therefore, the dual 
emission is most likely not due to the presence of an additional ground-state rotamer, but 
might originate from competition between radiative relaxation of the local excited state 
and formation of the proton-transfer phototautomer. To further investigate this hypothesis, 
a set of absorption and emission spectra were acquired over an extended temperature 
range. As shown in Figure 5-3, the absorption spectra changed very little as a function of 
the temperature changes; however, the ratio of the intensity of the higher energy emission 
vs. ESIPT emission gradually decreased as the temperature increased, an observation that 





Figure 5-2: Two-dimensional fluorescence contour plot for fluorophore 5-1b showing the 




Figure 5-3: Temperature dependent spectra of 5-1b in aqueous solution (pH = 6.5, 10 
mM PIPES, 0.1 M KCl). 
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increasing temperature. Hence, these data suggest that the proton transfer process is 
associated with an energy barrier, which would imply a reduced proton transfer rate and 
thus more effective competition between emission from a local excited state (LE) and the 
proton transfer tautomer. In conclusion, the temperature dependent measurements further 
support that the higher energy band originates from a local excited state. 
 
5.2.3.3. Time Resolved Spectroscopy.  
If the emission bands of 5-1b HL-1 originate from two distinct excited-states, the 
fluorescence life time measured at the two wavelengths is expected to be different. Indeed, 
the fluorescence lifetime of 5-1b was determined to be 1.7 ns for the LE emission band, 
3.9 ns for the ESIPT band, and 6.6 ns for emission of the deprotonated species L2- (Figure 
5-4). Again, the shorter lifetime of the LE emission band compared to the ESIPT band is 
consistent with the hypothesized competition between radiative deactivation of the local 
excited state (LE) and the proton transfer process. By Gaussian fitting of the fluorescence 
spectrum of the monoprotonated species of 5-1b (Figure 5-1), the quantum yield of the 
two emission processes was estimated to be 0.06 (for ESIPT emission) and 0.03 (for LE). 
Combined with the fluorescence lifetime data, the radiative decay rates were calculated to 






Figure 5-4: Fluorescence decay data of 5-1b in aqueous solution: a) in pH 6.5 buffer (10 
mM PIPES, 0.1 M KCl), 365 nm; b) in pH 6.5 buffer, 600 nm; c) in pH 11 buffer (0.1 M 
KCl), 480 nm. The curve fit is based on a monoexponential decay law (for 
monoprotonated species HL-: at 365 nm: τ = 1.7 ns, χ2 = 1.07; at 600 nm: τ = 3.9 ns, χ2 = 
1.01; for deprotonated species L2-: τ = 6.6 ns, χ2 = 1.07) 
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5.2.3.4. Fluorescence Quantum Yield and Brightness.  
The quantum yield of the deprotonated species L2- was found to be consistently 
higher compared to the monoprotonated species HL-, an observation that is presumably 
due to the intrinsically larger Stokes’ shift of the ESIPT emission. Derivative 5-3b has the 
highest quantum yield (L2-: 0.34, HL-: 0.25), followed by the parent compound 5-4b (L2-: 
0.26, HL-: 0.23). The quantum yield of 5-2b is relatively low (L2-: 0.13, HL-: 0.10), which 
is consistent with the fact that there is the photochemical decomposition as an alternative 
deactivation pathway. For the monoprotonated species HL- of 5-1b, the slow proton 
transfer rate could result in more irradiative relaxation of the excited state which might be 
responsible for the lower quantum yield (0.09). The brightness of all fluorophores is best 
compared by combining the corresponding quantum yield and extinction coefficients (εϕ). 
According to these data, the parent compound is significantly brighter (2829 Lmol–1cm–1) 
compared to the derivatives with extended conjugated system, whose brightness follows 
the order of 5-1b (1620 Lmol–1cm–1), 5-3b (1340 Lmol–1cm–1), 5-2b (1177 Lmol–1cm–1). 
 
5.2.4. Photochemical Studies  
Unlike all other derivatives, compound 5-2b undergoes photodecomposition under 
irradiation of UV light. The photodecomposition is associated with the absorption spectra 
blue shift. (Figure 5-5). One of the photoproducts is the naphthylamine derivative (5-11) 
as determined by NMR and mass spectrometry (Scheme 5-1). The photo-cleavage of the 
weakened sulfur-nitrogen bond that is presumably due to steric effects imposed through 
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the hydrogen in position 3 of the naphthyl ring (Scheme 5-2). Since this photoreaction 
results in a blue-shifted absorption spectrum, its efficiency could be determined by 
actinometry. By using azobenzene as the actinometric standard, the quantum yield of the 
photoreaction was determined to be ϕA=0.40. Furthermore, measurements at high pH 
revealed that deprotonation of the sulfonamide nitrogen significantly reduced 
photodecomposition (Figure 5-6, ϕA=0.04). The uniformity of the reaction was 




















In this chapter, the impact of the extension of π-conjugated system on 
2-(2’-sulfonamidophenyl)benzimidazoles fluorophores was investigated in detail. The 
annulation position of the additional benzene ring strongly influences the photophysical 
properties and photochemical stability. Similar to what was observed in chapter 3, the 
radiative relaxation of the local excited state causes dual emission for derivative 5-1. 
Presumably due to the introduced steric strain, compound 5-2 was rendered photolabile. 
More importantly, the absorption maxima depended on the annulation position, thus 
 159
leading to fluorophore 5-3 with good ratiometric properties combined with a substantial 
absorption cross section beyond 350 nm. Unlike the fluorophores obtained by substituent 
engineering, the sulfonamide nitrogen of 5-3b has a pKa value as 7.94, and is almost 
unaffected by the structural modifications. Hence, fluorophore 5-3 represents a promising 




   
 




Figure 5-6. Absorbance-time diagrams. a) Azobenzene and 5-2a were 50 µM solution in methanol. 5-2a in base was 50 µM in 1 mM 
KOH methanol solution. And 5-1a was 30µM solution in methanol. The absorbance change was measured at 334 nm following every 




5.4. Experimental Section 
5.4.1. Synthesis.  
Fluorophores 5-4a and b were synthesized following published procedures.2 NMR: 
δ in ppm vs SiMe4 (0 ppm, 1H, 400 MHz). MS: selected peaks; m/z. Melting points are 
uncorrected. Flash chromatography (FC): Merck silica gel (240-400 mesh). TLC: 0.25 
mm, Merck silica gel 60 F254, visualizing at 254 nm or with 2% KMnO4 solution. 
(a) (3-Amino-naphthalen-2-yl)-methanol (5-6). Acid 5-5 (200 mg, 1.0 mmol) was 
suspended in dry THF (10 ml) and the mixture cooled to 0oC. Then solid lithium 
aluminum hydride (120 mg, 3.2 mmol) was added in portions with stirring. After the gas 
evolution subsided, the mixture was heated under reflux for 1 hour. After cooling to room 
temperature, the reaction mixture was quenched with ice-cold wtaer water (4 eqv. to 
LAH). Silica gel was added to absorb the precipitate, all solid material was filtered off 
and washed by EtOAc. The combined organic solutions were dried over anhydrous 
MgSO4, filtered, and concentrated under reduced pressure, providing 175.5 mg yellow 
solid (1.0 mmol, 100% yield). Mp>150°C (dec.); Rf 0.50 (1:1 EtOAc:Hexane). 1H-NMR 
(CDCl3, 400 MHz) δ 4.36 (s, 2H), 4.84 (s, 2H), 7.02 (s, 1H), 7.22 (t, J = 7.8 Hz, 1H), 
7.36 (t, J = 7.9 Hz, 1H), 7.57 (s, 1H), 7.58 (d, J = 10 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H). 
MS (70 eV) 173 (M+, 58), 155 (72), 128(100). EI-HRMS m/e calculated for (M+) 
C11H11NO 173.08406, observed 173.08422. 
(b) [4-(3-Hydroxymethyl-naphthalen-2-ylsulfamoyl)-phenoxy]-acetic acid ethyl 
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ester (5-7). Amine 5-6 (90 mg, 0.52 mmol) and 5-15 (180 mg, 0.65 mmol) were 
dissolved in pyridine (1 ml) and stirred overnight. The mixture was then poured into 1 N 
HCl, extracted with EtOAc, dried with anhydrous MgSO4, and evaporated to dryness. 
The crude product was purified on silica gel (1:1.5 EtOAc/hexanes), providing 100 mg of 
a beige solid (0.24 mmol, 46% yield). Mp 149-151°C; Rf 0.42 (1:1 EtOAc:Hexane). 
1H-NMR (CDCl3, 400 MHz) δ 1.23 (t, J = 7.1 Hz, 3H), 4.20 (q, J = 7.1 Hz, 2H), 4.46 (s, 
2H), 4.54 (s, 2H), 6.77 (d, J = 8.9 Hz, 2H), 7.39 (t, J = 7.9 Hz, 1H), 7.44 (t, J = 8.2 Hz, 
1H), 7.47 (s, 1H), 7.63-7.70 (m, 3H), 7.73 (d, J = 8.0 Hz, 1H), 7.85 (s, 1H), 8.22 (s, 1H). 
MS (70 eV) 415 (M+, 4), 155 (50), 106 (77), 41 (100). EI-HRMS m/e calculated for (M+) 
C21H21NO6S  415.10896, observed 415.10668. 
 
(c) [4-(3-Formyl-naphthalen-2-ylsulfamoyl)-phenoxy]-acetic acid ethyl ester 
(5-8). Alcohol 5-7 (100 mg, 0.24 mmol) was dissolved in CHCl3 (20 ml), then MnO2 
(200 mg, 2.3 mmol) was added. The mixture was stirred overnight at room temperature, 
and subsequently filter through Celite. The filtrate was evaporated to dryness providing 
87 mg of a yellow solid (0.21 mmol, 88% yield). Mp 155-157°C; Rf 0.63 (1:1 
EtOAc:hexanes). 1H-NMR (CDCl3, 400 MHz) δ 1.23 (t, J = 7.1 Hz, 3H), 4.22 (q, J = 7.1 
Hz, 2H), 4.58 (s, 2H), 6.85 (d, J = 9.0 Hz, 2H), 7.48 (t, J = 8.0 Hz, 1H), 7.63 (t, J = 8.0 
Hz, 1H), 7.80-7.88 (m, 4H), 8.04 (s, 1H), 8.14 (s, 1H), 9.96 (s, 1H), 10.40 (s, 1H). MS 
(70 eV) 413 (M+, 58), 170 (100), 142(23), 115(28). EI-HRMS m/e calculated for (M+) 
C21H19NO6S 413.09331, observed 413.09352. 
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(d) {4-[3-(1H-Benzoimidazol-2-yl)-naphthalen-2-ylsulfamoyl]-phenoxy}-acetic 
acid ethyl ester (5-1a). Phenylenediamine (28 mg, 0.26 mmol) was dissolved in 
EtOH/H2O (1:1, 4 ml), and then acetic acid (22 µl), aldehyde 5-6 (90 mg, 0.22 mmol) in 
EtOH (2 ml), and Cu(OAc)2 H2O (52.7 mg, 0.26 mmol) in water (2 ml) were added. The 
mixture was refluxed overnight, the formed precipitate was filtered off and redissolved in 
EtOH/conc. HCl (10:1). Saturated Na2S 9H2O in water was added and the mixture was 
refluxed for 1 hour. After filtering off the black residue, the filtrate was neutralized with 
saturated aqueous NaHCO3. Tthe remaining EtOH was distilled off under reduced 
pressure, and the aqueous solution was extracted with EtOAc. The combined organic 
layer were dried with anhydrous MgSO4 and concentrated under reduced pressure, 
providing 7 mg of a yellow solid (0.014 mmol, 6% yield). Mp 88-90°C; Rf 0.13 (1:2 
EtOAc:hexanes). 1H-NMR (CDCl3, 400 MHz) δ 1.32 (t, J = 7.1 Hz, 3H), 4.31 (q, J = 7.1 
Hz, 2H), 4.59 (s, 2H), 6.20 (d, J = 9.0 Hz, 2H), 7.11(d, J = 9.0 Hz, 2H), 7.28-7.35 (m, 
2H), 7.44-7.50 (m, 2H), 7.54 (t, J = 6.9 Hz, 1H), 7.76 (d, J = 8.3 Hz, 1H), 7.82 (s, 1H), 
7.86 (d, J = 8.2 Hz, 1H), 7.93 (s, 1H), 8.18 (s, 1H), 9.94 (s, 1H), 11.42 (s, 1H). MS (70 
eV) 501 (M+, 14), 259 (49), 44 (100). EI-HRMS m/e calculated for (M+) C27H23N3O5S 
501.14842, observed 501.13590. 
(e) {4-[3-(1H-Benzoimidazol-2-yl)-naphthalen-2-ylsulfamoyl]-phenoxy}-acetic 
acid (5-1b). To a solution of LiOH H2O (50 mg, 1.2 mmol) in MeOH/H2O (1:1, 0.6 ml), 
1a (30 mg, 0.060 mmol) in THF (500 µl) was added, and the resulting mixture was stirred 
at room temperature for 1 hour. The organic solvent was removed under reduced pressure. 
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The residue was diluted with water and the solution neutralized with 1 N HCl until the 
product started to precipitate. The yellow solid was filtered off, washed with water, and 
dried in vacuo, affording 22 mg of a yellow solid. Yield 77%. Mp>175°C (dec.); Rf  
0.10 (1:9 MeOH: CH2Cl2). 1H-NMR (DMSO, 400 MHz) δ 4.62 (s, 1H ), 6.85 (d, J = 7.4 
Hz, 2H), 7.30-7.38 (m, 2H), 7.48 (t, J = 7.6 Hz, 1H), 7.56 (t, J = 8.0 Hz, 1H), 7.65-7.72 
(m, 4H), 7.84-7.90 (m, 2H), 7.98 (s, 1H), 8.62 (s, 1H), 13.36 (s, 2H). MS (70 eV) 473 
(M+, 8), 415 (25), 299 (79), 269 (60), 259 (100), 209 (83), 44 (44). EI-HRMS m/e 
calculated for (M+) C25H19N3O5S 473.09262, observed 473.10435. 
(f) 2-(1-Nitro-naphthalen-2-yl)-1H-benzoimidazole (5-10). A solution of 
o-phenylenediamine (64.5 mg, 0.60 mmol), 1-nitro-2-naphthaldehyde 5-9 (100 mg, 0.50 
mmol), Cu(OAc)2⋅H2O (120 mg, 0.60 mmol) and acetic acid (50 µL) in 10 mL of 
MeOH/H2O (1:1) was reflux overnight. After all starting materials had been consumed 
(TLC), the organic solvent was removed under reduced pressure. After addition of 10 mL 
aqueous ammonium hydroxide (28%), the mixture was extracted twice with 
dichloromethane. The combined organic layers were dried over anhydrous MgSO4, and 
concentrated under reduced pressure. The crude product was purified on silica gel (FC, 
1:1.5 EtOAc : Hexane) affording 93 mg of a yellow solid (0.32 mmol, 64% yield). Mp > 
230oC (dec.); Rf 0.37 (1:1 EtOAc : Hexane). 1H-NMR (DMSO, 400 MHz) δ 7.23-7.29 
(m, 2H), 7.63-7.68 (m, 2H), 7.70-7.75 (m, 1H), 7.77-7.82 (m, 2H), 8.15-8.24 (m, 2H), 
8.40 (d, J = 8.7Hz, 1H), 13.30 (s, 1H). EI-MS (70eV) 289.1 (M+, 100), 272.1 (90), 247.1 
(62), 231.1 (25), 126.1 (30). EI-HRMS m/e calculated for (M+) C17H11N3O2 289.08513, 
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observed 289.08563. 
(g) 2-(1H-Benzoimidazol-2-yl)-naphthalen-1-ylamine (5-11). Compound 5-10 (90 
mg, 0.31 mmol) was suspended in 10 mL ethanol and hydrogenated at ambient pressure 
in the presence of Pd/C (3% wt, 20 mg) as catalyst. Upon completion of the reaction 
(TLC), the solution was filtered through celite and concentrated under reduced pressure, 
providing 70mg of a yellow solid (0.27mmol, 87% yield). Mp > 232oC (dec.); Rf 0.53 
(1:2 EtOAc : Hexane). 1H-NMR (CDCl3, 400 MHz) δ 7.22-7.28 (m, 2H), 7.25-7.30 (m, 
2H), 7.50-7.55 (m, 2H), 7.61 (d, J = 8.7 Hz, 2H), 7.77-7.83 (m, 1H), 7.96-8.01 (m, 1H). 
EI-MS (70eV) 259.1 (M+, 100). EI-HRMS m/e calculated for (M+) C17H13N3 259.11095, 
observed 259.11043. 
(h) {4-[2-(1H-Benzoimidazol-2-yl)-naphthalen-1-ylsulfamoyl]-phenoxy}-acetic 
acid ethyl ester (5-2a). A solution of amine 5-11 (70 mg, 0.27 mmol) and sulfonyl 
chloride 5-15 (97 mg, 0.34 mmol) in 2 ml pyridine was stirred at room temperature 
overnight. The resulting mixture was poured in 20 ml 1 N HCl and extracted twice with 
EtOAc. The combined organic extracts were dried with anhydrous MgSO4 and 
evaporated under reduced pressure. The crude product was recrystalized from 
CH2Cl2/hexane and further purified on a short silica gel column (EtOAc:hexanes, 1:1), 
providing 50 mg of a yellow solid (0.10 mmol, 37%). Mp 216-218oC; Rf 0.41 (1:1 
hexanes:EtOAc). 1H-NMR (CDCl3, 400 MHz) δ 1.44 (t, J = 7.1 Hz, 3H), 4.44 (q, J = 
7.1 Hz, 2H), 4.69 (s, 1H), 5.98 (d, J = 8.7 Hz, 2H), 6.67 (d, J = 8.6 Hz, 2H), 7.30-7.35 (m, 
2H), 7.39 (d, J = 8.4 Hz, 1H), 7.61-7.66 (m, 3H), 7.77 (d, J = 8.4 Hz, 1H), 7.82 (d, J = 8.4 
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Hz, 1H), 8.85 (d, J = 8.2 Hz, 1H). MS (70 eV) 501.2(M+, 19), 437.2 (5), 350.1 (5), 258.1 
(100), 231.1 (13). EI-HRMS m/e calculated for (M+) C27H23N3O5S 501.13519, observed  
501.13463. 
(i) {4-[2-(1H-Benzoimidazol-2-yl)-naphthalen-1-ylsulfamoyl]-phenoxy}-acetic 
acid (5-2b). A mixture of LiOH H2O (20 mg, 0.48 mmol) and 5-2a (10 mg, 0.020 mmol) 
in MeOH/H2O/THF (0.1 mL/0.1 mL/0.3 mL) was stirred overnight at room temperature. 
The organic solvent was removed under reduced pressure. The residue was diluted with 
water and the solution neutralized with 1 N HCl until the product started to precipitate. 
The yellow solid was filtered off, washed with water, and dried in vacuo (9 mg, 0.019 
mmol, 95%). Mp > 245°C(dec.); Rf  0.42 (1:6 MeOH : CH2Cl2). 1H-NMR (DMSO, 400 
MHz) δ 4.56 (s, 2H), 6.53-6.60 (m, 2H), 7.08-7.13 (m, 2H), 7.48-7.56 (m, 3H), 7.66 (t, J 
= 7.6 Hz, 1H), 7.74-7.79 (m, 2H), 7.89 (d, J = 8.6 Hz, 1H), 8.04 (d, J = 8.1 Hz, 1H), 8.14 
(d, J = 8.8 Hz, 2H). MS (70 eV) 473.1 (M+, 8), 259.1 (100). EI-HRMS m/e calculated for 
(M+) C25H19N3O5S 423.08889, observed 473.10506. 
 
(j) 2-(2-Nitrophenyl)-1H-naphtho[2,3-d]imidazole (5-13). A mixture of 
naphthalene-2,3-diamine (625 mg, 4.0 mmol) and 2-nitrobenzaldehyde (500 mg, 3.3 
mmol) in 100 mL of ethanol was heated under reflux overnight. After addition of 1, 
4-benzoquinone (715 mg, 6.6 mmol), the solution was refluxed for an additional hour and 
then the solvent was removed under reduced pressure. The residue was redissolved in 
EtOAc and washed with 5% NaOH. The combined organic layers were dried with 
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anhydrous MgSO4 and concentrated in vacuo. The crude product was purified by silica 
gel flash chromatography (1:1, EtOAc:hexanes), providing 800 mg of a beige solid 
(2.8mmol, 84% yield.). Mp > 280oC (dec.); Rf  0.28 (1:1 EtOAc:Hexane). 1H-NMR 
(CDCl3, 400 MHz) δ 7.40-7.48 (m, 2H), 7.70 (t, J = 7.6 Hz, 1H), 7.79 (t, J = 7.6 Hz, 1H), 
7.91-7.98 (m, 2H), 8.02 (d, J = 8.1 Hz, 2H), 8.18 (d, J = 7.6 Hz, 1H), 8.32 (s, 1H), 9.63 (s, 
1H). MS (70 eV) 289.1 (M+, 78), 256.1 (100), 243.1 (28), 140.1 (65). EI-HRMS m/e 
calculated for (M+) C17H11N3O2 289.08513, observed 289.08519. 
(k) 2-(1H-Naphtho[2,3-d]imidazol-2-yl)aniline (5-14). A suspension of compound 
5-13 (800 mg, 2.8 mmol) in 300 mL ethanol was hydrogenated at ambient pressure in the 
presence of Pd/C (3% wt, 120 mg) as catalyst. The reaction mixture was filtered through 
celite and concentrated under reduced pressure, providing 660 mg of a brown solid (2.5 
mmol, 89% yield). Mp > 250oC (dec); Rf 0.67 (1:1 EtOAc : Hexane). 1H-NMR (CDCl3, 
400 MHz) 6.47 (br, 2H), 6.79 (t, J = 8.0 Hz, 1H), 6.84 (d, J = 8.3 Hz, 1H), 7.37-7.45 (m, 
2H), 7.59 (d, J = 8.0 Hz, 1H), 7.84 (s, 1H), 7.91 (d, J = 7.5 Hz, 1H), 7.99 (d, J = 7.5 Hz, 
1H), 8.21 (s, 1H), 9.18 (br, 1H). EI-MS (70eV) 259.1 (M+, 100). EI-HRMS m/e 
calculated for (M+) C17H13N3 259.11095, observed 259.11034. 
(l) Ethyl 2-(4-(N-(2-(1H-naphtho[2,3-d]imidazol-2-yl)phenyl)sulfamoyl)-phen-
oxy)acetate (5-3a). A solution of amine 5-14 (440 mg, 1.7 mmol) and sulfonyl chloride 
5-15 (800 mg, 2.8 mmol) in 10 ml pyridine was stirred at room temperature overnight. 
Then the mixture was poured into 100 ml 1 N HCl, extracted twice with EtOAc, dried by 
anhydrous MgSO4 and evaporated. The crude product was purified by a short silica gel 
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column (EtOAc:hexanes, 1:2-1:1), afording 360 mg of a yellow solid (0.72 mmol, 42%). 
Mp 235-237oC; Rf 0.32 (1:1 hexane:EtOAc). 1H-NMR (CDCl3, 400 MHz) δ 1.11 (t, J = 
7.1 Hz, 3H), 4.08 (q, J = 7.1 Hz, 2H), 4.77 (s, 2H), 6.94 (d, J = 9.0 Hz, 2H), 7.26 (t, J = 
7.7 Hz, 1H), 7.41-7.46 (m, 2H), 7.49 (t, J = 7.7 Hz, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.72 (d, 
J = 9.0 Hz, 2H), 8.05-8.11 (m, 2H), 8.15 (dd, J = 7.8, 1.2 Hz, 1H), 8.21 (br, 2H), 13.34 
(br, 1H). EI-HRMS m/e calculated for (M+) C27H23N3O5S 501.13584, observed 
501.13411. 
(m) 2-(4-(N-(2-(1H-naphtho[2,3-d]imidazol-2-yl)phenyl)sulfamoyl)phenoxy)- 
acetic acid (5-3b). A mixture of LiOH H2O (150 mg, 3.6 mmol) and 5-3a (65 mg, 0.13 
mmol) in MeOH/H2O/THF (0.9 mL/0.9 mL/2 mL) was stirred at room temperature 
overnight. The organic solvent was removed under reduced pressure. The residue was 
diluted with water and the solution neutralized with 1 N HCl until the product started to 
precipitate. The solid was collected by filtration, washed with water, and dried in vacuo, 
(50 mg, 0.11 mmol, 85%). Mp > 112oC (dec.); Rf  0.18 (2:9 MeOH:CH2Cl2). 1H-NMR 
(DMSO, 400 MHz) δ 4.47 (s, 2H), 6.80 (d, J = 8.8 Hz, 2H), 7.23 (t, J = 7.4Hz, 1H), 
7.39-7.44 (m, 2H), 7.47 (t, J = 7.4 Hz, 1H), 7.60 (d, J = 8.8 Hz, 2H), 7.63 (d, J = 8.0 Hz, 
1H), 8.04-8.09 (m, 2H), 8.13 (d, J = 8.0 Hz, 1H), 8.29 (br, 2H). ESI-HRMS m/e 
calculated for (M-) C25H18N3O5S 472.097266, observed 472.0979. 
(n) 2-(1H-Benzoimidazol-2-yl)-naphthalen-1-ylamine (5-11). Compound 5-2a 
(5.09 mg, 0.010 mmol) was dissolved in 0.5 mL DMSO, and exposed to 250 nm UV light 
irradiation from a mercury lamp. The decomposition reaction was monitored by TLC 
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until starting material was completely consumed. After purification on a short silica gel 
column (EtOAc : Hexane 1:1), 2 mg of a yellow solid were obtained (0.0077 mmol, 77%). 
Mp 216-218oC; Rf 0.41 (1:1 hexane:EtOAc). 1H-NMR (CDCl3, 400 MHz) δ 1.44 (t, J 
= 7.1 Hz, 3H), 4.44 (q, J = 7.1 Hz, 2H), 4.69 (s, 1H), 5.98 (d, J = 8.7 Hz, 2H), 6.67 (d, J = 
8.6 Hz, 2H), 7.30-7.38 (m, 2H), 7.39 (d, J = 8.4 Hz, 1H), 7.61-7.67 (m, 3H), 7.77 (d, J = 
8.4 Hz, 1H), 7.82 (d, J = 8.4 Hz, 1H), 8.85 (d, J = 8.2 Hz, 1H). MS (70 eV) 501.2(M+, 
19), 437.2 (5), 350.1 (5), 258.1 (100), 231.1 (13). EI-HRMS m/e calculated for (M+) 
C19H27N5O7S2 501.13519, observed 501.13463. 
 
5.4.2. Steady-state Absorption and Fluorescence Spectroscopy.  
All spectroscopic measurements were carried out in a quartz cuvette with 3.0 mL 
volume and 1cm path length. For spectrophotometric titrations the sample solution was 
continuously stirred. Steady-state UV-vis spectra were recorded on a Varian Cary Bio50 
UV-vis spectrometer at 25oC, maintained by a temperature control accessory. 
Fluorescence emission and excitation spectra were recorded on a PTI fluorimeter with 
FELIX software. All fluorescence spectra were corrected by the correction file provided 
by the instrument manufacturer. Quinine sulfate in 1.0 N H2SO4 (Φ = 0.54) was used as 
the standard for quantum yield measurements.9 
 
5.4.3. Electrode Calibration in Aqueous Solution.  
A Ross ultra semimicro pH glass electrode (Orion No. 8103BNUMP) was used for 
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all measurements. The electrode was calibrated for –log[H3O
+] by titration of 0.1 N 
volumetric standard HCl with 0.1 N volumetric standard KOH under 0.1 M ionic strength 
(KCl). The software GLEE was used to determine the end point Eo and slope.10 A 
Corning pH/Ion Analyzer 355 was used to measure the electron potential. 
 
5.4.4. Determination of pKa Values.  
To determine pKa values, the UV-vis spectra of the sample solution in 0.1 M KCl 
were monitored from –log[H3O
+] 5 to 11. The emf was converted to –log[H3O
+] by Eo 
and slope determined from the electrode calibration. All data were processed by 
non-linear least-squares fit analysis using the SPECFIT software package.11 
 
5.4.5. Actinometry. 
The Xenon arc-lamp of a PTI fluorimeter was used as the light source for 
actinometric measurements. The wavelength of the incident beam was set to 334 nm. 
UV-vis absorption spectra were recorded with a Varian Cary Bio50 UV-vis spectrometer. 
All solutions were measured in a 3.0 mL volume cell with stirring at 23oC. 
 
5.4.6. Determination of Quantum Yield (ϕ) of Photochemical Reactions.  
The trans-cis photoisomerisation ( BA h→← γ ) of azobenzene was used as the 
chemical actinometer to determine the incident irradiance intensity. In this investigation, 
the UV absorbance of 50 µM azobenzene in pure methanol was measured at 334 nm 
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multiple times following one minute of irradiation at 334 nm. The relationship of the 
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=  is the photokinetic factor in decadic units. If the UV 
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This is a linear equation with zλ1 and zλ2 corresponding to the intercept and slope of 
the fitted line, respectively. Q was obtained from ref. 8. Hence, the irradiance intensity I0 
and Eλ∞ can be calculated from Eq. 5-3. 
For a uniform photoreaction BA h→ γ (in this investigation, the uniformity of the 
photoreaction is demonstrated by E-diagram and ED-diagram shown in Appendix B), Eq. 


















= ∞                              Eq. 5-5 
 
With I0 obtained from above, the quantum yield ϕ
A and Eλ∞ can then be calculated 
with Eq. 5-5. 
 
 
5.4.7. Time-Resolved Measurements.  
Time resolved measurements were done with a Photon Technology International 
(PTI) fluorescence lifetime instrument. The light source was a nitrogen laser (model 
GL-3300). All samples were excited at 337 nm with a repetition rate of 10 Hz (pulse 
width 3.5 ns), and the fluorescence signal was analyzed after passing through a 
monochromator set at the peak emission of the corresponding sample. The fluorescence 




5.4.8. 2D Fluorescence Spectra.  
40 µM solution of 5-1b in pH 6.50 buffer was prepared. A set of 101 emission 
spectra (350-700 nm) were collected with a PTI fluorimeter and FELIX software. The 
excitation wavelength was programmed by the macro of FELIX as 1 nm interval from 
250-350 nm. The data were processed with proFit software to get a contour plot. 
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Table A-1: Selected solvent parameters utilized in the solvatochromic shift analyses in 
Chapter 4. 
 
No. Solvent εr n ETN π∗ α β 
1 1,4-dioxane 2.27 1.422 0.164 0.490 0.000 0.370 
2 di-n-butylether 3.18 1.398 0.071 0.180 0.000 0.460 
3 diethylether 4.42 1.352 0.117 0.240 0.000 0.470 
4 tetrahdyrofuran 7.47 1.406 0.207 0.550 0.000 0.550 
5 n-butylacetate 5.01 1.394 0.241 0.529343 0.000 0.450 
6 ethylacetate 6.053 1.372 0.228 0.450 0.000 0.450 
7 chloroform 4.89 1.446 0.259 0.690 0.200 0.100 
8 1,2-dichloroethane 10.74 1.445 0.327 0.730 0.000 0.100 
9 dichloromethane 24.56 1.424 0.309 0.730 0.130 0.100 
10 n-butanenitrile 24.56 1.383 0.364 0.630 0.000 0.400 
11 acetonitrile 35.94 1.344 0.460 0.660 0.190 0.400 
12 n-butanol 17.51 1.3993 0.586 0.36173 0.840 0.840 
13 ethanol 24.55 1.36143 0.654 0.340535 0.860 0.750 
14 methanol 32.04 1.3284 0.762 0.345582 0.980 0.660 
15 water 78 1.33 1.000 1.09 1.100 0.180 
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Summary of Spectroscopic Data (Tables A-2-A-6) 
The reported absorption energies refer to the peak of the lowest energy band. 
Fluorescence peak emission energies are corrected as described in the experimental 
section of Chapter 4. All spectra were acquired at 298 K. 
 






1 1,4-dioxane 31443 20408 
2 di-n-butylether 31443 20408 
3 diethyl ether 31552 20534 
4 Tetrahdyrofuran 31443 20408 
5 n-butylacetate 31443 20492 
6 Ethylacetate 31552 20492 
7 Chloroform 33327 20619 
8 1,2-dichloroethane 33449 20450 
9 Dichloromethane 33327 20408 
10 n-butanenitrile 31552 20576 
11 Acetonitrile 31739 20833 
12 n-butanol 31645 21322 
13 Ethanol 31739 21322 
14 Methanol 31850 21322 
 







1 1,4-dioxane 33650 18490 
2 di-n-butylether 33270 18580 
3 diethyl ether 33400 18540 
4 tetrahdyrofuran 33120 18570 
5 n-butylacetate 33340 18600 
6 ethylacetate 33400 18650 
7 chloroform 33610 18760 
8 1,2-dichloroethane 33530 18570 
9 dichloromethane 33380 18620 
10 n-butanenitrile 33170 18890 
11 acetonitrile 33350 19080 
12 n-butanol 33630 19590 
13 ethanol 33660 19550 
14 methanol 33670 19540 
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1 1,4-dioxane 31800 21430 
2 di-n-butylether 31360 21540 
3 diethyl ether 31530 21460 
4 tetrahdyrofuran 31630 21470 
5 n-butylacetate 31480 21500 
6 ethylacetate 31570 21530 
7 chloroform 31890 21700 
8 1,2-dichloroethane 31850 21520 
9 dichloromethane 31310 21530 
10 n-butanenitrile 31490 21680 
11 acetonitrile 31670 21910 
12 n-butanol 31840 22540 
13 ethanol 31995 22460 
14 methanol 32060 22460 
 







1 1,4-dioxane 19240  
2 di-n-butylether 33340 19270 
3 diethyl ether 33450 19230 
4 tetrahdyrofuran 19260  
5 n-butylacetate 33410 19260 
6 ethylacetate 33520 19330 
7 chloroform 19490  
8 1,2-dichloroethane 19310  
9 dichloromethane 33340 19300 
10 n-butanenitrile 33280 19440 
11 acetonitrile 33400 19650 
12 n-butanol 20140  
13 ethanol 20020  
14 methanol 20110  
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1 1,4-dioxane 30400 20940 
2 di-n-butylether 30165 21040 
3 diethyl ether 30310 20990 
4 tetrahdyrofuran 30580 20980 
5 n-butylacetate 30260 20990 
6 ethylacetate 30320 21060 
7 chloroform 31270 21150 
8 1,2-dichloroethane 30790 21070 
9 dichloromethane 30490 21060 
10 n-butanenitrile 30270 21220 
11 acetonitrile 30500 21400 
12 n-butanol 30670 21980 
13 ethanol 30590 21930 


















Figure B-2. Evaluations of the quantum yields (ϕA) of the photoreactions of 5-2a b) in MeOH and c) in 1mM KOH methanol solution. 
a) is curve-fitting graph of azobenzene in methanol. 
 
 
